<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery - Legg, LA - 2021 | Cochrane Library</title> <meta content="Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery - Legg, LA - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009286.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery - Legg, LA - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009286.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009286.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery" name="citation_title"/> <meta content="Lynn A Legg" name="citation_author"/> <meta content="NHS Greater Glasgow and Clyde Health Board" name="citation_author_institution"/> <meta content="Ann-Sofie Rudberg" name="citation_author"/> <meta content="Karolinska Institutet Danderyd Hospital" name="citation_author_institution"/> <meta content="Xing Hua" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Simiao Wu" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Maree L Hackett" name="citation_author"/> <meta content="The George Institute for Global Health, Faculty of Medicine, University of New South Wales" name="citation_author_institution"/> <meta content="Russel Tilney" name="citation_author"/> <meta content="Mater Dei Hospital" name="citation_author_institution"/> <meta content="Linnea Lindgren" name="citation_author"/> <meta content="Uppsala University" name="citation_author_institution"/> <meta content="Mansur A Kutlubaev" name="citation_author"/> <meta content="Bashkir State Medical University" name="citation_author_institution"/> <meta content="Cheng-Fang Hsieh" name="citation_author"/> <meta content="Kaohsiung Medical University" name="citation_author_institution"/> <meta content="Amanda J Barugh" name="citation_author"/> <meta content="University of Edinburgh" name="citation_author_institution"/> <meta content="Graeme J Hankey" name="citation_author"/> <meta content="The University of Western Australia" name="citation_author_institution"/> <meta content="Erik Lundström" name="citation_author"/> <meta content="Uppsala University" name="citation_author_institution"/> <meta content="Martin Dennis" name="citation_author"/> <meta content="University of Edinburgh" name="citation_author_institution"/> <meta content="Gillian E Mead" name="citation_author"/> <meta content="University of Edinburgh" name="citation_author_institution"/> <meta content="gillian.e.mead@ed.ac.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD009286.pub4" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/11/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009286.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009286.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009286.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anxiety; Anxiety Disorders; Fluoxetine [adverse effects]; *Selective Serotonin Reuptake Inhibitors [adverse effects]; *Stroke [drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009286.pub4&amp;doi=10.1002/14651858.CD009286.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009286.pub4&amp;doi=10.1002/14651858.CD009286.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009286.pub4&amp;doi=10.1002/14651858.CD009286.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009286.pub4&amp;doi=10.1002/14651858.CD009286.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009286.pub4&amp;doi=10.1002/14651858.CD009286.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009286.pub4&amp;doi=10.1002/14651858.CD009286.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009286.pub4&amp;doi=10.1002/14651858.CD009286.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009286.pub4&amp;doi=10.1002/14651858.CD009286.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009286.pub4&amp;doi=10.1002/14651858.CD009286.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009286.pub4&amp;doi=10.1002/14651858.CD009286.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009286.pub4&amp;doi=10.1002/14651858.CD009286.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009286.pub4&amp;doi=10.1002/14651858.CD009286.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009286.pub4&amp;doi=10.1002/14651858.CD009286.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009286.pub4&amp;doi=10.1002/14651858.CD009286.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009286.pub4&amp;doi=10.1002/14651858.CD009286.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009286.pub4&amp;doi=10.1002/14651858.CD009286.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009286.pub4&amp;doi=10.1002/14651858.CD009286.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009286.pub4&amp;doi=10.1002/14651858.CD009286.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009286.pub4&amp;doi=10.1002/14651858.CD009286.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009286.pub4&amp;doi=10.1002/14651858.CD009286.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009286.pub4&amp;doi=10.1002/14651858.CD009286.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009286.pub4&amp;doi=10.1002/14651858.CD009286.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009286.pub4&amp;doi=10.1002/14651858.CD009286.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="77cjsSG8";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009286\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009286\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009286\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009286\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ms","ja","hr","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009286.pub4",title:"Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery",firstPublishedDate:"Nov 15, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Stroke Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=77cjsSG8&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009286.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009286.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009286.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009286.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009286.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009286.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009286.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009286.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009286.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009286.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5551 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009286.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/full#CD009286-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/full#CD009286-sec-0091"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/full#CD009286-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/full#CD009286-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/full#CD009286-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/full#CD009286-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/full#CD009286-sec-0040"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/full#CD009286-sec-0085"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/appendices#CD009286-sec-0096"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/table_n/CD009286StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/table_n/CD009286StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/information#CD009286-cr-0004">Lynn A Legg</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/information#CD009286-cr-0005">Ann-Sofie Rudberg</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/information#CD009286-cr-0006">Xing Hua</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/information#CD009286-cr-0007">Simiao Wu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/information#CD009286-cr-0008">Maree L Hackett</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/information#CD009286-cr-0009">Russel Tilney</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/information#CD009286-cr-0010">Linnea Lindgren</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/information#CD009286-cr-0011">Mansur A Kutlubaev</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/information#CD009286-cr-0012">Cheng-Fang Hsieh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/information#CD009286-cr-0013">Amanda J Barugh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/information#CD009286-cr-0014">Graeme J Hankey</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/information#CD009286-cr-0015">Erik Lundström</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/information#CD009286-cr-0016">Martin Dennis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009286.pub4/information#CD009286-cr-0017"><i class="icon corresponding-author fa fa-envelope"></i>Gillian E Mead</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/information/en#CD009286-sec-0107">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 November 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009286.pub4">https://doi.org/10.1002/14651858.CD009286.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009286-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009286-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009286-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009286-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009286-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009286-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009286-abs-0001" lang="en"> <section id="CD009286-sec-0001"> <h3 class="title" id="CD009286-sec-0001">Background</h3> <p>Selective serotonin reuptake inhibitors (SSRIs) might theoretically reduce post‐stroke disability by direct effects on the brain. This Cochrane Review was first published in 2012 and last updated in 2019. </p> </section> <section id="CD009286-sec-0002"> <h3 class="title" id="CD009286-sec-0002">Objectives</h3> <p>To determine if SSRIs are more effective than placebo or usual care at improving outcomes in people less than 12 months post‐stroke, and to determine whether treatment with SSRIs is associated with adverse effects. </p> </section> <section id="CD009286-sec-0003"> <h3 class="title" id="CD009286-sec-0003">Search methods</h3> <p>We searched the Cochrane Stroke Group Trials Register (last searched 7 January 2021), Cochrane Controlled Trials Register (CENTRAL, Issue 7 of 12, 7 January 2021), MEDLINE (1946 to 7 January 2021), Embase (1974 to 7 January 2021), CINAHL (1982 to 7 January 2021), PsycINFO (1985 to 7 January 2021), and AMED (1985 to 7 January 2021). PsycBITE had previously been searched (16 July 2018). We searched clinical trials registers. </p> </section> <section id="CD009286-sec-0004"> <h3 class="title" id="CD009286-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) recruiting stroke survivors within the first year. The intervention was any SSRI, at any dose, for any period, and for any indication. The comparator was usual care or placebo. Studies reporting at least one of our primary (disability score or independence) or secondary outcomes (impairments, depression, anxiety, quality of life, fatigue, cognition, healthcare cost, death, adverse events and leaving the study early) were included in the meta‐analysis. The primary analysis included studies at low risk of bias. </p> </section> <section id="CD009286-sec-0005"> <h3 class="title" id="CD009286-sec-0005">Data collection and analysis</h3> <p>We extracted data on demographics, stroke type and, our pre‐specified outcomes, and bias sources. Two review authors independently extracted data. We used mean difference (MD) or standardised mean differences (SMDs) for continuous variables, and risk ratios (RRs) for dichotomous variables, with 95% confidence intervals (CIs). We assessed bias risks and applied GRADE criteria. </p> </section> <section id="CD009286-sec-0006"> <h3 class="title" id="CD009286-sec-0006">Main results</h3> <p>We identified 76 eligible studies (13,029 participants); 75 provided data at end of treatment, and of these two provided data at follow‐up. Thirty‐eight required participants to have depression to enter. The duration, drug, and dose varied. Six studies were at low risk of bias across all domains; all six studies did not need participants to have depression to enter, and all used fluoxetine. Of these six studies, there was little to no difference in disability between groups SMD ‐0.0; 95% CI ‐0.05 to 0.05; 5 studies, 5436 participants, high‐quality evidence) or in independence (RR 0.98; 95% CI 0.93 to 1.03; 5 studies, 5926 participants; high‐quality evidence) at the end of treatment. </p> <p>In the studies at low risk of bias across all domains, SSRIs slightly reduced the average depression score (SMD 0.14 lower, 95% CI 0.19 lower to 0.08 lower; 4 studies; 5356 participants, high‐quality evidence) and there was a slight reduction in the proportion with depression (RR 0.75, 95% CI 0.65 to 0.86; 3 studies, 5907 participants, high‐quality evidence). </p> <p>Cognition was slightly better in the control group (MD ‐1.22, 95% CI ‐2.37 to ‐0.07; 4 studies, 5373 participants, moderate‐quality evidence). </p> <p>Only one study (n = 30) reported neurological deficit score (SMD ‐0.39, 95% CI ‐1.12 to 0.33; low‐quality evidence). </p> <p>SSRIs resulted in little to no difference in motor deficit (SMD 0.03, ‐0.02 to 0.08; 6 studies, 5518 participants, moderate‐quality evidence). </p> <p>SSRIs slightly increased the proportion leaving the study early (RR 1.57, 95% CI 1.03 to 2.40; 6 studies, 6090 participants, high‐quality evidence). </p> <p>SSRIs slightly increased the outcome of a seizure (RR 1.40, 95% CI 1.00 to 1.98; 6 studies, 6080 participants, moderate‐quality evidence) and a bone fracture (RR 2.35, 95% CI 1.62 to 3.41; 6 studies, 6080 participants, high‐quality evidence). </p> <p>One study at low risk of bias across all domains reported gastrointestinal side effects (RR 1.71, 95% CI 0.33, to 8.83; 1 study, 30 participants). </p> <p>There was no difference in the total number of deaths between SSRI and placebo (RR 1.01, 95% CI 0.82 to 1.24; 6 studies, 6090 participants, moderate quality evidence). </p> <p>SSRIs probably result in little to no difference in fatigue (MD ‐0.06; 95% CI ‐1.24 to 1.11; 4 studies, 5524 participants, moderate‐quality of evidence), nor in quality of life (MD 0.00; 95% CI ‐0.02 to 0.02, 3 studies, 5482 participants, high‐quality evidence). </p> <p>When all studies, irrespective of risk of bias, were included, SSRIs reduced disability scores but not the proportion independent. </p> <p>There was insufficient data to perform a meta‐analysis of outcomes at end of follow‐up.</p> <p>Several small ongoing studies are unlikely to alter conclusions.</p> </section> <section id="CD009286-sec-0007"> <h3 class="title" id="CD009286-sec-0007">Authors' conclusions</h3> <p>There is high‐quality evidence that SSRIs do not make a difference to disability or independence after stroke compared to placebo or usual care, reduced the risk of future depression, increased bone fractures and probably increased seizure risk. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009286-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009286-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009286-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009286-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009286-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD009286-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD009286-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009286-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD009286-abs-0014">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD009286-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009286-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD009286-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009286-abs-0002" lang="en"> <h3>Selective serotonin reuptake inhibitors for stroke recovery</h3> <p><b>Review question</b><br/>What are the effects of selective serotonin uptake inhibitor (SSRI) drugs on recovery from stroke? </p> <p><b>Background</b><br/>Stroke is a major cause of disability. Stroke‐related disability can include difficulty with daily tasks such as toileting, washing, and walking. Sometimes disability is so severe that a person becomes dependent on others for performing basic activities (this is known as 'dependence'). We previously published an update of this Cochrane Review which aimed to find out whether SSRIs (a class of drug usually used to treat mood problems, which work by changing the level of chemicals in the brain) might improve recovery after stroke. </p> <p>Since the update in 2019, two large studies have now been completed and so it is necessary to perform a further update of this review. In our main analyses we included only high‐quality trials, that is those which used rigorous methods to avoid biases (such as the person assessing outcome being aware of whether the stroke survivor received the active drug or placebo). We refer to these studies as 'low risk of bias' studies. </p> <p>We also wanted to find out whether SSRIs had other benefits, for example improving the severity of any arm or leg weakness, mood, anxiety, cognition, quality of life, and whether SSRIs were associated with side effects such as bleeding or seizures. </p> <p><b>Study characteristics</b><br/>In total we found 76 studies recruiting 13,029 stroke survivors within one year of their stroke. There was a wide age range. About half the studies required participants to have depression to enter the trial. The duration, drug, and dose varied between studies. However, only six of these studies were at low risk of bias; the participants in these studies did not have to be depressed to enter the study, and they were all recruited soon after their stroke. </p> <p><b>Key results</b><br/>When we combined data from these six studies at low risk of bias, SSRIs did not reduce disability or dependency. SSRIs reduced the risk of future depression by about a quarter, but led to a slight increase in the risk of seizures and also increased the risk of bone fractures. The evidence is current until January 2021. </p> <p><b>Quality of the evidence</b><br/>We are very confident that the results are reliable for the effect on disability, dependency and bone fractures, and moderately confident about the effect on seizure risk. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009286-sec-0091" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009286-sec-0091"></div> <h3 class="title" id="CD009286-sec-0092">Implications for practice</h3> <section id="CD009286-sec-0092"> <p>Based on our meta‐analysis of the studies at low risk of bias, most of which provided selective serotonin reuptake inhibitors (SSRIs) early after stroke and did not require participants to have depression, there is currently no indication for the routine prescription of SSRIs in order to reduce disability and increase independence after stroke. Fluoxetine, which was the most commonly used SSRI and used in the three largest trials, reduces the risk of depression and the severity of depression, but this is probably not a sufficiently strong rationale to give all people with stroke a six‐month course of the drug, particularly as there is an increased risk of seizures and fractures. As the studies at low risk of bias all did not require patients to have depression at entry, we do not know for certain whether SSRIs might reduce disability in people who do have depression after stroke. Also, we do not know what effect SSRIs other than fluoxetine might have on recovery after stroke. </p> </section> <h3 class="title" id="CD009286-sec-0093">Implications for research</h3> <section id="CD009286-sec-0093"> <p>This review found high‐quality evidence that SSRIs do not improve recovery after stroke and provided reliable evidence about their risks, though this conclusion is based mainly on evidence about fluoxetine. Thus, further trials of SSRI for stroke recovery are almost certainly not needed, unless they are designed only to include people with depression. This is because all the studies in this review which were at low risk of bias did not require participants to have depression at entry. </p> <p>We have published a protocol for an individual patient data meta‐analysis of the three largest studies included in this review, all of which were of high quality (<a href="./references#CD009286-bbs2-0002" title="ACTRN12611000774921. Assessment of fluoxetine in stroke recovery (AFFINITY) trial, 2011. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000774921 (first received 22 July 2011). ACTRN12619000986178. The assessment of fluoxetine in stroke recovery imaging and blood biomarkers sub-study AFFINITY BM. www.anzctr.org.au/Trial/Registration/TrialReview.aspx ?ACTRN=12619000986178 (first received 11 July 2019). AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):651-60. HankeyG . Assessment oF FluoxetINe In sTroke recoverY (AFFINITY). www.affinitytrial.org/ (accessed 19th February 2019). ">AFFINITY 2020</a>; <a href="./references#CD009286-bbs2-0021" title="EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661-9. ISRCTN13020412. Establishing the effect(s) and safety of fluoxetine initiated in the acute phase of stroke. www.isrctn.com/ISRCTN13020412 (first received 19 December 2014). LundströmE , IsakssonE , NäsmanP , WesterP , MårtenssonB , NorrvingB . Correction to: Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(388):s13063-020-04327-w. LundströmE , IsakssonE , Näsman P et al. Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(233):s13063-020-4124-7. LundstromE , IsakssonE , NasmanP , WesterP , MartenssonB , NorrvingB , et al. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661‐9. ">EFFECTS 2020</a>; <a href="./references#CD009286-bbs2-0023" title="Anonymous. The FOCUS (Fluoxetine or Control under Supervision) trial results: effects of a 6 month course of fluoxetine on the Stroke Impact Scale, mood and fatigue in patients with stroke. www.ed.ac.uk/clinical-brain-sciences/research/completed-studies-trials/focus-stroke-trial (accessed 12 02 2021). CookR , ThomasV , MartinR . Does fluoxetine improve recovery after stroke?BMJ2019;364:1029. DennisM , ForbesJ , GrahamC , HackettM , HankeyGJ , HouseA , et al. Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT. Health Technology Assessment2020;24(22):1-94. DennisM , ForbesJ , GrahamC , HackettML , HankeyGJ , HouseA , et al. Fluoxetine and fractures after stroke: exploratory analyses from the FOCUS Trial. Stroke2019;50(11):3280-2. FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet2019;393(10168):265-74. GrahamC , LewisS , ForbesJ , MeadG , HackettML , HankeyGJ , et al. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. Trials2017;18(1):627. LundstromE , DennisM , MeadG . The effects of fluoxetine on fracture risk after stroke: Further analyses from the focus trial. European Stroke Journal2019;4 suppl 1:7142019. MeadG , DennisM . Feasibility of reporting results of large randomised controlled trials to participants: experience from the Fluoxetine or Control under Supervision (FOCUS) trial. BMJ Open2020;10(11):e0404922020. MeadG . Fluoxetine Or Control Under Supervision (FOCUS) trial: to establish the effect(s) of routine administration of Fluoxetine in patients with a recent stroke. www.isrctn.com/ISRCTN83290762 (first received 23 May 2012). MeadGE , DennisMS , InnesK , MacLeodM , SandercockPA , HouseA , et al. A multicentre randomised trial to establish the effect(s) of routine administration of fluoxetine in patients with a recent stroke (Fluoxetine Or Control Under Supervision, FOCUS). In: 21st European Stroke Conference. 2012:Abst OAID 26. MeadGE , GrahamC , BillotL , NäsmanP , LundströmE , LewisS , on behalf of the FOCUS , AFFINITY and EFFECTS trialists. Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis. Trials2020;21(1):971. MeadGE , LeggL , TilneyR , HsiehCF , WuS , LundströmE , et al. Fluoxetine for stroke recovery: meta-analysis of randomized controlled trials. International Journal of Stroke2020;15(4):365-76. ">FOCUS 2019</a>). This individual patient data meta‐analysis may provide more precise estimates of treatment effects and may be able to identify any differences in outcome related to country or ethnicity. We are also planning to publish a series of other papers, using these data, which we have already described (<a href="./references#CD009286-bbs2-0137" title="MeadGE , GrahamC , BillotL , NäsmanP , LundströmE , LewisS , forFOCUS , AFFINITY and EFFECTS trialists. Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis. Trials2020;21(1):971. [DOI: https://doi.org/10.1186/s13063-020-04875-1]">Mead 2020</a>). </p> <p>We have carefully considered whether to update this review again. Currently there are several small ongoing studies but, because they are small, the results will not make a material difference to the results of this review. Thus, we think that it is unlikely that further updates of this Cochrane Review will be needed. However, if further large studies are established in the future, we will reconsider this decision. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009286-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009286-sec-0008"></div> <div class="table" id="CD009286-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Fluoxetine versus control at end of treatment, for stroke recovery, using data from high quality trials only</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fluoxetine versus control at end of treatment, by SSRI, for stroke recovery*</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with stroke recovery<br/><b>Settings:</b> hospital<br/><b>Intervention:</b> fluoxetine versus control at end of treatment </p> <p>*Summary of findings table based on studies with low risk of bias.</p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Fluoxetine versus control at end of treatment</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disability (primary analysis)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.0 (‐0.05, 0.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5436 <br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Independent on modified Rankin score (mRS 0 to 2) (primary analysis)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.98<br/>(0.93 to 1.03) </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5926 <br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1541/2971 (i.e. 52 per hundred)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1498/2955</p> <p>(i.e. 51 per hundred)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological deficit score</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.39 (95% CI (‐1.12 to 0.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 participants, one study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This is a small effect (based on the 'rule‐of‐thumb' method for interpreting SMD)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depression (continuous data)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.14 (‐0.19 to ‐0.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5356<br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This is a small effect (based on the 'rule‐of‐thumb' method for interpreting SMD)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/>(0.82 to 1.24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6090<br/>(6 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>168/3029 (i.e. 55 per thousand)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>170/3061</p> <p>(i.e. 56 per thousand)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of seizures</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.40<br/>(1.00 to 1.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6080 <br/>(6 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54/3024 (i.e. 18 per thousand)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76/3056 (i.e. 25 per thousand)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bone fractures</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.35 <br/>(1.62 to 3.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6080<br/>(6 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕ ⊕ <br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40/3024</p> <p>(i.e. 13 per thousand)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>93/3056</p> <p>(i.e. 30 per thousand)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the mean control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Neurological deficit from only one trial of 30 people so we have downgraded for imprecision (<a href="./references#CD009286-bbs2-0126" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">GRADE 2013</a>). </p> <p><sup>b</sup>Death downgraded for imprecision. </p> <p><sup>c</sup>Seizures downgraded for imprecision. </p> <p>Note that because we included only the low risk of bias studies in our review, none of the evidence was downgraded because of study quality. </p> <p>A range of different outcome scales were used for disability (including Barthel Index and daily activities subscale of the Stroke Impact Scale), and depression (including emotional role function of the Stroke Impact Scale). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009286-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009286-sec-0009"></div> <section id="CD009286-sec-0010"> <h3 class="title" id="CD009286-sec-0010">Description of the condition</h3> <p>Worldwide, stroke is the second leading cause of death, the third leading cause of disability (<a href="./references#CD009286-bbs2-0130" title="JohnsonW , OnumaO , OwolabiM , SachdevS . Stroke: a global response is needed. Bulletin of the World Health Organization2016;94(9):634-634A.">Johnson 2016</a>), and results in 6.5 million years being lived with disability (<a href="./references#CD009286-bbs2-0125" title="GBD 2015. Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study. Lancet2016;388(10053):1545–602.">GBD 2015</a>). Although major advances in the early reperfusion of ischaemic stroke have been achieved in recent years (e.g. by intravenous thrombolysis, thrombectomy), and more is known about prevention of recurrent stroke), effective, safe and widely accessible and affordable treatments that facilitate early and sustained recovery after stroke are urgently needed to further reduce the burdens of disability and dependency after stroke. </p> </section> <section id="CD009286-sec-0011"> <h3 class="title" id="CD009286-sec-0011">Description of the intervention</h3> <p>Selective serotonin reuptake inhibitors (SSRIs) are drugs that have been available for many years. There are several different SSRIs which all increase brain serotonin levels by preventing its reuptake by the presynaptic neurons. They are widely used to treat mood disorders, including those that occur after stroke, such as depression and emotional lability (i.e. emotional behaviour that is outside normal control and that occurs in situations that previously would not have provoked such behaviour) (<a href="./references#CD009286-bbs2-0122" title="AllidaS , PatelK , HouseA , HackettML . Pharmaceutical interventions for emotionalism after stroke. Cochrane Database of Systematic Reviews2019, Issue 3. Art. No: CD003690. [DOI: 10.1002/14651858.CD003690.pub4]">Allida 2019</a>). SSRIs are sometimes used to manage anxiety. </p> <p>Small studies have suggested that fluoxetine, one of the SSRIs, might have a favourable effect on motor recovery after stroke (<a href="./references#CD009286-bbs2-0018" title="CholletF , TardyJ , Albucher J-F, ThalamasE , BerardE , LamyC , et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurology2011;10(2):123-30. ">Chollet 2011</a>; <a href="./references#CD009286-bbs2-0153" title="YiZM , LiuF , ZhaiSD . Fluoxetine for the prophylaxis of post-stroke depression in patients with stroke: a meta-analysis. International Journal of Clinical Practice2010;64(9):1310-7.">Yi 2010</a>), even in people without mood disorders. Our 2019 Cochrane Review of SSRI for stroke recovery included 63 studies of SSRIs recruiting 9168 stroke survivors within one year of their stroke, where SSRIs were used in people with or without depression (<a href="./references#CD009286-bbs2-0132" title="LeggLA , TilneyR , HsiehC , WuS , LundströmE , RudbergA , et al. Selective serotonin reuptake inhibitors for stroke recovery. Cochrane Database of Systematic Reviews2019, Issue 11. Art. No: CD009286. [DOI: 10.1002/14651858.CD009286.pub3]">Legg 2019</a>). Combining the studies suggested a benefit on recovery but this benefit was not apparent when low‐quality studies were excluded from the meta‐analysis. </p> </section> <section id="CD009286-sec-0012"> <h3 class="title" id="CD009286-sec-0012">How the intervention might work</h3> <p>In animal studies, multiple potentially beneficial effects of SSRIs have been demonstrated in both normal and diseased brains. First, SSRIs have a neurotrophic effect. Neurotrophins are a family of proteins that are involved in embryogenesis (formulation of an embryo) and organogenesis (development of organs). They control neural plasticity (ability to change, or easily changed or shaped) in adults, regulate synaptic activity and neurotransmitter synthesis, and are essential for the regeneration of nerves (<a href="./references#CD009286-bbs2-0131" title="LangUE , Jockers-ScherüblMC , HellwegR . State of the art of the neurotrophin hypothesis in psychiatric disorders: implications and limitations. Journal of Neural Transmission2004;111(3):387-411.">Lang 2004</a>). The development of new nerve cells in adults is generally restricted to specific areas of the brain, namely the subependymal cells of the ventricular system and the subgranular zone of the dentate gyrus in the hippocampus (<a href="./references#CD009286-bbs2-0138" title="MingGL , SongH . Adult neurogenesis in the mammalian central nervous system. Annual Review of Neuroscience2005;28:223-50.">Ming 2005</a>). SSRIs increase neurogenesis and expression of neurotrophic or growth factors in the adult hippocampus (<a href="./references#CD009286-bbs2-0145" title="SchmidtHD , DumanRS . The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behaviour. Behavioural Pharmacology2007;18(5-6):391-418.">Schmidt 2007</a>), and this is likely to account for the behavioural benefits of antidepressants in animals (<a href="./references#CD009286-bbs2-0144" title="SantarelliL , SaxeM , GrossC , SurgetA , BattagliaF , DulawaS , et al. Requirement of hippocampal neurogenesis antidepressant treatments and animal models of depressive-like behaviour. Behavioural Pharmacology2003;301:805-9.">Santarelli 2003</a>). Importantly, several studies have shown that migration of new neurones to damaged areas of brain may occur (<a href="./references#CD009286-bbs2-0151" title="WiltroutC , LangB , YanY , DempseyRJ , VemugantiR . Repairing brain after stroke: a review on post-ischaemic neurogenesis. Neurochemistry International2007;50(7-8):1028-41.">Wiltrout 2007</a>), and that neurogenesis can also occur within areas of damaged brain, for example in people with Alzheimer's disease and in animal models of Alzheimer's disease (<a href="./references#CD009286-bbs2-0149" title="TaupinP . Adult neurogenesis and neuroplasticity. Restorative Neurology and Neuroscience2006;24(1):9-15.">Taupin 2006</a>). </p> <p>Second, fluoxetine may have a neuroprotective effect (i.e. protect nerve cells when the brain is damaged, e.g. by a stroke). In animals, there may be several mechanisms for neuroprotective effects of SSRIs, such as reducing inflammation (e.g. repression of microglia activation) (<a href="./references#CD009286-bbs2-0134" title="LimCM , KimSW , ParkJY , KimC , YoonSH , LeeJK . Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. Journal of Neuroscience Research2009;87(4):1037-45.">Lim 2009</a>), and by enhancement of specific protein expression (hypoxia inducible factor–1 alpha, heme oxygenase‐1) (<a href="./references#CD009286-bbs2-0147" title="ShinTK , KangMS , LeeHY , SeoMS , KimSG , KimCD , et al. Fluoxetine and sertraline attenuate postischemic brain injury in mice. Korean Journal of Physiology and Pharmacology2009;13(3):257-63.">Shin 2009</a>). </p> <p>Third, SSRIs can indirectly affect an important hormonal system in the body, the adrenergic system, through up‐regulation (i.e. increase a cellular component of a cell, such as ribonucleic acid (RNA) or protein, in response to an external variable) of beta1 receptors (<a href="./references#CD009286-bbs2-0141" title="Pälvimäki E-P, LaaksoA , KuoppamäkiM , SyvälahtiE , HietalaJ . Up-regulation of beta l-adrenergic receptors in rat brain after chronic citalopram and fluoxetine treatments. Psychopharmacology1994;115(4):543-6.">Pälvimäki 1994</a>). </p> <p>In healthy humans, functional magnetic resonance imaging (fMRI) studies have demonstrated that fluoxetine can modulate cerebral motor activity (<a href="./references#CD009286-bbs2-0135" title="LoubinouxI , BoulanouarK , RanjevaJP , CarelC , BerryI , RascolO , et al. Cerebral functional magnetic resonance imaging activation modulated by a single dose of the monoamine neurotransmission enhancers fluoxetine and fenozolone during hand sensorimotor tasks. Journal of Cerebral Blood Flow and Metabolism1999;19(12):1365-75.">Loubinoux 1999</a>). For example, in eight chronic stroke participants in (<a href="./references#CD009286-bbs2-0154" title="ZittelS , WeillerC , LiepertJ . Citalopram improves dexterity in chronic stroke patients. Neurorehabilitation and Neural Repair2008;22(3):311-4. [DOI: 10.1177/1545968307312173]">Zittel 2008</a>) , a single dose of citalopram 40 mg led to improvements in dexterity. A 2017 review paper discussed the hypothesis that SSRI might modulate inhibitory pathways, and that this modulation might enhances reorganisation and reestablishment of excitatory‐inhibitory control, and thus promote motor recovery after stroke (<a href="./references#CD009286-bbs2-0142" title="PintoCB , Saleh VelezFG , LopesF , deToledo PizaPV , DipietroL , WangQM , et al. SSRI and motor recovery in stroke: reestablishment of inhibitory neural network tonus. Frontiers in Neuroscience2017;11:637. [DOI: 10.3389/fnins.2017.00637]">Pinto 2017</a>). </p> <p>SSRIs may also improve recovery after stroke simply through their effect on preventing or treating depression and anxiety, and through improving sleep and alertness. </p> </section> <section id="CD009286-sec-0013"> <h3 class="title" id="CD009286-sec-0013">Why it is important to do this review</h3> <p>Our 2012 Cochrane Review of SSRIs for stroke recovery showed that SSRIs appeared to reduce dependence, disability, neurological impairment, anxiety, and depression after stroke, even in participants without depression, but when we included only those studies at low risk of bias, effect sizes were much smaller (<a href="./references#CD009286-bbs2-0157" title="MeadGE , HsiehCF , LeeR , KutlubaevMA , ClaxtonA , HankeyGJ , et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD009286. [DOI: 10.1002/14651858.CD009286.pub2]">Mead 2012</a>). The review generated the hypothesis that SSRIs might promote recovery after stroke. </p> <p>SSRIs interact with platelet function and clotting, and therefore may have adverse effects in people with stroke, particularly those with haemorrhagic stroke, and these adverse effects might outweigh any potential benefits. </p> <p>Three large collaborative studies (<a href="./references#CD009286-bbs2-0002" title="ACTRN12611000774921. Assessment of fluoxetine in stroke recovery (AFFINITY) trial, 2011. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000774921 (first received 22 July 2011). ACTRN12619000986178. The assessment of fluoxetine in stroke recovery imaging and blood biomarkers sub-study AFFINITY BM. www.anzctr.org.au/Trial/Registration/TrialReview.aspx ?ACTRN=12619000986178 (first received 11 July 2019). AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):651-60. HankeyG . Assessment oF FluoxetINe In sTroke recoverY (AFFINITY). www.affinitytrial.org/ (accessed 19th February 2019). ">AFFINITY 2020</a>; <a href="./references#CD009286-bbs2-0021" title="EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661-9. ISRCTN13020412. Establishing the effect(s) and safety of fluoxetine initiated in the acute phase of stroke. www.isrctn.com/ISRCTN13020412 (first received 19 December 2014). LundströmE , IsakssonE , NäsmanP , WesterP , MårtenssonB , NorrvingB . Correction to: Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(388):s13063-020-04327-w. LundströmE , IsakssonE , Näsman P et al. Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(233):s13063-020-4124-7. LundstromE , IsakssonE , NasmanP , WesterP , MartenssonB , NorrvingB , et al. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661‐9. ">EFFECTS 2020</a>; <a href="./references#CD009286-bbs2-0023" title="Anonymous. The FOCUS (Fluoxetine or Control under Supervision) trial results: effects of a 6 month course of fluoxetine on the Stroke Impact Scale, mood and fatigue in patients with stroke. www.ed.ac.uk/clinical-brain-sciences/research/completed-studies-trials/focus-stroke-trial (accessed 12 02 2021). CookR , ThomasV , MartinR . Does fluoxetine improve recovery after stroke?BMJ2019;364:1029. DennisM , ForbesJ , GrahamC , HackettM , HankeyGJ , HouseA , et al. Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT. Health Technology Assessment2020;24(22):1-94. DennisM , ForbesJ , GrahamC , HackettML , HankeyGJ , HouseA , et al. Fluoxetine and fractures after stroke: exploratory analyses from the FOCUS Trial. Stroke2019;50(11):3280-2. FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet2019;393(10168):265-74. GrahamC , LewisS , ForbesJ , MeadG , HackettML , HankeyGJ , et al. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. Trials2017;18(1):627. LundstromE , DennisM , MeadG . The effects of fluoxetine on fracture risk after stroke: Further analyses from the focus trial. European Stroke Journal2019;4 suppl 1:7142019. MeadG , DennisM . Feasibility of reporting results of large randomised controlled trials to participants: experience from the Fluoxetine or Control under Supervision (FOCUS) trial. BMJ Open2020;10(11):e0404922020. MeadG . Fluoxetine Or Control Under Supervision (FOCUS) trial: to establish the effect(s) of routine administration of Fluoxetine in patients with a recent stroke. www.isrctn.com/ISRCTN83290762 (first received 23 May 2012). MeadGE , DennisMS , InnesK , MacLeodM , SandercockPA , HouseA , et al. A multicentre randomised trial to establish the effect(s) of routine administration of fluoxetine in patients with a recent stroke (Fluoxetine Or Control Under Supervision, FOCUS). In: 21st European Stroke Conference. 2012:Abst OAID 26. MeadGE , GrahamC , BillotL , NäsmanP , LundströmE , LewisS , on behalf of the FOCUS , AFFINITY and EFFECTS trialists. Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis. Trials2020;21(1):971. MeadGE , LeggL , TilneyR , HsiehCF , WuS , LundströmE , et al. Fluoxetine for stroke recovery: meta-analysis of randomized controlled trials. International Journal of Stroke2020;15(4):365-76. ">FOCUS 2019</a>), were designed based on the results of the 2012 Cochrane Review (<a href="./references#CD009286-bbs2-0157" title="MeadGE , HsiehCF , LeeR , KutlubaevMA , ClaxtonA , HankeyGJ , et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD009286. [DOI: 10.1002/14651858.CD009286.pub2]">Mead 2012</a>), to test the hypothesis that fluoxetine given early after stroke would improve recovery, or in other words, lead to less dependency and less disability at follow‐up. The 2019 Cochrane review <a href="./references#CD009286-bbs2-0132" title="LeggLA , TilneyR , HsiehC , WuS , LundströmE , RudbergA , et al. Selective serotonin reuptake inhibitors for stroke recovery. Cochrane Database of Systematic Reviews2019, Issue 11. Art. No: CD009286. [DOI: 10.1002/14651858.CD009286.pub3]">Legg 2019</a> included the results of <a href="./references#CD009286-bbs2-0023" title="Anonymous. The FOCUS (Fluoxetine or Control under Supervision) trial results: effects of a 6 month course of fluoxetine on the Stroke Impact Scale, mood and fatigue in patients with stroke. www.ed.ac.uk/clinical-brain-sciences/research/completed-studies-trials/focus-stroke-trial (accessed 12 02 2021). CookR , ThomasV , MartinR . Does fluoxetine improve recovery after stroke?BMJ2019;364:1029. DennisM , ForbesJ , GrahamC , HackettM , HankeyGJ , HouseA , et al. Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT. Health Technology Assessment2020;24(22):1-94. DennisM , ForbesJ , GrahamC , HackettML , HankeyGJ , HouseA , et al. Fluoxetine and fractures after stroke: exploratory analyses from the FOCUS Trial. Stroke2019;50(11):3280-2. FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet2019;393(10168):265-74. GrahamC , LewisS , ForbesJ , MeadG , HackettML , HankeyGJ , et al. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. Trials2017;18(1):627. LundstromE , DennisM , MeadG . The effects of fluoxetine on fracture risk after stroke: Further analyses from the focus trial. European Stroke Journal2019;4 suppl 1:7142019. MeadG , DennisM . Feasibility of reporting results of large randomised controlled trials to participants: experience from the Fluoxetine or Control under Supervision (FOCUS) trial. BMJ Open2020;10(11):e0404922020. MeadG . Fluoxetine Or Control Under Supervision (FOCUS) trial: to establish the effect(s) of routine administration of Fluoxetine in patients with a recent stroke. www.isrctn.com/ISRCTN83290762 (first received 23 May 2012). MeadGE , DennisMS , InnesK , MacLeodM , SandercockPA , HouseA , et al. A multicentre randomised trial to establish the effect(s) of routine administration of fluoxetine in patients with a recent stroke (Fluoxetine Or Control Under Supervision, FOCUS). In: 21st European Stroke Conference. 2012:Abst OAID 26. MeadGE , GrahamC , BillotL , NäsmanP , LundströmE , LewisS , on behalf of the FOCUS , AFFINITY and EFFECTS trialists. Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis. Trials2020;21(1):971. MeadGE , LeggL , TilneyR , HsiehCF , WuS , LundströmE , et al. Fluoxetine for stroke recovery: meta-analysis of randomized controlled trials. International Journal of Stroke2020;15(4):365-76. ">FOCUS 2019</a>, which recruited over 3000 participants; in the 2019 update, meta‐analysis of the studies at low risk of bias indicated that SSRIs did not improve recovery from stroke. There were improvements in disability only when studies at high risk of bias were included. </p> <p>Cochrane Reviews should be updated regularly (ideally every two years when substantial new evidence becomes available). In 2020, the results of two large studies (<a href="./references#CD009286-bbs2-0002" title="ACTRN12611000774921. Assessment of fluoxetine in stroke recovery (AFFINITY) trial, 2011. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000774921 (first received 22 July 2011). ACTRN12619000986178. The assessment of fluoxetine in stroke recovery imaging and blood biomarkers sub-study AFFINITY BM. www.anzctr.org.au/Trial/Registration/TrialReview.aspx ?ACTRN=12619000986178 (first received 11 July 2019). AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):651-60. HankeyG . Assessment oF FluoxetINe In sTroke recoverY (AFFINITY). www.affinitytrial.org/ (accessed 19th February 2019). ">AFFINITY 2020</a>; <a href="./references#CD009286-bbs2-0021" title="EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661-9. ISRCTN13020412. Establishing the effect(s) and safety of fluoxetine initiated in the acute phase of stroke. www.isrctn.com/ISRCTN13020412 (first received 19 December 2014). LundströmE , IsakssonE , NäsmanP , WesterP , MårtenssonB , NorrvingB . Correction to: Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(388):s13063-020-04327-w. LundströmE , IsakssonE , Näsman P et al. Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(233):s13063-020-4124-7. LundstromE , IsakssonE , NasmanP , WesterP , MartenssonB , NorrvingB , et al. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661‐9. ">EFFECTS 2020</a>) were published and therefore we decided to update this review. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009286-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009286-sec-0014"></div> <p>To determine if selective serotonin reuptake inhibitors (SSRIs) are more effective than placebo or usual care at improving outcomes in people less than 12 months post‐stroke, and to determine whether treatment with SSRIs is associated with adverse effects. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009286-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009286-sec-0015"></div> <section id="CD009286-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009286-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included all randomised controlled trials (RCTs) in people with a clinical diagnosis of stroke (<a href="./references#CD009286-bbs2-0128" title="HatanoS . Experience from a multicentre stroke register: a preliminary report. Bulletin of the World Health Organization1976;54(5):541-53.">Hatano 1976</a>), where an SSRI had been given within the first year of stroke onset i.e. 1) studies had to state that participants were recruited within 12 months of stroke onset, or 2) studies where the mean (or median) time since stroke was less than 12 months. Studies had to have reported at least one of our outcomes of interest in order to be included in the meta‐analysis. For those studies which did not report data in a form that we could use, we attempted to get the raw data from the authors, and if this was not possible, we retained the studies in the list of included studies, even though they could not be included in the meta‐analysis . </p> <p>We included studies:</p> <p> <ul id="CD009286-list-0001"> <li> <p>with more than two arms (e.g. SSRI versus another active treatment versus placebo). We included data from the SSRI arm and the placebo arm (or usual‐care arm if a placebo was not used), and discarded data from the other active treatment arms; </p> </li> <li> <p>in all languages.</p> </li> </ul> </p> <p>We excluded studies:</p> <p> <ul id="CD009286-list-0002"> <li> <p>using a quasi‐experimental design (i.e. where investigators describe a non‐random component in the sequence generation process, such as date of admission); </p> </li> <li> <p>using a cross‐over design.</p> </li> </ul> </p> <p>There was no restriction on the eligibility of RCTs on the basis of sample size or duration of follow‐up. </p> </section> <section id="CD009286-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included studies that had recruited survivors of a stroke, defined as a sudden‐onset focal neurological disturbance, assumed to be vascular in origin, and lasting more than 24 hours (<a href="./references#CD009286-bbs2-0128" title="HatanoS . Experience from a multicentre stroke register: a preliminary report. Bulletin of the World Health Organization1976;54(5):541-53.">Hatano 1976</a>). Studies had to recruit participants within 12 months of stroke onset, or the mean/median time since stroke had to be less than 12 months. We intended to include studies in subarachnoid haemorrhage and perform a subgroup analysis but we did not find any such studies. We intended to exclude trials of mixed populations (e.g. stroke and head injury) unless separate results for those with stroke were available, but we found no such studies. </p> </section> <section id="CD009286-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included any drug classified as a SSRI (e.g. fluvoxamine, fluoxetine, sertraline, citalopram and paroxetine). We included any dose or mode of delivery, given for any duration and for any reason (e.g. to aid neurological recovery, to treat depression or anxiety or emotionalism, or to prevent depression or anxiety or other mood disorders). We did not include drugs that have mixed effects that include SSRI actions. </p> <p>The comparator arm could include usual care or a placebo.</p> <p>We excluded studies in which an SSRI was compared with another active intervention (e.g. another type of drug or herb or acupuncture). We also excluded studies that combined an SSRI with another active treatment and compared with the active treatment alone, because of the potential for interaction between the SSRI and other active treatment. </p> <p>If studies had two SSRI arms, we combined these and compared with control.</p> </section> <section id="CD009286-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We included several outcomes.</p> <section id="CD009286-sec-0021"> <h5 class="title">Primary outcomes</h5> <p>We had two co‐primary outcomes:</p> <p> <ul id="CD009286-list-0003"> <li> <p>independence at end of treatment. In stroke trials this is typically measured using the modified Rankin Scale (mRS), with a score of 0 to 2 conventionally considered to represent independence; </p> </li> <li> <p>disability score at the end of treatment. Measures included, but were not limited to, Barthel index (BI) or Functional Independence Measure (FIM). If FIM or Barthel was not measured, we included an outcome reported in the trial that reported a construct as similar as possible to FIM or Barthel. For the trials which reported the Stroke Impact Scale, we used the daily activities subscale as a measure of disability. </p> </li> </ul> </p> <p>Although disability scores and independence (or not) are arguably measuring the same concept, disability scores provide a more detailed description of functional outcome than simply using a dichotomous outcome such as independence. In other words, we were interested in performance in personal activities of daily living (ADL)/disability (measured using disability scores) and also independence in performance in personal ADL/disability measured using dichotomous outcome (independent or not). </p> <p>Note that 'end of treatment' depends on the duration of treatment, and so the outcome might be measured at different time points in different studies. But we justified this approach because we were interested in whether an SSRI, given for any duration, led to better outcomes immediately after completing the course of the SSRI. However, to be included, the outcome measure had to be assessed at the same time in the control and SRRI group. </p> </section> <section id="CD009286-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD009286-list-0004"> <li> <p>Impairments (which can include neurological deficit scores such as the National Institute of Health Score, Motor deficit scores‐such as the Fugl‐Meyer motor score). If the total score was reported, and also motor deficit alone, we performed two separate meta‐analyses. For the trials which reported Stroke Impact Scale, we elected to use the self‐reported 'strength' domain for motor deficit. </p> </li> <li> <p>Depression. We accepted any depression score. We did not decide which score to prioritise as we anticipated that trials would use only one depression score. W e included both continuous and dichotomous scores and analysed these separately. </p> </li> <li> <p>Anxiety. We intended to accept any anxiety score. We intended to include both continuous and dichotomous scores and analyse these separately. </p> </li> <li> <p>Quality of life. We accepted any score.</p> </li> <li> <p>Fatigue. This could include any fatigue score, or the vitality component of the SF‐36 ( Short Form Survey). </p> </li> <li> <p>Healthcare cost.</p> </li> <li> <p>Death</p> </li> <li> <p>Adverse events including gastrointestinal (GI) side effects, bleeding, seizures, and any other side effect. For this update, there were sufficient data on fractures to include this as an additional analysis, and so we included this as an additional Forest plot. </p> </li> <li> <p>Cognition‐this could include self report or directly measured cognition. We would have prioritised directly measured cognition if these data had been available. In the previous update no trials reported this‐but the new trials included in this update did include cognition. </p> </li> <li> <p>Leaving the trial early (for reasons other than death).</p> </li> </ul> </p> <p>We anticipated that most studies would assess these at the end of treatment and possibly at one or more time points. We did not stipulate a minimum follow‐up time. We did not stipulate in advance precisely how multiple time points would be handled (if they had been found). </p> <p>In the previous update we stated that we would also analyse change in depression scores over time. For this update, we made the decision just to analyse depression score at the end of the studies, as change in scores were not reported by the new included trials. </p> </section> </section> </section> <section id="CD009286-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>See the methods for the Cochrane Stroke Group <a href="http://www.dcn.ed.ac.uk/csrg/entity/searchmethods.pdf" target="_blank">Specialised register</a>. We searched for studies in all languages and arranged for the translation of trials where necessary. </p> <section id="CD009286-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We developed the MEDLINE search strategy with the help of the Cochrane Stroke Group Information Specialist and adapted it for the other databases. </p> <p>We searched the following electronic bibliographic databases.</p> <p> <ul id="CD009286-list-0005"> <li> <p>Cochrane Stroke Group Trials Register (7 January 2021)</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2021, Issue 1) in the Cochrane Library (searched 7 January 2021) (<a href="./appendices#CD009286-sec-0097">Appendix 1</a>) </p> </li> <li> <p>MEDLINE (from 1948 to 7 January 2021) (<a href="./appendices#CD009286-sec-0098">Appendix 2</a>) </p> </li> <li> <p>Embase Ovid (from 1980 to 7 January 2021) (<a href="./appendices#CD009286-sec-0099">Appendix 3</a>) </p> </li> <li> <p>CINAHL EBSCO (Cumulative Index to Nursing and Allied Health Literature ; 1982 to 7 January 2021) (<a href="./appendices#CD009286-sec-0100">Appendix 4</a>) </p> </li> <li> <p>AMED Ovid (Allied and Complementary Medicine) (from 1985 to 7 January 2021) (<a href="./appendices#CD009286-sec-0101">Appendix 5</a>) </p> </li> <li> <p>PsycINFO Ovid (from 1967 to 7 January 2021) (<a href="./appendices#CD009286-sec-0102">Appendix 6</a>) </p> </li> <li> <p>PsycBITE Psychological Database for Brain Impairment Treatment Efficacy (<a href="http://www.psycbite.com/" target="_blank">www.psycbite.com/</a>) (16 July 2018) </p> </li> </ul> </p> <p>In addition, we searched the following ongoing trials registers (<a href="./appendices#CD009286-sec-0103">Appendix 7</a>). </p> <p> <ul id="CD009286-list-0006"> <li> <p>Stroke Trials Registry (<a href="http://www.strokecenter.org/trials" target="_blank">www.strokecenter.org/trials</a>) (26 June 2018) </p> </li> <li> <p>US National Institutes of Health ongoing Trials Register ClinicalTrials.gov (<a href="http://www.ClinicalTrials.gov" target="_blank">www.ClinicalTrials.gov</a>) (7 January 2021) </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) (7 September 2020) </p> </li> </ul> </p> <p>Evidence for this update included search results from the previous version of this review), combined with results from the above searches. In <a href="./references#CD009286-bbs2-0157" title="MeadGE , HsiehCF , LeeR , KutlubaevMA , ClaxtonA , HankeyGJ , et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD009286. [DOI: 10.1002/14651858.CD009286.pub2]">Mead 2012</a> there had been no date limits and searches had been applied from inception of databases. </p> <p>Following editorial review, one review author (GM) searched the WHO ICTRP using the term 'stroke' on 8 August 2021 to identify any new trials registered after 7 July 2020 i.e. &gt; 1 year since last search. </p> </section> <section id="CD009286-sec-0025"> <h4 class="title">Searching other resources</h4> <p>In an effort to identify further published, unpublished and ongoing studies, we:</p> <p> <ul id="CD009286-list-0007"> <li> <p>searched reference lists of included trials and relevant reviews when full texts were retrieved for detailed scrutiny; </p> </li> <li> <p>contacted researchers in the field.</p> </li> </ul> </p> </section> </section> <section id="CD009286-sec-0026"> <h3 class="title" id="CD009286-sec-0026">Data collection and analysis</h3> <section id="CD009286-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Joshua Cheyne (Cochrane Stroke Group Information Specialist), ran the searches of CENTRAL, MEDLINE, Embase, CINAHL, AMED, and PsycINFO, and downloaded the resulting references into Reference Manager. These were imported into Covidence, which automatically removed some, but not all, of the duplicates. </p> <p>Any two review authors (from GM, EL, LAL, MK, SW, RT, A‐SR, LL,C‐FH, MH or XH) independently scrutinised the resulting titles and abstracts and excluded obviously irrelevant reports and duplicates. We obtained full texts of potentially eligible studies. Any two review authors (from GM, AB, EL, LAL, MK, SW, RT, A‐SR, LL C‐FH or XH) independently applied inclusion and exclusion criteria; if there was lack of consensus, a third review author (usually GM unless she had already scrutinised the paper) also applied inclusion and exclusion criteria. </p> <p>We include a flow diagram that includes the number of unique references identified by the searches, the number of records excluded after preliminary screening of titles and abstracts, the number of records retrieved in full text, and the number of studies fulfilling our inclusion criteria (<a href="#CD009286-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD009286-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flow diagram for this update" data-id="CD009286-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram for this update</p> </div> </div> </div> </section> <section id="CD009286-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>For the new eligible studies that we had identified, any two review authors (from GM, EL, LAL, MK, MH, SW, RT, LL, A‐SR, LL, C‐FH or XH) independently extracted data from each new study. </p> <p>We extracted the following data:</p> <p> <ul id="CD009286-list-0008"> <li> <p>the report: author, year and source of publication;</p> </li> <li> <p>the study: sample characteristics, social demography;</p> </li> <li> <p>the participants: stroke sequence (first‐ever versus recurrent), social situation, time since stroke onset, prior history of psychiatric illness, current neurological status, stroke severity, whether people with aphasia were recruited, the proportion with depression at baseline (if recorded by trialists), we did not extract information on location or size of lesion as this was unlikely to have been recorded by the trialists, and brain imaging often does not show a visible infarct in people with minor strokes; </p> </li> <li> <p>the research design and features: adherence, non‐response and length of follow‐up;</p> </li> <li> <p>the intervention: type, duration, dose, timing and mode of delivery;</p> </li> <li> <p>the effect size: sample size, nature of outcome, estimate and standard deviation (SD) (or standard error (SE)); </p> </li> <li> <p>source of funding.</p> </li> </ul> </p> <p>Methods in previous versions were broadly similar and are fully reported in previous versions (<a href="./references#CD009286-bbs2-0132" title="LeggLA , TilneyR , HsiehC , WuS , LundströmE , RudbergA , et al. Selective serotonin reuptake inhibitors for stroke recovery. Cochrane Database of Systematic Reviews2019, Issue 11. Art. No: CD009286. [DOI: 10.1002/14651858.CD009286.pub3]">Legg 2019</a>; <a href="./references#CD009286-bbs2-0157" title="MeadGE , HsiehCF , LeeR , KutlubaevMA , ClaxtonA , HankeyGJ , et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD009286. [DOI: 10.1002/14651858.CD009286.pub2]">Mead 2012</a>) </p> </section> <section id="CD009286-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed risks of bias using the Cochrane 'Risk of bias' tool (<a href="./references#CD009286-bbs2-0129" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Higgins 2017</a>). We assessed the methods used in each study to control for the following potential sources of bias: sequence generation (selection bias); allocation concealment (selection bias); blinding of participants, personnel and outcome assessors (performance and detection bias); incomplete outcome data (attrition bias); selective outcome reporting (reporting bias); and other potential threats to validity. </p> <p>Where there was a disagreement between the two review authors on risk of bias, a third review author (LAL, GM) reviewed the data and reached a consensus in discussion with the first two review authors. </p> <p>For incomplete outcome data, we categorised as 'low risk' if missing data were imputed using appropriate methods or if missing outcome data overall were less than 5%. For this update, we decided to categorise studies as low risk of bias if more than 5% of data were missing providing the number of participants with missing data was balanced between groups and the reasons for missing data were unrelated to treatment allocation. </p> <p>We extracted data on source of funding, and listed this under 'Other sources of bias'. If the source of funding was not given, or if there were links with the pharmaceutical industry and no explicit statement that the funder had no input into the design or analysis of the study, we classified this as 'unclear risk'. We also recorded any other potential threats to validity. </p> <p>We also extracted data on how adverse effects were reported, and listed these in the descriptions of the studies. </p> <p>If a study author was also one of the review authors, a review author who was not involved in the study extracted data and assessed quality. </p> <p>For this 2021 update, we contacted study authors to obtain more information to enable us to make judgements about risk of bias if this was unclear from the paper, AND if this was going to influence whether a study was categorised as low risk of bias across all seven domains i.e. changing a judgement of 'uncertain' to 'low risk' of bias. </p> </section> <section id="CD009286-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous data, we reported risk ratios (RRs). For ordinal scales, where there was a well‐recognised cut‐point in the scale (e.g. mRS) we analysed the data as a dichotomous outcome (dependent or independent). </p> <p>For ordinal scales with no recognised cut‐point, we analysed the data as continuous data. The data required for meta‐analyses of continuous data in Review Manager 5 are means and standard deviations (SDs) (<a href="./references#CD009286-bbs2-0143" title="The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. The Cochrane Collaboration, 2020.">Review Manager 2014</a>). When extracting continuous data from the study reports, we checked whether trials reported the SD or the standard error (SE). We had planned to use the SE or 95% confidence interval (CI) to compute the SD when SDs were missing, but this was not needed as all the trials reported SDs. </p> <p>For ordinal scales and continuous data, we calculated standardised mean differences (SMDs), because different scales were used for the same outcomes (e.g. Barthel Index (BI) and Funtional Independence Measure (FIM) for disability score, the Beck Depression Inventory (BDI) or the Hamilton Rating Scale for Depression (HAMD) for depression). The SMD does not correct for differences in the direction of the scale. Some scales increase with disease severity and others decrease, so we multiplied the mean value from one set of trials by −1. For example, in the National Institute of Health Stroke Scale (NIHSS), a low score indicates a less severe stroke, whilst a low score in the Scandinavian Stroke Scale (SSS) indicates a more severe stroke. </p> <p>If there was more than one outcome measure in the same domain (e.g. two different depression scales), we made a post‐hoc decision to select the one with the most complete data. </p> </section> <section id="CD009286-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The number of observations in the analysis should match the number of 'units' that were randomised. We considered outcomes measured at the end of treatment and at the end of follow‐up in separate analyses. For side effects, we considered the number of participants developing a specified side effect rather than the total number of side effects in each group. </p> </section> <section id="CD009286-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>For this update, we contacted authors of new trials to obtain any data that we needed for our meta‐analysis that had not been included in a published full‐text article or an abstract. </p> <p>Note that for some analyses, the sample size is slightly different for different outcomes, this is because of the missing responses for some outcomes. </p> </section> <section id="CD009286-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed whether there was evidence of inconsistency in our results by considering possible clinical, methodological, and statistical heterogeneity. We assessed clinical and methodological heterogeneity by comparing similarities in our included studies between study designs, participants, interventions, and outcomes. </p> <p>We quantified the effect of heterogeneity using the I<sup>2</sup> statistic. We assessed statistical heterogeneity by visually examining forest plots. Thresholds for the interpretation of the I<sup>2</sup> statistic can be misleading, since the importance of inconsistency depends on several factors. A rough guide to interpretation in the context of meta‐analyses of randomised trials is as follows: (Section 9.5.2; <a href="./references#CD009286-bbs2-0123" title="DeeksJJ , HigginsJP , AltmanDG , editors. Chapter 10 : Analysing data and performing metaanalyses. In: Higgins JP , Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al( editor s) . ) , Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021) Cochrane 2021. Available at www.training.cochrane.org/handbook.">Deeks 2021</a>): </p> <p> <ul id="CD009286-list-0009"> <li> <p>0% to 40% is not considered important;</p> </li> <li> <p>30% to 60% suggests moderate heterogeneity;</p> </li> <li> <p>50% to 90% suggests substantial heterogeneity;</p> </li> <li> <p>75% to 100% is considerable heterogeneity.</p> </li> </ul> </p> </section> <section id="CD009286-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We searched clinical trials registers to identify published protocols for each of our included studies. We checked for selective reporting of results by comparing the published protocol with the published full‐text article and by scrutinising the aims and methods of the trials and comparing these with outcomes reported. We found several papers by the same authors, and contacted the authors to check whether the publications were duplicates or to check if the included study populations were unique. If it was not possible to determine whether different publications reported overlapping groups of participants, we included just one of the papers and listed the others as awaiting assessment. </p> <p>If we had identified a sufficient number of included studies at low risk of bias (i.e. more than 10 studies (<a href="./references#CD009286-bbs2-0148" title="SterneJA , EggerM , MoherD , BoutronI , editor(s). Chapter 10: Addressing reporting biases. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Sterne 2017</a>), we would have generated a funnel plot of low risk of bias studies, to assess risk of publication bias, an asymmetrical funnel plot might have suggested publication of only positive results (<a href="./references#CD009286-bbs2-0124" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315(7109):629-34.">Egger 1997</a>). We made a post‐hoc decision to perform a funnel plot for all studies, irrespective of risk of bias, for the co‐primary outcome of disability. </p> <p>We deployed a comprehensive search strategy in an effort to avoid reporting biases in our review methodology. See <a href="#CD009286-sec-0023">Search methods for identification of studies</a>. </p> <p>We tried to avoid language bias by including all trials, irrespective of language: we sought translation where needed. </p> </section> <section id="CD009286-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We completed meta‐analysis of outcomes for which we had comparable effect measures from more than one study, and when measures of heterogeneity indicated that pooling of results was appropriate. We used the statistical calculator provided in Review Manager 5 to perform meta‐analysis (<a href="./references#CD009286-bbs2-0143" title="The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. The Cochrane Collaboration, 2020.">Review Manager 2014</a>). </p> <p>We used a fixed‐effect model (<a href="./references#CD009286-bbs2-0136" title="MantelN , HaenszelW . Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute1959;22(4):719-48.">Mantel 1959</a>), rather than a random‐effects model because of the dominance of the three largest trials (<a href="./references#CD009286-bbs2-0002" title="ACTRN12611000774921. Assessment of fluoxetine in stroke recovery (AFFINITY) trial, 2011. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000774921 (first received 22 July 2011). ACTRN12619000986178. The assessment of fluoxetine in stroke recovery imaging and blood biomarkers sub-study AFFINITY BM. www.anzctr.org.au/Trial/Registration/TrialReview.aspx ?ACTRN=12619000986178 (first received 11 July 2019). AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):651-60. HankeyG . Assessment oF FluoxetINe In sTroke recoverY (AFFINITY). www.affinitytrial.org/ (accessed 19th February 2019). ">AFFINITY 2020</a>, <a href="./references#CD009286-bbs2-0021" title="EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661-9. ISRCTN13020412. Establishing the effect(s) and safety of fluoxetine initiated in the acute phase of stroke. www.isrctn.com/ISRCTN13020412 (first received 19 December 2014). LundströmE , IsakssonE , NäsmanP , WesterP , MårtenssonB , NorrvingB . Correction to: Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(388):s13063-020-04327-w. LundströmE , IsakssonE , Näsman P et al. Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(233):s13063-020-4124-7. LundstromE , IsakssonE , NasmanP , WesterP , MartenssonB , NorrvingB , et al. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661‐9. ">EFFECTS 2020</a>; <a href="./references#CD009286-bbs2-0023" title="Anonymous. The FOCUS (Fluoxetine or Control under Supervision) trial results: effects of a 6 month course of fluoxetine on the Stroke Impact Scale, mood and fatigue in patients with stroke. www.ed.ac.uk/clinical-brain-sciences/research/completed-studies-trials/focus-stroke-trial (accessed 12 02 2021). CookR , ThomasV , MartinR . Does fluoxetine improve recovery after stroke?BMJ2019;364:1029. DennisM , ForbesJ , GrahamC , HackettM , HankeyGJ , HouseA , et al. Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT. Health Technology Assessment2020;24(22):1-94. DennisM , ForbesJ , GrahamC , HackettML , HankeyGJ , HouseA , et al. Fluoxetine and fractures after stroke: exploratory analyses from the FOCUS Trial. Stroke2019;50(11):3280-2. FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet2019;393(10168):265-74. GrahamC , LewisS , ForbesJ , MeadG , HackettML , HankeyGJ , et al. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. Trials2017;18(1):627. LundstromE , DennisM , MeadG . The effects of fluoxetine on fracture risk after stroke: Further analyses from the focus trial. European Stroke Journal2019;4 suppl 1:7142019. MeadG , DennisM . Feasibility of reporting results of large randomised controlled trials to participants: experience from the Fluoxetine or Control under Supervision (FOCUS) trial. BMJ Open2020;10(11):e0404922020. MeadG . Fluoxetine Or Control Under Supervision (FOCUS) trial: to establish the effect(s) of routine administration of Fluoxetine in patients with a recent stroke. www.isrctn.com/ISRCTN83290762 (first received 23 May 2012). MeadGE , DennisMS , InnesK , MacLeodM , SandercockPA , HouseA , et al. A multicentre randomised trial to establish the effect(s) of routine administration of fluoxetine in patients with a recent stroke (Fluoxetine Or Control Under Supervision, FOCUS). In: 21st European Stroke Conference. 2012:Abst OAID 26. MeadGE , GrahamC , BillotL , NäsmanP , LundströmE , LewisS , on behalf of the FOCUS , AFFINITY and EFFECTS trialists. Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis. Trials2020;21(1):971. MeadGE , LeggL , TilneyR , HsiehCF , WuS , LundströmE , et al. Fluoxetine for stroke recovery: meta-analysis of randomized controlled trials. International Journal of Stroke2020;15(4):365-76. ">FOCUS 2019</a>); random effects would have given too much weight to the smaller trials. The dominance of the three large trials makes a fixed‐effect model a more reliable indicator of the effect than the average across the smaller trials. We assessed the robustness of the results to choice of model using a sensitivity analysis for our primary outcomes. </p> <p>In the initial 2012 review, we had performed multiple meta‐analyses of all the primary and secondary outcomes, included all trials irrespective of risk of bias, and then explored the influence of each aspect of bias on estimates of effects in a series of sensitivity analyses. </p> <p>In the 2019 review we limited our analyses of all outcome measures to studies at low risk of bias (<a href="./references#CD009286-bbs2-0129" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Higgins 2017</a>), as we wanted reliable data, not confounded by bias, to find out whether SSRIs were more effective than placebo or usual care at improving a range of important outcomes. Also, had we included all studies, irrespective or risk of bias, for all available outcomes, the number of analyses would have become unmanageable within the resources we had. However, in the 2019 review, we performed a sensitivity analysis by using data on our two primary outcomes (disability and independence) from all trials, irrespective of risk of bias. For this current update, we use the same approach. </p> <p>We reached decisions on overall risk of bias by study by consideration of six risk of bias domains: sequence generation, allocation concealment, blinding of participants and trial personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting and other risk of bias. We required a study to have a judgement of low risk of bias in all domains in order to categorise it as having an overall low risk of bias. </p> </section> <section id="CD009286-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If there had been at least two studies at low risk of bias across all six domains of risk of bias, we would have explored variability in the participants, interventions, and outcomes among studies using the following subgroups. </p> <p> <ul id="CD009286-list-0010"> <li> <p>Type of SSRI.</p> </li> <li> <p>Studies with depression at baseline as an inclusion criterion and those where depression was not an inclusion criterion. </p> </li> <li> <p>Time since stroke at recruitment. We categorised these as less than three months (0 ‐ 90 days), three to six months (91 to 108 days), six to nine months (181 to 271 days) or nine to 12 months (272 to 365 days). </p> </li> </ul> </p> <p>Finding high statistical heterogeneity (I<sup>2</sup> &gt; 50%) would not have prevented us from performing a subgroup analysis, rather we would have considered the reason for this heterogeneity. </p> <p>We did not perform subgroup analyses by type of SSRI or time since stroke as all studies included in the main analyses were similar with regard to these characteristics. </p> </section> <section id="CD009286-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We explored the potential effects of decisions made as part of the review process as follows. </p> <p> <ul id="CD009286-list-0011"> <li> <p>We included all studies regardless of risk of bias judgement for our primary outcomes of disability score and independence. </p> </li> <li> <p>We conducted meta‐analysis using the alternate meta‐analytical effects model (fixed‐effect or random‐effects) for just those studies at low risk of bias across all six domains. </p> </li> <li> <p>We intended to conduct a meta‐analysis using the alternate 'last available follow‐up' time point if studies had reported more than one follow‐up after the end of treatment, but none of the included studies did this. </p> </li> <li> <p>We compared effect estimates from the above results with effect estimates from the main analysis. We reported differences that altered the interpretation of effects. </p> </li> </ul> </p> </section> <section id="CD009286-sec-0038"> <h4 class="title">Summary of findings and assessment of the quality of the evidence</h4> <p>We created a summary of findings table using the following outcomes: disability; dependent according to the mRS; neurological deficit score; depression (continuous data); death; seizures; and gastrointestinal side effects (<a href="./full#CD009286-tbl-0001">summary of findings Table 1</a>). We chose these outcomes as they are of high clinical relevance. We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence as it relates to the studies that contribute data to the meta‐analyses for the prespecified outcomes (<a href="https://archie.cochrane.org/sections/documents/view?version=z1801171616374433821300534839850&amp;format=REVMAN#REF-Atkins-2004" target="_blank">Atkins 2004</a>). We used methods and recommendations described in Chapter 11 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009286-bbs2-0146" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , AklE , Guyatt GH on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Completing ‘Summary of findings’ tables and grading the confidence in or quality of the evidence. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Schünemann 2017</a>), using GRADEproGDT software (<a href="./references#CD009286-bbs2-0127" title="McMaster University (developed by Evidence Prime, Inc.)GRADEpro Guideline Development Tool [Software]. McMaster University (developed by Evidence Prime, Inc.), 2015.">GRADEproGDT 2015</a>). We justified all decisions to downgrade the quality of studies using footnotes, and made comments to aid the reader's understanding of the review where necessary. </p> </section> <section id="CD009286-sec-0039"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created a 'Summary of findings' table using the following outcomes: disability; dependent according to the mRS; neurological deficit score; depression (continuous data); death; seizures; and gastrointestinal side effects (<a href="./full#CD009286-tbl-0001">summary of findings Table 1</a>). We chose these outcomes as they are of high clinical relevance. We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence as it relates to the studies that contribute data to the meta‐analyses for the prespecified outcomes (<a href="https://archie.cochrane.org/sections/documents/view?version=z1801171616374433821300534839850&amp;format=REVMAN#REF-Atkins-2004" target="_blank">Atkins 2004</a>). We used methods and recommendations described in Chapter 11 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009286-bbs2-0146" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , AklE , Guyatt GH on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Completing ‘Summary of findings’ tables and grading the confidence in or quality of the evidence. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Schünemann 2017</a>), using GRADEproGDT software (<a href="./references#CD009286-bbs2-0127" title="McMaster University (developed by Evidence Prime, Inc.)GRADEpro Guideline Development Tool [Software]. McMaster University (developed by Evidence Prime, Inc.), 2015.">GRADEproGDT 2015</a>). We justified all decisions to downgrade the quality of studies using footnotes, and made comments to aid the reader's understanding of the review where necessary. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009286-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009286-sec-0040"></div> <section id="CD009286-sec-0041"> <h3 class="title">Description of studies</h3> <p>For substantive descriptions of studies see: <a href="./references#CD009286-sec-0116" title="">Characteristics of included studies</a>, <a href="./references#CD009286-sec-0117" title="">Characteristics of excluded studies</a>, <a href="./references#CD009286-bbs1-0003" title="">Studies awaiting classification</a><a href="http://onlinelibrary.wiley.com/enhanced/doi/10.1002/14651858.CD000197.pub3#CD000197-sec2-0023" target="_blank">, and Characteristics of ongoing studies</a>. </p> <section id="CD009286-sec-0042"> <h4 class="title">Results of the search</h4> <p>For this update, we screened 221 references from database searches and accessed the available full‐text reports for 10 6 studies.  This included a systematic review from which we identified five new studies from China (<a href="./references#CD009286-bbs2-0016" title="ChenZ , XuX , WuY , HuangL . Clinical efficacy of drug intervention in patients with acute depression after stroke. International Journal of Psychiatry2015;42(5):97-100. ">Chen 2015</a>; <a href="./references#CD009286-bbs2-0033" title="HuH , WangM . Effects of escitalopram on post-stroke depression and cognitive function of patients with neurological function. Hebei Medicine2018;24(2):325-8. ">Hu 2018</a>; <a href="./references#CD009286-bbs2-0043" title="LiZ . Clinical efficacy of paroxetine in the treatment of post-stroke depression. Modern Journal of Integrated Traditional Chinese and Western Medicine2007;16(34):5103-4. ">Li 2007</a>; <a href="./references#CD009286-bbs2-0045" title="LiJ , WangJ , LiY , ZhangW , ZhaoJ . Effects of escitalopram oxalate on post-stroke depression, cognition and neurological function. Journal of Hebei Medical University2017;38(5):589-92. ">Li 2017</a>; <a href="./references#CD009286-bbs2-0066" title="WangX . The efficacy of paroxetine in the treatment of post-stroke depression in 55 cases. Chinese Community Physician (Medical Professional Half-monthly)2009;11(7):11. ">Wang 2009</a>).  </p> <p>As a final check for new studies, WHO ICTRP was searched by one review author (GM) on 8 August 2021 and 1600 citations screened. </p> <p>The flow diagram is shown in <a href="#CD009286-fig-0001">Figure 1</a>. This includes the results of the August 2021 search of the WHO ICTRP.  </p> <p>The 2019  version of this review (<a href="./references#CD009286-bbs2-0132" title="LeggLA , TilneyR , HsiehC , WuS , LundströmE , RudbergA , et al. Selective serotonin reuptake inhibitors for stroke recovery. Cochrane Database of Systematic Reviews2019, Issue 11. Art. No: CD009286. [DOI: 10.1002/14651858.CD009286.pub3]">Legg 2019</a>), identified 63 completed studies recruiting 9168 stroke survivors within one year of their stroke; and 16 ongoing studies (<a href="./references#CD009286-bbs2-0002" title="ACTRN12611000774921. Assessment of fluoxetine in stroke recovery (AFFINITY) trial, 2011. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000774921 (first received 22 July 2011). ACTRN12619000986178. The assessment of fluoxetine in stroke recovery imaging and blood biomarkers sub-study AFFINITY BM. www.anzctr.org.au/Trial/Registration/TrialReview.aspx ?ACTRN=12619000986178 (first received 11 July 2019). AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):651-60. HankeyG . Assessment oF FluoxetINe In sTroke recoverY (AFFINITY). www.affinitytrial.org/ (accessed 19th February 2019). ">AFFINITY 2020</a>; <a href="./references#CD009286-bbs2-0006" title="AsadollahiM , RamezaniM , KhanmoradiZ , KarimialavijehE . The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial. Clinical Rehabilitation2018;32(8):1069-75. ">Asadollahi 2018</a>; <a href="./references#CD009286-bbs2-0007" title="BembenekJP , NiewadaM , KlyszB , MazurA , KurczychK , GluszkiewiczM , et al. Fluoxetine for stroke recovery improvement - the doubleblind, randomised placebo-controlled FOCUS-Poland trial. Neurologia i Neurochirurgia Polska2020;54(6):544-51. Fluoxetine or control under supervision: Poland. Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products - EduraCT No: 2014-001335-372014. ">Bembenek 2020</a>; <a href="./references#CD009286-bbs2-0020" title="DikeF . Pharmacological enhancement of motor function recovery in patients with ischaemic stroke: a trial of fluoxetine. www.pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=967 (last accessed 16 February 2021). DikeFO , EkehBC , OgunAS , EkrikpoEU , WalshakP , OgunniyAA . Pharmacological enhancement of motor function recovery in patients with ischaemic stroke: a trial of fluoxetine. Journal of Neurology and Stroke2019;9(1):47-51. ">Dike 2019</a>; <a href="./references#CD009286-bbs2-0021" title="EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661-9. ISRCTN13020412. Establishing the effect(s) and safety of fluoxetine initiated in the acute phase of stroke. www.isrctn.com/ISRCTN13020412 (first received 19 December 2014). LundströmE , IsakssonE , NäsmanP , WesterP , MårtenssonB , NorrvingB . Correction to: Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(388):s13063-020-04327-w. LundströmE , IsakssonE , Näsman P et al. Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(233):s13063-020-4124-7. LundstromE , IsakssonE , NasmanP , WesterP , MartenssonB , NorrvingB , et al. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661‐9. ">EFFECTS 2020</a>; <a href="./references#CD009286-bbs2-0111" title="EudraCT 2005-005266-37. Influence of escitalopram on the incidence of depression and dementia following acute middle cerebral artery territory infarction. A randomised placebo-controlled double blind study. www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005266-37 (first received 7 April 2006). ">EudraCT 2005‐005266‐37</a>; <a href="./references#CD009286-bbs2-0084" title="Bonin PintoC , Morales-QuezadaL , deToledo PizaPV , ZengD , Saleh VélezFG , FerreiraIS , et al. Combining fluoxetine and rTMS in poststroke motor recovery: a placebo-controlled double-blind randomized phase 2 clinical trial. Neurorehabilitation and Neural Repair2019;33:643-55. [DOI: 10.1177/1545968319860483.]NCT02208466. Effects rTMS combined with fluoxetine on motor recovery in stroke patients. www.clinicaltrials.gov/ct2/show/NCT02208466 (first received 5 August 2014). ">Bonin Pinto 2019</a> ; <a href="./references#CD009286-bbs2-0112" title="IRCT201112228490N1. Effect of fluoxetine on functional recovery of patients with cerebrovascular accident following middle cerebral artery trunk obstruction: a randomized clinical trial. www.en.irct.ir/trial/8954 (first received 25 January 2012). ">IRCT201112228490N1</a>; <a href="./references#CD009286-bbs2-0113" title="IRCT2012101011062N1. A study of sertraline effect on quality of life in stroke inpatients. www.en.irct.ir/trial/11413 (first received 28 November 2012). ">IRCT2012101011062N1</a>; <a href="./references#CD009286-bbs2-0114" title="IRCT2017041720258N37. Evaluation of fluoxetine and standard treatment efficacy on change to side effect of stroke of ischemic strokes in both hemispheres in anterior circulation. www.irct.ir/trial/17976 (first received 11 October 2017). ">IRCT2017041720258N37</a>; <a href="./references#CD009286-bbs2-0116" title="NCT02386475. Effect of serotonin and levodopa in ischemic stroke. www.clinicaltrials.gov/ct2/show/NCT02386475 (first received 12 March 2015). ">NCT02386475</a>; <a href="./references#CD009286-bbs2-0053" title="NCT02737930. Fluoxetine for visual recovery after ischaemic stroke (FLUORESCE). www.clinicaltrials.gov/ct2/show/NCT02737930 (first received 14 April 2016). ">NCT02737930</a>; <a href="./references#CD009286-bbs2-0117" title="NCT02767999. Serotonin Selective Reuptake Inhibitor (SSRI) effects on cerebral connectivity in acute ischemic stroke (RECONISE). www.clinicaltrials.gov/ct2/show/NCT02767999 (first received 11 May 2016). ">NCT02767999</a>; <a href="./references#CD009286-bbs2-0118" title="NCT02865642. Cortical ischemic stroke and serotonin (CISS). www.clinicaltrials.gov/ct2/show/NCT02865642 (first received 12 August 2016). ">NCT02865642</a>; <a href="./references#CD009286-bbs2-0119" title="NCT03448159. Fluoxetine Opens Window to improve motor recovery after stroke (FLOW). www.clinicaltrials.gov/ct2/show/NCT03448159 (first received 27 February 2018). ">NCT03448159</a>; <a href="./references#CD009286-bbs2-0120" title="NCT03826875. Depression in hemorrhagic stroke. www.clinicaltrials.gov/ct2/show/NCT03826875 (first received 1 February 2019). ">NCT03826875</a>).   </p> <p>Of these 16 previously ongoing studies, six have now been published (<a href="./references#CD009286-bbs2-0002" title="ACTRN12611000774921. Assessment of fluoxetine in stroke recovery (AFFINITY) trial, 2011. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000774921 (first received 22 July 2011). ACTRN12619000986178. The assessment of fluoxetine in stroke recovery imaging and blood biomarkers sub-study AFFINITY BM. www.anzctr.org.au/Trial/Registration/TrialReview.aspx ?ACTRN=12619000986178 (first received 11 July 2019). AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):651-60. HankeyG . Assessment oF FluoxetINe In sTroke recoverY (AFFINITY). www.affinitytrial.org/ (accessed 19th February 2019). ">AFFINITY 2020</a>; <a href="./references#CD009286-bbs2-0006" title="AsadollahiM , RamezaniM , KhanmoradiZ , KarimialavijehE . The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial. Clinical Rehabilitation2018;32(8):1069-75. ">Asadollahi 2018</a>; <a href="./references#CD009286-bbs2-0007" title="BembenekJP , NiewadaM , KlyszB , MazurA , KurczychK , GluszkiewiczM , et al. Fluoxetine for stroke recovery improvement - the doubleblind, randomised placebo-controlled FOCUS-Poland trial. Neurologia i Neurochirurgia Polska2020;54(6):544-51. Fluoxetine or control under supervision: Poland. Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products - EduraCT No: 2014-001335-372014. ">Bembenek 2020</a>; <a href="./references#CD009286-bbs2-0020" title="DikeF . Pharmacological enhancement of motor function recovery in patients with ischaemic stroke: a trial of fluoxetine. www.pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=967 (last accessed 16 February 2021). DikeFO , EkehBC , OgunAS , EkrikpoEU , WalshakP , OgunniyAA . Pharmacological enhancement of motor function recovery in patients with ischaemic stroke: a trial of fluoxetine. Journal of Neurology and Stroke2019;9(1):47-51. ">Dike 2019</a>; <a href="./references#CD009286-bbs2-0021" title="EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661-9. ISRCTN13020412. Establishing the effect(s) and safety of fluoxetine initiated in the acute phase of stroke. www.isrctn.com/ISRCTN13020412 (first received 19 December 2014). LundströmE , IsakssonE , NäsmanP , WesterP , MårtenssonB , NorrvingB . Correction to: Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(388):s13063-020-04327-w. LundströmE , IsakssonE , Näsman P et al. Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(233):s13063-020-4124-7. LundstromE , IsakssonE , NasmanP , WesterP , MartenssonB , NorrvingB , et al. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661‐9. ">EFFECTS 2020</a>;  <a href="./references#CD009286-bbs2-0084" title="Bonin PintoC , Morales-QuezadaL , deToledo PizaPV , ZengD , Saleh VélezFG , FerreiraIS , et al. Combining fluoxetine and rTMS in poststroke motor recovery: a placebo-controlled double-blind randomized phase 2 clinical trial. Neurorehabilitation and Neural Repair2019;33:643-55. [DOI: 10.1177/1545968319860483.]NCT02208466. Effects rTMS combined with fluoxetine on motor recovery in stroke patients. www.clinicaltrials.gov/ct2/show/NCT02208466 (first received 5 August 2014). ">Bonin Pinto 2019</a>); we excluded one of these at it recruited patients within two years (not one year) of stroke (<a href="./references#CD009286-bbs2-0084" title="Bonin PintoC , Morales-QuezadaL , deToledo PizaPV , ZengD , Saleh VélezFG , FerreiraIS , et al. Combining fluoxetine and rTMS in poststroke motor recovery: a placebo-controlled double-blind randomized phase 2 clinical trial. Neurorehabilitation and Neural Repair2019;33:643-55. [DOI: 10.1177/1545968319860483.]NCT02208466. Effects rTMS combined with fluoxetine on motor recovery in stroke patients. www.clinicaltrials.gov/ct2/show/NCT02208466 (first received 5 August 2014). ">Bonin Pinto 2019</a>). One trial which we had previously listed as 'excluded' has been moved to our list of included studies; this study recruited only 17 patients and was terminated due to slow recruitment and lack of funding to expand to other sites (<a href="./references#CD009286-bbs2-0053" title="NCT02737930. Fluoxetine for visual recovery after ischaemic stroke (FLUORESCE). www.clinicaltrials.gov/ct2/show/NCT02737930 (first received 14 April 2016). ">NCT02737930</a>). </p> <p>Based on information provided in trials registers: we found the following.        </p> <p> <ul id="CD009286-list-0012"> <li> <p>Five of these previously ongoing studies are still ongoing: <a href="./references#CD009286-bbs2-0111" title="EudraCT 2005-005266-37. Influence of escitalopram on the incidence of depression and dementia following acute middle cerebral artery territory infarction. A randomised placebo-controlled double blind study. www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005266-37 (first received 7 April 2006). ">EudraCT 2005‐005266‐37</a>, <a href="./references#CD009286-bbs2-0117" title="NCT02767999. Serotonin Selective Reuptake Inhibitor (SSRI) effects on cerebral connectivity in acute ischemic stroke (RECONISE). www.clinicaltrials.gov/ct2/show/NCT02767999 (first received 11 May 2016). ">NCT02767999</a>, <a href="./references#CD009286-bbs2-0118" title="NCT02865642. Cortical ischemic stroke and serotonin (CISS). www.clinicaltrials.gov/ct2/show/NCT02865642 (first received 12 August 2016). ">NCT02865642</a>, <a href="./references#CD009286-bbs2-0119" title="NCT03448159. Fluoxetine Opens Window to improve motor recovery after stroke (FLOW). www.clinicaltrials.gov/ct2/show/NCT03448159 (first received 27 February 2018). ">NCT03448159</a>, <a href="./references#CD009286-bbs2-0120" title="NCT03826875. Depression in hemorrhagic stroke. www.clinicaltrials.gov/ct2/show/NCT03826875 (first received 1 February 2019). ">NCT03826875</a>. </p> </li> <li> <p>There are no results for <a href="./references#CD009286-bbs2-0112" title="IRCT201112228490N1. Effect of fluoxetine on functional recovery of patients with cerebrovascular accident following middle cerebral artery trunk obstruction: a randomized clinical trial. www.en.irct.ir/trial/8954 (first received 25 January 2012). ">IRCT201112228490N1</a>; the authors were contacted on 20 April 2021 but no response was received; this trial is also listed as ongoing. </p> </li> <li> <p>Three studies are completed but the results are not yet available; these are still listed as ongoing (<a href="./references#CD009286-bbs2-0113" title="IRCT2012101011062N1. A study of sertraline effect on quality of life in stroke inpatients. www.en.irct.ir/trial/11413 (first received 28 November 2012). ">IRCT2012101011062N1</a>; <a href="./references#CD009286-bbs2-0114" title="IRCT2017041720258N37. Evaluation of fluoxetine and standard treatment efficacy on change to side effect of stroke of ischemic strokes in both hemispheres in anterior circulation. www.irct.ir/trial/17976 (first received 11 October 2017). ">IRCT2017041720258N37</a>; <a href="./references#CD009286-bbs2-0116" title="NCT02386475. Effect of serotonin and levodopa in ischemic stroke. www.clinicaltrials.gov/ct2/show/NCT02386475 (first received 12 March 2015). ">NCT02386475</a>). </p> </li> </ul> </p> <p>Our January 2021 searches identified two new completed studies (<a href="./references#CD009286-bbs2-0011" title="CaoJX , LiuL , SunYT , ZengQH , WangY , ChenJC . Effects of the prophylactic use of escitalopram on the prognosis and the plasma copeptin level in patients with acute cerebral infarction. Brazilian Journal of Medical and Biological Research2020;53(11):e8930. CaoJX , LiuL , SunYT , ZengQH , YangZD , ChenJC . Escitalopram improves neural functional prognosis and endothelial dysfunction in patients with acute cerebral infarction. Restorative Neurology and Neuroscience2020;38(5):385-93. ">Cao 2020</a>; <a href="./references#CD009286-bbs2-0027" title="GongL , YangX , FengY , FeiZ , WangM , QinB , et al. The efficacy of integrative anti-depressive therapy on motor recovery after ischemic stroke: a randomized clinical trial. European Journal of Integrative Medicine2020;35:101102. ">Gong 2020</a>) and three new ongoing studies (<a href="./references#CD009286-bbs2-0109" title="ChiCTR1800019467. The effect and mechanism of fluoxetine on the automatic regulation of cerebral blood flow for ischemic stroke. https://www.chictr.org.cn/showprojen.aspx?proj=32801. ">ChiCTR1800019467</a>; <a href="./references#CD009286-bbs2-0110" title="CTRI/2018/12/016568. An interventional study to look at efficacy of fluoxetine in patients with post-stroke anxiety. http://ctri.nic.in CTRI/2018/12/016568 (first received 10 December 2018). ">CTRI/2018/12/016568</a>; <a href="./references#CD009286-bbs2-0121" title="TCTR20181216001. Randomized controlled trial of fluoxetine or placebo on quality of life after acute ischemic stroke. www.thaiclinicaltrials.org/show/TCTR20181216001 (first received 16 December 2018). ">TCTR20181216001</a>). An additional study identified in the January 2021 searches did not start due to the COVID 19 pandemic (<a href="./references#CD009286-bbs2-0077" title="ACTRN12619000573156. FRAMBOISE: Fluoxetine, Recovery And Motor BiOmarkers In StrokE. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=377306 (first received 11 April 2019). ">ACTRN12619000573156</a>). </p> <p>The flow of search results for the previous version of the review are reported in <a href="./references#CD009286-bbs2-0132" title="LeggLA , TilneyR , HsiehC , WuS , LundströmE , RudbergA , et al. Selective serotonin reuptake inhibitors for stroke recovery. Cochrane Database of Systematic Reviews2019, Issue 11. Art. No: CD009286. [DOI: 10.1002/14651858.CD009286.pub3]">Legg 2019</a>. We report details of the search for this update in a PRISMA flow chart  (<a href="#CD009286-fig-0001">Figure 1</a>). This includes our additional searches of WHO ICTRP on 8 August 2021, to identify any new ongoing studies, where we used the broad search term 'STROKE' which identified 1600 records, of which two records which were scrutinised in detail; one of these is now included as an ongoing study (<a href="./references#CD009286-bbs2-0115" title="IRCT20210307050617N1. The efficacy comparison of fluoxetine and citalopram on motor recovery after ischemic stroke: single-blind placebo-controlled randomized clinical trial. https://en.irct.ir/trial/54896 (first received 27 March 2021). ">IRCT20210307050617N1</a>).   </p> </section> <section id="CD009286-sec-0043"> <h4 class="title">Included studies</h4> <p>In the previous version of the review (<a href="./references#CD009286-bbs2-0132" title="LeggLA , TilneyR , HsiehC , WuS , LundströmE , RudbergA , et al. Selective serotonin reuptake inhibitors for stroke recovery. Cochrane Database of Systematic Reviews2019, Issue 11. Art. No: CD009286. [DOI: 10.1002/14651858.CD009286.pub3]">Legg 2019</a>), there were 63 included studies recruiting a total of 9168 randomised participants. One study had previously been included in the list of excluded studies, but for this review we included it in our list of included studies as it now reports having recruited 17 participants although the results are not available (<a href="./references#CD009286-bbs2-0053" title="NCT02737930. Fluoxetine for visual recovery after ischaemic stroke (FLUORESCE). www.clinicaltrials.gov/ct2/show/NCT02737930 (first received 14 April 2016). ">NCT02737930</a>). </p> <p>For the current 2021 update, we identified a further 12 completed studies providing data for meta‐analysis and recruiting a total of 3845 more participants (<a href="./references#CD009286-bbs2-0002" title="ACTRN12611000774921. Assessment of fluoxetine in stroke recovery (AFFINITY) trial, 2011. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000774921 (first received 22 July 2011). ACTRN12619000986178. The assessment of fluoxetine in stroke recovery imaging and blood biomarkers sub-study AFFINITY BM. www.anzctr.org.au/Trial/Registration/TrialReview.aspx ?ACTRN=12619000986178 (first received 11 July 2019). AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):651-60. HankeyG . Assessment oF FluoxetINe In sTroke recoverY (AFFINITY). www.affinitytrial.org/ (accessed 19th February 2019). ">AFFINITY 2020</a>; <a href="./references#CD009286-bbs2-0006" title="AsadollahiM , RamezaniM , KhanmoradiZ , KarimialavijehE . The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial. Clinical Rehabilitation2018;32(8):1069-75. ">Asadollahi 2018</a>; <a href="./references#CD009286-bbs2-0007" title="BembenekJP , NiewadaM , KlyszB , MazurA , KurczychK , GluszkiewiczM , et al. Fluoxetine for stroke recovery improvement - the doubleblind, randomised placebo-controlled FOCUS-Poland trial. Neurologia i Neurochirurgia Polska2020;54(6):544-51. Fluoxetine or control under supervision: Poland. Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products - EduraCT No: 2014-001335-372014. ">Bembenek 2020</a>; <a href="./references#CD009286-bbs2-0011" title="CaoJX , LiuL , SunYT , ZengQH , WangY , ChenJC . Effects of the prophylactic use of escitalopram on the prognosis and the plasma copeptin level in patients with acute cerebral infarction. Brazilian Journal of Medical and Biological Research2020;53(11):e8930. CaoJX , LiuL , SunYT , ZengQH , YangZD , ChenJC . Escitalopram improves neural functional prognosis and endothelial dysfunction in patients with acute cerebral infarction. Restorative Neurology and Neuroscience2020;38(5):385-93. ">Cao 2020</a>; <a href="./references#CD009286-bbs2-0016" title="ChenZ , XuX , WuY , HuangL . Clinical efficacy of drug intervention in patients with acute depression after stroke. International Journal of Psychiatry2015;42(5):97-100. ">Chen 2015</a>; <a href="./references#CD009286-bbs2-0020" title="DikeF . Pharmacological enhancement of motor function recovery in patients with ischaemic stroke: a trial of fluoxetine. www.pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=967 (last accessed 16 February 2021). DikeFO , EkehBC , OgunAS , EkrikpoEU , WalshakP , OgunniyAA . Pharmacological enhancement of motor function recovery in patients with ischaemic stroke: a trial of fluoxetine. Journal of Neurology and Stroke2019;9(1):47-51. ">Dike 2019</a>; <a href="./references#CD009286-bbs2-0021" title="EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661-9. ISRCTN13020412. Establishing the effect(s) and safety of fluoxetine initiated in the acute phase of stroke. www.isrctn.com/ISRCTN13020412 (first received 19 December 2014). LundströmE , IsakssonE , NäsmanP , WesterP , MårtenssonB , NorrvingB . Correction to: Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(388):s13063-020-04327-w. LundströmE , IsakssonE , Näsman P et al. Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(233):s13063-020-4124-7. LundstromE , IsakssonE , NasmanP , WesterP , MartenssonB , NorrvingB , et al. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661‐9. ">EFFECTS 2020</a>; <a href="./references#CD009286-bbs2-0027" title="GongL , YangX , FengY , FeiZ , WangM , QinB , et al. The efficacy of integrative anti-depressive therapy on motor recovery after ischemic stroke: a randomized clinical trial. European Journal of Integrative Medicine2020;35:101102. ">Gong 2020</a>; <a href="./references#CD009286-bbs2-0033" title="HuH , WangM . Effects of escitalopram on post-stroke depression and cognitive function of patients with neurological function. Hebei Medicine2018;24(2):325-8. ">Hu 2018</a>; <a href="./references#CD009286-bbs2-0043" title="LiZ . Clinical efficacy of paroxetine in the treatment of post-stroke depression. Modern Journal of Integrated Traditional Chinese and Western Medicine2007;16(34):5103-4. ">Li 2007</a>; <a href="./references#CD009286-bbs2-0045" title="LiJ , WangJ , LiY , ZhangW , ZhaoJ . Effects of escitalopram oxalate on post-stroke depression, cognition and neurological function. Journal of Hebei Medical University2017;38(5):589-92. ">Li 2017</a>; <a href="./references#CD009286-bbs2-0066" title="WangX . The efficacy of paroxetine in the treatment of post-stroke depression in 55 cases. Chinese Community Physician (Medical Professional Half-monthly)2009;11(7):11. ">Wang 2009</a>). Five of these studies (<a href="./references#CD009286-bbs2-0016" title="ChenZ , XuX , WuY , HuangL . Clinical efficacy of drug intervention in patients with acute depression after stroke. International Journal of Psychiatry2015;42(5):97-100. ">Chen 2015</a>; <a href="./references#CD009286-bbs2-0033" title="HuH , WangM . Effects of escitalopram on post-stroke depression and cognitive function of patients with neurological function. Hebei Medicine2018;24(2):325-8. ">Hu 2018</a>; <a href="./references#CD009286-bbs2-0043" title="LiZ . Clinical efficacy of paroxetine in the treatment of post-stroke depression. Modern Journal of Integrated Traditional Chinese and Western Medicine2007;16(34):5103-4. ">Li 2007</a>; <a href="./references#CD009286-bbs2-0045" title="LiJ , WangJ , LiY , ZhangW , ZhaoJ . Effects of escitalopram oxalate on post-stroke depression, cognition and neurological function. Journal of Hebei Medical University2017;38(5):589-92. ">Li 2017</a>; <a href="./references#CD009286-bbs2-0066" title="WangX . The efficacy of paroxetine in the treatment of post-stroke depression in 55 cases. Chinese Community Physician (Medical Professional Half-monthly)2009;11(7):11. ">Wang 2009</a>), were identified from the reference list of a 2020 systematic review (<a href="./references#CD009286-bbs2-0133" title="Li, X, ZhangC . Comparative efficacy of nine antidepressants in treating Chinese patients with post-stroke depression: a network meta-analysis. Journal of Affective Disorders2020;266:540-8.">Li 2020</a>). For <a href="./references#CD009286-bbs2-0011" title="CaoJX , LiuL , SunYT , ZengQH , WangY , ChenJC . Effects of the prophylactic use of escitalopram on the prognosis and the plasma copeptin level in patients with acute cerebral infarction. Brazilian Journal of Medical and Biological Research2020;53(11):e8930. CaoJX , LiuL , SunYT , ZengQH , YangZD , ChenJC . Escitalopram improves neural functional prognosis and endothelial dysfunction in patients with acute cerebral infarction. Restorative Neurology and Neuroscience2020;38(5):385-93. ">Cao 2020</a>, there are two reports (one reporting 97 participants and the other reporting 100 participants, with overlapping periods for recruitment, almost identical stroke subtypes in the control and citalopram groups, the same funding source, and identical text in some sections of the papers); the author did not respond to our request for clarification, and the editors of the journals in which they were published also did not receive a response from the authors, so to avoid the possibility of double‐counting the same participants, we included just one paper reporting 100 participants. </p> <p>Overall, we now have a total of 76 included studies recruiting 13,029 participants (<a href="#CD009286-fig-0001">Figure 1</a>). Of these, 22 contributed to the quantitative syntheses; the remaining studies were not of sufficiently high quality to be included in the main analyses, or did not report our co‐primary outcomes of disability, or independence, or did not report any results . </p> <p>Of the 76 included studies:</p> <p> <ul id="CD009286-list-0013"> <li> <p>38 studies used fluoxetine (<a href="./references#CD009286-bbs2-0002" title="ACTRN12611000774921. Assessment of fluoxetine in stroke recovery (AFFINITY) trial, 2011. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000774921 (first received 22 July 2011). ACTRN12619000986178. The assessment of fluoxetine in stroke recovery imaging and blood biomarkers sub-study AFFINITY BM. www.anzctr.org.au/Trial/Registration/TrialReview.aspx ?ACTRN=12619000986178 (first received 11 July 2019). AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):651-60. HankeyG . Assessment oF FluoxetINe In sTroke recoverY (AFFINITY). www.affinitytrial.org/ (accessed 19th February 2019). ">AFFINITY 2020</a>; <a href="./references#CD009286-bbs2-0007" title="BembenekJP , NiewadaM , KlyszB , MazurA , KurczychK , GluszkiewiczM , et al. Fluoxetine for stroke recovery improvement - the doubleblind, randomised placebo-controlled FOCUS-Poland trial. Neurologia i Neurochirurgia Polska2020;54(6):544-51. Fluoxetine or control under supervision: Poland. Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products - EduraCT No: 2014-001335-372014. ">Bembenek 2020</a>; <a href="./references#CD009286-bbs2-0008" title="BirchenallJ , TérémetzM , RocaP , LamyJC , OppenheimC , MaierMA , et al. Individual recovery profiles of manual dexterity, and relation to corticospinal lesion load and excitability after stroke - a longitudinal pilot study. Neurophysiologie Clinique2019;49(2):149-64. NCT02063425. Evaluation by transcranial magnetic stimulation of the benefit of fluoxetine on motor recovery after stroke (EFLUSTIM). clinicaltrials.gov/ct2/show/NCT02063425 (first received 14 February 2014). ">Birchenall 2019</a>; <a href="./references#CD009286-bbs2-0009" title="BrownKW , SloanRL , PentlandB . Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatrica Scandinavica1998;98(6):455-8. ">Brown 1998</a>; <a href="./references#CD009286-bbs2-0012" title="ChenWY , LiuFY , YangAP . Study of effect of integrative Chinese herbs with fluoxetine on rehabilitation of neurological impairment in patients with post-stroke depression. Journal of Chengdu University of Traditional Chinese Medicine2001;24(4):20-3. ">Chen 2001</a>; <a href="./references#CD009286-bbs2-0017" title="ChengF , ShaoG , BaoS . Study of effect on neurologic function rehabilitation in patient with post-stroke depression. Chinese Journal of Clinical Rehabilitation2003;7(1):108-9. ">Cheng 2003</a>; <a href="./references#CD009286-bbs2-0018" title="CholletF , TardyJ , Albucher J-F, ThalamasE , BerardE , LamyC , et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurology2011;10(2):123-30. ">Chollet 2011</a>; <a href="./references#CD009286-bbs2-0019" title="DamM , ToninP , De BoniA , PizzolatoG , CassonS , ErmaniM , et al. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke1996;27(7):1211-4. ">Dam 1996</a>; <a href="./references#CD009286-bbs2-0020" title="DikeF . Pharmacological enhancement of motor function recovery in patients with ischaemic stroke: a trial of fluoxetine. www.pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=967 (last accessed 16 February 2021). DikeFO , EkehBC , OgunAS , EkrikpoEU , WalshakP , OgunniyAA . Pharmacological enhancement of motor function recovery in patients with ischaemic stroke: a trial of fluoxetine. Journal of Neurology and Stroke2019;9(1):47-51. ">Dike 2019</a>; <a href="./references#CD009286-bbs2-0021" title="EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661-9. ISRCTN13020412. Establishing the effect(s) and safety of fluoxetine initiated in the acute phase of stroke. www.isrctn.com/ISRCTN13020412 (first received 19 December 2014). LundströmE , IsakssonE , NäsmanP , WesterP , MårtenssonB , NorrvingB . Correction to: Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(388):s13063-020-04327-w. LundströmE , IsakssonE , Näsman P et al. Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(233):s13063-020-4124-7. LundstromE , IsakssonE , NasmanP , WesterP , MartenssonB , NorrvingB , et al. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661‐9. ">EFFECTS 2020</a>; <a href="./references#CD009286-bbs2-0022" title="Feng B-L, Wang Q-C, Zheng-YuanLI . Influence of Jieyu Huoxue decoction on rehabilitation of patients with depression after cerebral infarction. Journal of Chinese Integrated Medicine2004;2(3):182-4. ">Feng 2004</a>; <a href="./references#CD009286-bbs2-0023" title="Anonymous. The FOCUS (Fluoxetine or Control under Supervision) trial results: effects of a 6 month course of fluoxetine on the Stroke Impact Scale, mood and fatigue in patients with stroke. www.ed.ac.uk/clinical-brain-sciences/research/completed-studies-trials/focus-stroke-trial (accessed 12 02 2021). CookR , ThomasV , MartinR . Does fluoxetine improve recovery after stroke?BMJ2019;364:1029. DennisM , ForbesJ , GrahamC , HackettM , HankeyGJ , HouseA , et al. Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT. Health Technology Assessment2020;24(22):1-94. DennisM , ForbesJ , GrahamC , HackettML , HankeyGJ , HouseA , et al. Fluoxetine and fractures after stroke: exploratory analyses from the FOCUS Trial. Stroke2019;50(11):3280-2. FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet2019;393(10168):265-74. GrahamC , LewisS , ForbesJ , MeadG , HackettML , HankeyGJ , et al. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. Trials2017;18(1):627. LundstromE , DennisM , MeadG . The effects of fluoxetine on fracture risk after stroke: Further analyses from the focus trial. European Stroke Journal2019;4 suppl 1:7142019. MeadG , DennisM . Feasibility of reporting results of large randomised controlled trials to participants: experience from the Fluoxetine or Control under Supervision (FOCUS) trial. BMJ Open2020;10(11):e0404922020. MeadG . Fluoxetine Or Control Under Supervision (FOCUS) trial: to establish the effect(s) of routine administration of Fluoxetine in patients with a recent stroke. www.isrctn.com/ISRCTN83290762 (first received 23 May 2012). MeadGE , DennisMS , InnesK , MacLeodM , SandercockPA , HouseA , et al. A multicentre randomised trial to establish the effect(s) of routine administration of fluoxetine in patients with a recent stroke (Fluoxetine Or Control Under Supervision, FOCUS). In: 21st European Stroke Conference. 2012:Abst OAID 26. MeadGE , GrahamC , BillotL , NäsmanP , LundströmE , LewisS , on behalf of the FOCUS , AFFINITY and EFFECTS trialists. Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis. Trials2020;21(1):971. MeadGE , LeggL , TilneyR , HsiehCF , WuS , LundströmE , et al. Fluoxetine for stroke recovery: meta-analysis of randomized controlled trials. International Journal of Stroke2020;15(4):365-76. ">FOCUS 2019</a>; <a href="./references#CD009286-bbs2-0024" title="FruehwaldS , GatterbauerE , RehakP , BaumhacklU . Early fluoxetine treatment of post-stroke depression: a three-month double-blind placebo-controlled study with an open-label long-term follow up. Journal of Neurology2003;250(3):347-51. ">Fruehwald 2003</a>; <a href="./references#CD009286-bbs2-0027" title="GongL , YangX , FengY , FeiZ , WangM , QinB , et al. The efficacy of integrative anti-depressive therapy on motor recovery after ischemic stroke: a randomized clinical trial. European Journal of Integrative Medicine2020;35:101102. ">Gong 2020</a>; <a href="./references#CD009286-bbs2-0029" title="HeP . Randomized controlled observation on the effect of early application of fluoxetine in preventing depression after stroke. Chinese Journal of Clinical Rehabilitation2004;8(28):6016-7. ">He 2004</a>; <a href="./references#CD009286-bbs2-0031" title="ChiCTR-TRC-12002078. Multi-center randomized clinical study of antidepressant treatment (fluoxetine) on secondary prevention of ischemic stroke. www.chictr.org.cn/showprojen.aspx?proj=7471 (first received 3 April 2012). GuoY , HeY , TangB , MaK , CaiZ , ZengS , et al. Effect of using fluoxetine at different time windows on neurological functional prognosis after ischaemic stroke. Restorative Neurology and Neuroscience2016;34:177-87. HeY , CaiZ , ZengS , ChenS , TangB , LiangY , et al. Effect of fluoxetine on three-year recurrence in acute ischemic stroke: a randomized controlled clinical study. Clinical Neurology and Neurosurgery2018;168:1-6. He Y-T, Tang B-S, Cai Z-L, Zeng S-L, JiangX , Guo Yi. Effects of fluoxetine on neural functional prognosis after ischemic stroke: a randomized controlled study in China. Journal of Stroke and Cerebrovascular Diseases2016;25(4):761-70. ">He 2016</a>; <a href="./references#CD009286-bbs2-0032" title="HuY , SuoA , XiangL . The comparative study of the effectiveness of fluoxetine on the stroke patients with depressive symptoms. Shanghai Archives of Psychiatry2002;14:149-50. ">Hu 2002</a>; <a href="./references#CD009286-bbs2-0034" title="Huang X-H. The clinical correlation study and the effect of fluoxetine intervention on poststroke depression. Chinese Journal of Clinical Rehabilitation2002;6(15):2296-7. ">Huang 2002</a>; <a href="./references#CD009286-bbs2-0037" title="KongY . Fluoxetine for poststroke depression: a randomized placebo controlled clinical trial. Neural Regeneration Research2007;2(3):162-5. ">Kong 2007</a>; <a href="./references#CD009286-bbs2-0039" title="LiJ , He Q-Y, Han M-F. Recent effect of fluoxetine in improving neurologic impairment and preventing post-stroke depression in the early stage. Chinese Journal of Clinical Rehabilitation2004;8(7):1208-9. ">Li 2004a</a>; <a href="./references#CD009286-bbs2-0040" title="Li C-M, Jiang X-D, LiaoG , Lei J-M, LanS , Ni F-W. Effect of antidepressant drugs in early period on the recovery of post-stroke depression. Chinese Journal of Clinical Rehabilitation2004;8(19):3713-5. ">Li 2004b</a>; <a href="./references#CD009286-bbs2-0044" title="Li L-T, Wang S-H, Ge H-Y, ChenJ , Yue S-W, YuM . The beneficial effects of the herbal medicine free and easy wanderer plus (FEWP) and fluoxetine on post-stroke depression. Journal of Alternative and Complementary Medicine2008;14(7):841-6. ">Li 2008</a>; <a href="./references#CD009286-bbs2-0047" title="Marquez-RomeroJM , ArauzA , Ruiz-SandovalJL , Cruz-Estrada EdeL , Huerta-FrancoMR , Aguayo-LeytteG , et al. Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH): study protocol for a randomized, double-blind, placebo-controlled, multicenter trial. Trials2013;14:77. Marquez-RomeroJM , Reyes-MartínezM , Huerta-FrancoMR , Ruiz-FrancoA , SilosH , ArauzA . Fluoxetine for motor recovery after acute intracerebral hemorrhage, the FMRICH trial. Clinical Neurology and Neurosurgery2020;190:105656. Marquez-RomeroJM , Reyes-MartínezM , Huerta-FrancoMR , Ruiz-FrancoA , SilosH , ArauzA . Fluoxetine for motor recovery after acute intracerebral hemorrhage, the FMRICH Trial. Correspondence from Marquez-Romero2018. Marquez-RomeroJM . Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH). www.clinicaltrials.gov/ct2/show/NCT01737541 (first received 29 November 2012). ">Marquez Romero 2013</a>; <a href="./references#CD009286-bbs2-0052" title="NCT01674868. Fluoxetine for motor, aphasia, and neglect recovery after ischemic stroke (FLAN). www.clinicaltrials.gov/ct2/show/NCT01674868 (first received 29 August 2012). ">NCT01674868</a>; <a href="./references#CD009286-bbs2-0053" title="NCT02737930. Fluoxetine for visual recovery after ischaemic stroke (FLUORESCE). www.clinicaltrials.gov/ct2/show/NCT02737930 (first received 14 April 2016). ">NCT02737930</a>; <a href="./references#CD009286-bbs2-0055" title="Guiraud-ChaumeilB , ParienteJ , Albucher J-F, LoubinouxI , CholletF . Rehabilitation after stroke [Recuperation neurologique post-ischemique]. Bulletin de l'Académie Nationale de Médecine2002;6:1015-24. ParienteJ , LoubinouxI , CarelC , AlbucherJF , LegerA , ManelfeC , et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Annals of Neurology2001;50(6):718-29. ">Pariente 2001</a>; <a href="./references#CD009286-bbs2-0057" title="RazazianN , EsmaeiliO , AlmasiA . Effect of fluoxetine on motor improvement in ischemic stroke patients: a double blind clinical trial study. Zahedan Journal of Research in Medical Sciences2016;18(7):e75492016. RazazianN . A survey for assessment of effectiveness of fluoxetine on motor improvement in ischemic stroke patients. www.en.irct.ir/trial/8797 (first received 9 January 2014). ">Razazian 2014</a>; <a href="./references#CD009286-bbs2-0058" title="RestifoDA , Lo PrestR , LanzaS , GiuffridaS , D'AleoG , Rifici Di BellaC , et al. Motor cortex reorganization induced by fluoxetine in poststroke hemiplegic patients undergoing rehabilitation therapy: a study with transcranial magnetic stimulation. Neurorehabilitation and Neural Repair2001;15(4):284. ">Restifo 2001</a>; <a href="./references#CD009286-bbs2-0059" title="JorgeRE , RobinsonRG , ArndtS , StarksteinS . Mortality and post-stroke depression: a placebo controlled trial of antidepressants. American Journal of Psychiatry2003;160:1823-9. NarushimaK , KosierJT , RobinsonRG . Preventing post-stroke depression: a 12 week double blind randomised treatment trial and 21 month follow-up. Journal of Nervous and Mental Diseases2002;190:296-303. RobinsonRG , SchultzSK , CastilloC , KopelT , KosierJT , NewmanRM , et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. American Journal of Psychiatry2000;157(3):351-9. ">Robinson 2000a</a>; <a href="./references#CD009286-bbs2-0060" title="JorgeRE , RobinsonRG , ArndtS , StarksteinS . Mortality and post-stroke depression: a placebo controlled trial of antidepressants. American Journal of Psychiatry2003;160:1823-9. NarushimaK , RobinsonRG . Preventing post-stroke depression: a 12 week double blind randomised treatment trial and 21 month follow-up. Journal of Nervous and Mental Diseases2002;190:296-303. RobinsonRG , SchultzSK , CastilloC , KopelT , KosierJT , NewmanRM , et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. American Journal of Psychiatry2000;157(3):351-9. ">Robinson 2000b</a>; <a href="./references#CD009286-bbs2-0063" title="ShahIA , AsimiRP , KawoosY , WaniMA , WaniMA , DarMA . Effect of fluoxetine on motor recovery after acute haemorrhagic stroke: a randomized trial. Journal of Neurology and Neurophysiology2016;7(2). [DOI: 10.4172/2155-9562.1000364]">Shah 2016</a>; <a href="./references#CD009286-bbs2-0064" title="Song J-G. Effects of fluoxetine hydrochloride on depressive symptoms and P300 after cerebral stroke. Chinese Journal of Clinical Rehabilitation2006;10(14):160-2. ">Song 2006</a>; <a href="./references#CD009286-bbs2-0065" title="WangX , TanZ , WuZ , GaoJ , FengM . The effects of anti-depression therapy on post-stroke depression and neurologic rehabilitation in the elderly patients. Chinese Journal of Geriatrics2003;22(5):270-3. ">Wang 2003</a>; <a href="./references#CD009286-bbs2-0067" title="Wen Z-X. The influence of post-stroke prophylactic anti-depression treatment on nerve functional rehabilitation. Acta Academiae Medicinae Qingdao Universitatis2006;42(3):253-4. ">Wen 2006</a>; <a href="./references#CD009286-bbs2-0068" title="WiartL , PetitH , JosephPA , MazauxJM , BaratM . Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke2000;31(8):1829-32. ">Wiart 2000</a>; <a href="./references#CD009286-bbs2-0070" title="XuJ , TanJ , OuL . A study on treatment of fluoxetine to depression in early recovery stage of cerebral infarction. Chinese Journal of Rehabilitation Medicine2001;16(5):281-3. ">Xu 2001</a>; <a href="./references#CD009286-bbs2-0075" title="ZhaoP , Wang J-P. Effects of antidepressants on neurofunctional recovery of post-stroke patients with aphasia. Journal of Dalian Medical University2011;33(1):55-7. ">Zhao 2011</a>; <a href="./references#CD009286-bbs2-0076" title="Zhou Z-l, Liang L-Z, Yan Y-X. Preventive effects of fluoxetine on post-stroke depression. Chinese Journal of Modern Applied Pharmacy2008;25(3):263-4. ">Zhou 2008</a>); </p> </li> <li> <p>eight studies used sertraline (<a href="./references#CD009286-bbs2-0003" title="AlmeidaOP , WaterreusA , HankeyGJ . Preventing depression after stroke: results from a randomized placebo-controlled trial. Journal of Clinical Psychiatry2006;67(7):1104-9. ">Almeida 2006</a>; <a href="./references#CD009286-bbs2-0010" title="BurnsA , RussellE , Stratton-PowellH , TyrellP , O'NeillP , BaldwinR . Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry1999;14(8):681-5. ">Burns 1999</a>; <a href="./references#CD009286-bbs2-0028" title="Guo R-Y, SuL , WangCX . Effects of Linggui Bafa on the therapeutic effect and quality of life in patients of post-stroke depression. Chinese Acupuncture &amp; Moxibustion2009;29(10):785-90. ">Guo 2009</a>; <a href="./references#CD009286-bbs2-0048" title="MearaRJ , ThalananyM , BalonwuV , HobsonP . The treatment of depression after stroke with the selective serotonin reuptake inhibitor sertraline. Cerebrovascular Diseases1998;8 Suppl 4:90. ">Meara 1998</a>; <a href="./references#CD009286-bbs2-0050" title="MurrayV , Von ArbinM , BartfaiA , Berggren A-L, Landtblom A-M, LumdmarkJ , et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry2005;66(6):708-16. ">Murray 2005</a>; <a href="./references#CD009286-bbs2-0051" title="NCT00177424. Setraline for prevention post stroke depression and improving rehabilitation outcomes. clinicaltrials.gov/ct2/show/NCT00177424 (first received 15 September 2005). ">NCT00177424</a>; <a href="./references#CD009286-bbs2-0056" title="RasmussenA , LundeM , PoulsenD , SørensenK , QvitzauS , BechP . A double-blind placebo controlled study of sertraline in the prevention of depression in stroke patients. European Neuropyschopharmacology2002;12:231. RasmussenA , LundeM , PoulsenDL , SørensenK , QvitzauS , BechP . A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients. Psychosomatics2003;44(3):216-22. RasmussenA . Depression and stroke. Nordic Journal of Psychiatry2001;55(4):288. RasmussenA . Prophylactic treatment for post-stroke depression and comorbidity. Journal of Psychosomatic Research2000;48(3):66. ">Rasmussen 2003</a>; <a href="./references#CD009286-bbs2-0069" title="XieR , LiuJ , QuanH . A prospective random clinical contrast study of treatment with sertraline in elderly patients with post-stroke depression. Chinese Journal of Clinical Neuroscience2005;13(3):294-7. ">Xie 2005</a>); </p> </li> <li> <p>13 studies used paroxetine (<a href="./references#CD009286-bbs2-0013" title="ChenW , Wang G-F, Chen X-H, Sheng Y-L, ZhuH . Effects of paroxetine on function recovery in patients with post-stroke depression. Chinese Journal of Clinical Rehabilitation2002;6(13):2014-5. ">Chen 2002</a>; <a href="./references#CD009286-bbs2-0015" title="ChenT , LiJ , HanM . A study on paroxetine in the treatment for post-stroke depression. Jiangxi Medicine2005;40(7):382-4. ">Chen 2005b</a>; <a href="./references#CD009286-bbs2-0026" title="GlaxoSmithKline. An 8-week double-blind placebo controlled parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from depression following stroke. GSK Clinical Study Register www.gsk clinicalstudyregister.com (accessed 31 August 2012). ">GlaxoSmithKline 1998</a>; <a href="./references#CD009286-bbs2-0030" title="HeY , WangX , XiaoC . Prospective study of effects of paroxetine with mental intervention on depression and anxiety after stroke. Nervous Diseases and Mental Health2005;5(1):6-13. WangX , HeY , Xiao C-L. A clinical trial of paroxetine and psychotherapy in patients with post-stroke depression and anxiety. Chinese Mental Health Journal2005;19:564-6. ">He 2005</a>; <a href="./references#CD009286-bbs2-0038" title="LaiJ . The effect of using paroxetine to treat post stroke depression. Journal of Guangdong Medical College2006;24(6):585-6. ">Lai 2006</a>; <a href="./references#CD009286-bbs2-0041" title="LiY , WangX , QianFS . Related factors of post-stroke depression and effect of paroxetine. Shandong Archives of Psychiatry2005;18(4):209-10. ">Li 2005</a>; <a href="./references#CD009286-bbs2-0043" title="LiZ . Clinical efficacy of paroxetine in the treatment of post-stroke depression. Modern Journal of Integrated Traditional Chinese and Western Medicine2007;16(34):5103-4. ">Li 2007</a>; <a href="./references#CD009286-bbs2-0054" title="Pan X-L, Chen H-F, ChengX , Hu C-C, Wang J-W, Fu Y-M, et al. Effects of paroxetine on motor and cognitive function recovery in patients with non-depressed ischemic stroke: an open randomized controlled study. Brain Impairment;doi: 10.1017/BrImp.2018.6. ">Pan 2018</a>; <a href="./references#CD009286-bbs2-0066" title="WangX . The efficacy of paroxetine in the treatment of post-stroke depression in 55 cases. Chinese Community Physician (Medical Professional Half-monthly)2009;11(7):11. ">Wang 2009</a>; <a href="./references#CD009286-bbs2-0071" title="XuJ , WangJ , LiuJ . Preventive effects of antidepressants on post-stroke depression. Chinese Mental Health Journal2006;20(3):186-8. ">Xu 2006</a>; <a href="./references#CD009286-bbs2-0072" title="YangJ , ZhaoY , BaiS . Controlled study on antidepressant treatment of patients with post-stroke depression. Chinese Mental Health Journal2002;16(12):871-2. ">Yang 2002</a>; <a href="./references#CD009286-bbs2-0073" title="YangJ . Therapeutic effect of paroxetine on patients with early poststroke depression and the serum interleukins. Chinese Journal of Cerebrovascular Diseases2011;8(5):235-8. ">Yang 2011</a>; <a href="./references#CD009286-bbs2-0074" title="Ye L-X, WangH , Wang Y-D, ZhongL , Liang D-S, GuoY . Effect of anti-depressive therapy on the rehabilitation of psychological and neurological function after stroke. Chinese Journal of Clinical Rehabilitation2004;8(31):6826-8. YeLX . Effect of paxil and berhomine on post-stroke anxiety-depression and neurological recovery. Chinese Journal of Clinical Rehabilitation2006;10(6):153-5. ">Ye 2004</a>); </p> </li> <li> <p>nine studies used citalopram (<a href="./references#CD009286-bbs2-0001" title="AclerM , AvesaniA , FiaschiA , ManganottiP . Serotonergic modulation of brain excitability and motor recovery in patients affected by stroke. A double blind placebo RCT. International Journal of Stroke2008;3:336. AclerM , RobolE , FiaschiA , ManganottiP . A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. Journal of Neurology2009;256(7):1152-8. ">Acler 2009</a>; <a href="./references#CD009286-bbs2-0004" title="AndersenG , VestergaardK , LauritzenL . Effective treatment of post-stroke depression with selective serotonin reuptake inhibitors. Journal of Neurology1994;241:S42. AndersenG , VestergaardK , LauritzenL . Effective treatment of post-stroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke1994;25(6):1099-104. AndersenG , VestergaardK , LauritzenL . Post-stroke depression treated with citalopram. Acta Neurologica Scandinavica1994;89 Suppl 155:20. AndersenG , VestergaardK , LauritzenL . Post-stroke depression treated with citalopram - a selective serotonin reuptake inhibitor. Canadian Journal of Neurological Sciences1993;20:S115. AndersenG , VestergaardK , LauritzenL . Post-stroke depression treated with citalopram a selective serotonin reuptake inhibitor. In: 7th Scandinavian Meeting on Cerebrovascular Disease. 1993:54. AndersenG , VestergaardK , LauritzenLU . Effective treatment of depression following apoplexy with citalopram. Ugeskrift for Laeger1995;157(14):2000-3. FlickerC , AndersenG , BayerL . A placebo controlled study of citalopram treatment for post-stroke depression. In: 11th Annual Meeting of the American Association for Geriatric Psychiatry. 1998. ">Andersen 1994</a>; <a href="./references#CD009286-bbs2-0005" title="AndersenG . The efficacy of citalopram treatment in acute stroke (TALOS). www.clinicaltrials.gov/ct2/show/NCT01937182 (first received 9 September 2013). DamsboAG , MortensenJK , KraglundKL , JohnsenSP , AndersenG , BlauenfeldtRA . Prestroke physical activity and poststroke cognitive performance. Cerebrovascular Diseases2020;49(6):632-8. KraglundKL , MortensenJK , DamsboAG , ModrauB , SimonsenSA , Iversen, HK, et al. Neuroregeneration and vascular protection by citalopram in acute ischemic stroke (TALOS). Stroke2018;49(11):2568-76. KraglundKL , MortensenJK , DamsboAG , ModrauB , SimonsenSA , IversenHK , et al. Neuroregeneration and vascular protection by citalopramin in acute ischemic stroke (TALOS). Stroke2018;49(11):2568-76. KraglundKL , MortensenJK , GroveEL , JohnsenSP , AndersenG . TALOS: a multicenter, randomised, double blind, placebo controlled trial to test the effects of citalopram in patients with acute stroke; protocol. International Journal of Stroke2015;10:985-87. KraglundKL , MortensenJK , JohnsenSP , AndersenG , GroveEL . Antiplatelet effects of citalopram in patients with ischaemic stroke: a randomized, placebo-controlled, double-blind study. Scientific Reports2019;9(1):200482019. ">Andersen 2013</a>; <a href="./references#CD009286-bbs2-0016" title="ChenZ , XuX , WuY , HuangL . Clinical efficacy of drug intervention in patients with acute depression after stroke. International Journal of Psychiatry2015;42(5):97-100. ">Chen 2015</a>; <a href="./references#CD009286-bbs2-0025" title="GaoJ , LinM , ZhaoJ , BiS , NiZ , ShangX . Different interventions for post-ischaemic stroke depression in different time periods: a single-blind randomized controlled trial with stratification by time after stroke. Clinical Rehabilitation2017;31(7):71-81. ">Gao 2017</a>; <a href="./references#CD009286-bbs2-0042" title="Li W-Q, Li D-X. The efficacy of citalopram for post-stroke depression and its effects on stroke rehabilitation. International Journal of Cerebrovascular Diseases2006;14(4):275-8. ">Li 2006</a>; <a href="./references#CD009286-bbs2-0046" title="LiuY , XuR . Effect of citalopram treatment on post-stroke depression and neurological functional rehabilitation. Chinese Journal of Rehabilitation2006;21(3):174-5. ">Liu 2006</a>; <a href="./references#CD009286-bbs2-0049" title="Miao S-Y, Shi Y-J. Related factors of post-stroke depression and therapeutical effect of citalopram. Chinese Journal of Clinical Rehabilitation2004;8(19):3718-9. ">Miao 2004</a>; <a href="./references#CD009286-bbs2-0062" title="Savadi OskouieD , SharifipourE , Sadeghi BazarganiH , HashemilarM , NikanfarM , Ghazanfari AmlashiS , et al. Efficacy of citalopram on acute ischemic stroke outcome: a randomized clinical trial. Neurorehabilitation and Neural Repair2017;31(7):638-47. Savadi OskouieD . Evaluation of the effect of citalopram on three months functional prognosis of acute ischemic stroke patients: a randomized clinical trial. www.en.irct.ir/trial/1766 (first received 22 April 2012). ">Savadi Oskouie 2012</a>) </p> </li> <li> <p>five studies used escitalopram (<a href="./references#CD009286-bbs2-0011" title="CaoJX , LiuL , SunYT , ZengQH , WangY , ChenJC . Effects of the prophylactic use of escitalopram on the prognosis and the plasma copeptin level in patients with acute cerebral infarction. Brazilian Journal of Medical and Biological Research2020;53(11):e8930. CaoJX , LiuL , SunYT , ZengQH , YangZD , ChenJC . Escitalopram improves neural functional prognosis and endothelial dysfunction in patients with acute cerebral infarction. Restorative Neurology and Neuroscience2020;38(5):385-93. ">Cao 2020</a>; <a href="./references#CD009286-bbs2-0033" title="HuH , WangM . Effects of escitalopram on post-stroke depression and cognitive function of patients with neurological function. Hebei Medicine2018;24(2):325-8. ">Hu 2018</a>; <a href="./references#CD009286-bbs2-0036" title="KimJS , Lee E-J, Chang D-ll, Park J-H, AhnSH , Cha J-K, et al. Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Psychiatry2017;4(1):33-41. LeeEJ , KimJS , ChangDI , ParkJH , AhnSH , ChaJK , et al. Differences in therapeutic responses and factors affecting post-stroke depression at a later stage according to baseline depression. Journal of Stroke2018;20(2):258-67. LeeEJ , KimJS , ChangDI , ParkJH , AhnSH , ChaJK , et al. Post-stroke depressive symptoms: varying responses to escitalopram by individual symptoms and lesion location. Journal of Geriatric Psychiatry and Neurology2020;10:891988720957108. LeeEJ , OhMS , KimJS , ChangDI , ParkJH , ChaJK , EMOTION investigators. Serotonin transporter gene polymorphisms may be associated with poststroke neurological recovery after escitalopram use. Journal of Neurology, Neurosurgery and Psychiatry2018;89(3):271-6. NCT01278498. The preventative effect of escitalopram on depression and related emotional disorders in acute stroke patients, 2011. clinicaltrials.gov/ct2/show/NCT01278498 (first received 19 January 2011). [NCT01278498]">Kim 2017</a>; <a href="./references#CD009286-bbs2-0045" title="LiJ , WangJ , LiY , ZhangW , ZhaoJ . Effects of escitalopram oxalate on post-stroke depression, cognition and neurological function. Journal of Hebei Medical University2017;38(5):589-92. ">Li 2017</a>; <a href="./references#CD009286-bbs2-0061" title="JorgeRE , AcionL , MoserD , AdamsHP , RobinsonRG . Escitalopram and enhancement of cognitive recovery following stroke. Archives of General Psychiatry2010;67(2):187-96. RobinsonRG , ArndtS . Incomplete financial disclosure in a study of escitalopram and problem solving therapy for prevention of post-stroke depression. JAMA2009;301:1023-4. RobinsonRG , JorgeRE , MoserDJ , AcionL , SolodkinA , SmallSL , et al. Escitalopram and problem-solving therapy for prevention of poststroke depression. JAMA2008;299(20):2391-400. ">Robinson 2008</a>); </p> </li> <li> <p>one study used either sertraline or fluoxetine (<a href="./references#CD009286-bbs2-0035" title="JiaW . Effect of early intervention on recovery of motor function and recurrent stroke in patients with post-stroke depression. Chinese Journal of Clinical Rehabilitation2005;9(12):4-5. ">Jia 2005</a>); </p> </li> <li> <p>two studies used citalopram or fluoxetine (<a href="./references#CD009286-bbs2-0014" title="ChenKN . Changes of neurotransmitter in patients with post-stroke depression observed with encephalofluctuography technology. Chinese Journal of Clinical Rehabilitation2005;9(16):118-9. ">Chen 2005a</a>; <a href="./references#CD009286-bbs2-0006" title="AsadollahiM , RamezaniM , KhanmoradiZ , KarimialavijehE . The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial. Clinical Rehabilitation2018;32(8):1069-75. ">Asadollahi 2018</a>). </p> </li> </ul> </p> <section id="CD009286-sec-0044"> <h5 class="title">Baseline sociodemographic and clinical characteristics</h5> <p>The mean age of participants ranged from 51 ± 7 years (<a href="./references#CD009286-bbs2-0064" title="Song J-G. Effects of fluoxetine hydrochloride on depressive symptoms and P300 after cerebral stroke. Chinese Journal of Clinical Rehabilitation2006;10(14):160-2. ">Song 2006</a>), to 75.6 years (<a href="./references#CD009286-bbs2-0065" title="WangX , TanZ , WuZ , GaoJ , FengM . The effects of anti-depression therapy on post-stroke depression and neurologic rehabilitation in the elderly patients. Chinese Journal of Geriatrics2003;22(5):270-3. ">Wang 2003</a>), with most studies recruiting participants in their 60s. There are more men than women. Patients with ischaemic stroke and/or primary intracerebral haemorrhage were included. </p> </section> <section id="CD009286-sec-0045"> <h5 class="title">Mean time since stroke</h5> <p>Of the 76 included studies: (numbers below add up to 76 not 75).</p> <p> <ul id="CD009286-list-0014"> <li> <p>Forty‐four studies report recruiting participants between 0 and 90 days after stroke onset (<a href="./references#CD009286-bbs2-0002" title="ACTRN12611000774921. Assessment of fluoxetine in stroke recovery (AFFINITY) trial, 2011. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000774921 (first received 22 July 2011). ACTRN12619000986178. The assessment of fluoxetine in stroke recovery imaging and blood biomarkers sub-study AFFINITY BM. www.anzctr.org.au/Trial/Registration/TrialReview.aspx ?ACTRN=12619000986178 (first received 11 July 2019). AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):651-60. HankeyG . Assessment oF FluoxetINe In sTroke recoverY (AFFINITY). www.affinitytrial.org/ (accessed 19th February 2019). ">AFFINITY 2020</a>; <a href="./references#CD009286-bbs2-0001" title="AclerM , AvesaniA , FiaschiA , ManganottiP . Serotonergic modulation of brain excitability and motor recovery in patients affected by stroke. A double blind placebo RCT. International Journal of Stroke2008;3:336. AclerM , RobolE , FiaschiA , ManganottiP . A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. Journal of Neurology2009;256(7):1152-8. ">Acler 2009</a>; <a href="./references#CD009286-bbs2-0003" title="AlmeidaOP , WaterreusA , HankeyGJ . Preventing depression after stroke: results from a randomized placebo-controlled trial. Journal of Clinical Psychiatry2006;67(7):1104-9. ">Almeida 2006</a>; <a href="./references#CD009286-bbs2-0004" title="AndersenG , VestergaardK , LauritzenL . Effective treatment of post-stroke depression with selective serotonin reuptake inhibitors. Journal of Neurology1994;241:S42. AndersenG , VestergaardK , LauritzenL . Effective treatment of post-stroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke1994;25(6):1099-104. AndersenG , VestergaardK , LauritzenL . Post-stroke depression treated with citalopram. Acta Neurologica Scandinavica1994;89 Suppl 155:20. AndersenG , VestergaardK , LauritzenL . Post-stroke depression treated with citalopram - a selective serotonin reuptake inhibitor. Canadian Journal of Neurological Sciences1993;20:S115. AndersenG , VestergaardK , LauritzenL . Post-stroke depression treated with citalopram a selective serotonin reuptake inhibitor. In: 7th Scandinavian Meeting on Cerebrovascular Disease. 1993:54. AndersenG , VestergaardK , LauritzenLU . Effective treatment of depression following apoplexy with citalopram. Ugeskrift for Laeger1995;157(14):2000-3. FlickerC , AndersenG , BayerL . A placebo controlled study of citalopram treatment for post-stroke depression. In: 11th Annual Meeting of the American Association for Geriatric Psychiatry. 1998. ">Andersen 1994</a>; <a href="./references#CD009286-bbs2-0005" title="AndersenG . The efficacy of citalopram treatment in acute stroke (TALOS). www.clinicaltrials.gov/ct2/show/NCT01937182 (first received 9 September 2013). DamsboAG , MortensenJK , KraglundKL , JohnsenSP , AndersenG , BlauenfeldtRA . Prestroke physical activity and poststroke cognitive performance. Cerebrovascular Diseases2020;49(6):632-8. KraglundKL , MortensenJK , DamsboAG , ModrauB , SimonsenSA , Iversen, HK, et al. Neuroregeneration and vascular protection by citalopram in acute ischemic stroke (TALOS). Stroke2018;49(11):2568-76. KraglundKL , MortensenJK , DamsboAG , ModrauB , SimonsenSA , IversenHK , et al. Neuroregeneration and vascular protection by citalopramin in acute ischemic stroke (TALOS). Stroke2018;49(11):2568-76. KraglundKL , MortensenJK , GroveEL , JohnsenSP , AndersenG . TALOS: a multicenter, randomised, double blind, placebo controlled trial to test the effects of citalopram in patients with acute stroke; protocol. International Journal of Stroke2015;10:985-87. KraglundKL , MortensenJK , JohnsenSP , AndersenG , GroveEL . Antiplatelet effects of citalopram in patients with ischaemic stroke: a randomized, placebo-controlled, double-blind study. Scientific Reports2019;9(1):200482019. ">Andersen 2013</a>; <a href="./references#CD009286-bbs2-0007" title="BembenekJP , NiewadaM , KlyszB , MazurA , KurczychK , GluszkiewiczM , et al. Fluoxetine for stroke recovery improvement - the doubleblind, randomised placebo-controlled FOCUS-Poland trial. Neurologia i Neurochirurgia Polska2020;54(6):544-51. Fluoxetine or control under supervision: Poland. Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products - EduraCT No: 2014-001335-372014. ">Bembenek 2020</a>; <a href="./references#CD009286-bbs2-0008" title="BirchenallJ , TérémetzM , RocaP , LamyJC , OppenheimC , MaierMA , et al. Individual recovery profiles of manual dexterity, and relation to corticospinal lesion load and excitability after stroke - a longitudinal pilot study. Neurophysiologie Clinique2019;49(2):149-64. NCT02063425. Evaluation by transcranial magnetic stimulation of the benefit of fluoxetine on motor recovery after stroke (EFLUSTIM). clinicaltrials.gov/ct2/show/NCT02063425 (first received 14 February 2014). ">Birchenall 2019</a>; <a href="./references#CD009286-bbs2-0012" title="ChenWY , LiuFY , YangAP . Study of effect of integrative Chinese herbs with fluoxetine on rehabilitation of neurological impairment in patients with post-stroke depression. Journal of Chengdu University of Traditional Chinese Medicine2001;24(4):20-3. ">Chen 2001</a>; <a href="./references#CD009286-bbs2-0015" title="ChenT , LiJ , HanM . A study on paroxetine in the treatment for post-stroke depression. Jiangxi Medicine2005;40(7):382-4. ">Chen 2005b</a>; <a href="./references#CD009286-bbs2-0017" title="ChengF , ShaoG , BaoS . Study of effect on neurologic function rehabilitation in patient with post-stroke depression. Chinese Journal of Clinical Rehabilitation2003;7(1):108-9. ">Cheng 2003</a>; <a href="./references#CD009286-bbs2-0018" title="CholletF , TardyJ , Albucher J-F, ThalamasE , BerardE , LamyC , et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurology2011;10(2):123-30. ">Chollet 2011</a>; <a href="./references#CD009286-bbs2-0020" title="DikeF . Pharmacological enhancement of motor function recovery in patients with ischaemic stroke: a trial of fluoxetine. www.pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=967 (last accessed 16 February 2021). DikeFO , EkehBC , OgunAS , EkrikpoEU , WalshakP , OgunniyAA . Pharmacological enhancement of motor function recovery in patients with ischaemic stroke: a trial of fluoxetine. Journal of Neurology and Stroke2019;9(1):47-51. ">Dike 2019</a>; <a href="./references#CD009286-bbs2-0021" title="EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661-9. ISRCTN13020412. Establishing the effect(s) and safety of fluoxetine initiated in the acute phase of stroke. www.isrctn.com/ISRCTN13020412 (first received 19 December 2014). LundströmE , IsakssonE , NäsmanP , WesterP , MårtenssonB , NorrvingB . Correction to: Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(388):s13063-020-04327-w. LundströmE , IsakssonE , Näsman P et al. Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(233):s13063-020-4124-7. LundstromE , IsakssonE , NasmanP , WesterP , MartenssonB , NorrvingB , et al. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661‐9. ">EFFECTS 2020</a>; <a href="./references#CD009286-bbs2-0022" title="Feng B-L, Wang Q-C, Zheng-YuanLI . Influence of Jieyu Huoxue decoction on rehabilitation of patients with depression after cerebral infarction. Journal of Chinese Integrated Medicine2004;2(3):182-4. ">Feng 2004</a>; <a href="./references#CD009286-bbs2-0023" title="Anonymous. The FOCUS (Fluoxetine or Control under Supervision) trial results: effects of a 6 month course of fluoxetine on the Stroke Impact Scale, mood and fatigue in patients with stroke. www.ed.ac.uk/clinical-brain-sciences/research/completed-studies-trials/focus-stroke-trial (accessed 12 02 2021). CookR , ThomasV , MartinR . Does fluoxetine improve recovery after stroke?BMJ2019;364:1029. DennisM , ForbesJ , GrahamC , HackettM , HankeyGJ , HouseA , et al. Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT. Health Technology Assessment2020;24(22):1-94. DennisM , ForbesJ , GrahamC , HackettML , HankeyGJ , HouseA , et al. Fluoxetine and fractures after stroke: exploratory analyses from the FOCUS Trial. Stroke2019;50(11):3280-2. FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet2019;393(10168):265-74. GrahamC , LewisS , ForbesJ , MeadG , HackettML , HankeyGJ , et al. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. Trials2017;18(1):627. LundstromE , DennisM , MeadG . The effects of fluoxetine on fracture risk after stroke: Further analyses from the focus trial. European Stroke Journal2019;4 suppl 1:7142019. MeadG , DennisM . Feasibility of reporting results of large randomised controlled trials to participants: experience from the Fluoxetine or Control under Supervision (FOCUS) trial. BMJ Open2020;10(11):e0404922020. MeadG . Fluoxetine Or Control Under Supervision (FOCUS) trial: to establish the effect(s) of routine administration of Fluoxetine in patients with a recent stroke. www.isrctn.com/ISRCTN83290762 (first received 23 May 2012). MeadGE , DennisMS , InnesK , MacLeodM , SandercockPA , HouseA , et al. A multicentre randomised trial to establish the effect(s) of routine administration of fluoxetine in patients with a recent stroke (Fluoxetine Or Control Under Supervision, FOCUS). In: 21st European Stroke Conference. 2012:Abst OAID 26. MeadGE , GrahamC , BillotL , NäsmanP , LundströmE , LewisS , on behalf of the FOCUS , AFFINITY and EFFECTS trialists. Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis. Trials2020;21(1):971. MeadGE , LeggL , TilneyR , HsiehCF , WuS , LundströmE , et al. Fluoxetine for stroke recovery: meta-analysis of randomized controlled trials. International Journal of Stroke2020;15(4):365-76. ">FOCUS 2019</a>; <a href="./references#CD009286-bbs2-0024" title="FruehwaldS , GatterbauerE , RehakP , BaumhacklU . Early fluoxetine treatment of post-stroke depression: a three-month double-blind placebo-controlled study with an open-label long-term follow up. Journal of Neurology2003;250(3):347-51. ">Fruehwald 2003</a>; <a href="./references#CD009286-bbs2-0025" title="GaoJ , LinM , ZhaoJ , BiS , NiZ , ShangX . Different interventions for post-ischaemic stroke depression in different time periods: a single-blind randomized controlled trial with stratification by time after stroke. Clinical Rehabilitation2017;31(7):71-81. ">Gao 2017</a>; <a href="./references#CD009286-bbs2-0027" title="GongL , YangX , FengY , FeiZ , WangM , QinB , et al. The efficacy of integrative anti-depressive therapy on motor recovery after ischemic stroke: a randomized clinical trial. European Journal of Integrative Medicine2020;35:101102. ">Gong 2020</a>; <a href="./references#CD009286-bbs2-0029" title="HeP . Randomized controlled observation on the effect of early application of fluoxetine in preventing depression after stroke. Chinese Journal of Clinical Rehabilitation2004;8(28):6016-7. ">He 2004</a>; <a href="./references#CD009286-bbs2-0031" title="ChiCTR-TRC-12002078. Multi-center randomized clinical study of antidepressant treatment (fluoxetine) on secondary prevention of ischemic stroke. www.chictr.org.cn/showprojen.aspx?proj=7471 (first received 3 April 2012). GuoY , HeY , TangB , MaK , CaiZ , ZengS , et al. Effect of using fluoxetine at different time windows on neurological functional prognosis after ischaemic stroke. Restorative Neurology and Neuroscience2016;34:177-87. HeY , CaiZ , ZengS , ChenS , TangB , LiangY , et al. Effect of fluoxetine on three-year recurrence in acute ischemic stroke: a randomized controlled clinical study. Clinical Neurology and Neurosurgery2018;168:1-6. He Y-T, Tang B-S, Cai Z-L, Zeng S-L, JiangX , Guo Yi. Effects of fluoxetine on neural functional prognosis after ischemic stroke: a randomized controlled study in China. Journal of Stroke and Cerebrovascular Diseases2016;25(4):761-70. ">He 2016</a>; <a href="./references#CD009286-bbs2-0032" title="HuY , SuoA , XiangL . The comparative study of the effectiveness of fluoxetine on the stroke patients with depressive symptoms. Shanghai Archives of Psychiatry2002;14:149-50. ">Hu 2002</a>; <a href="./references#CD009286-bbs2-0034" title="Huang X-H. The clinical correlation study and the effect of fluoxetine intervention on poststroke depression. Chinese Journal of Clinical Rehabilitation2002;6(15):2296-7. ">Huang 2002</a>; <a href="./references#CD009286-bbs2-0006" title="AsadollahiM , RamezaniM , KhanmoradiZ , KarimialavijehE . The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial. Clinical Rehabilitation2018;32(8):1069-75. ">Asadollahi 2018</a>; <a href="./references#CD009286-bbs2-0036" title="KimJS , Lee E-J, Chang D-ll, Park J-H, AhnSH , Cha J-K, et al. Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Psychiatry2017;4(1):33-41. LeeEJ , KimJS , ChangDI , ParkJH , AhnSH , ChaJK , et al. Differences in therapeutic responses and factors affecting post-stroke depression at a later stage according to baseline depression. Journal of Stroke2018;20(2):258-67. LeeEJ , KimJS , ChangDI , ParkJH , AhnSH , ChaJK , et al. Post-stroke depressive symptoms: varying responses to escitalopram by individual symptoms and lesion location. Journal of Geriatric Psychiatry and Neurology2020;10:891988720957108. LeeEJ , OhMS , KimJS , ChangDI , ParkJH , ChaJK , EMOTION investigators. Serotonin transporter gene polymorphisms may be associated with poststroke neurological recovery after escitalopram use. Journal of Neurology, Neurosurgery and Psychiatry2018;89(3):271-6. NCT01278498. The preventative effect of escitalopram on depression and related emotional disorders in acute stroke patients, 2011. clinicaltrials.gov/ct2/show/NCT01278498 (first received 19 January 2011). [NCT01278498]">Kim 2017</a>; <a href="./references#CD009286-bbs2-0037" title="KongY . Fluoxetine for poststroke depression: a randomized placebo controlled clinical trial. Neural Regeneration Research2007;2(3):162-5. ">Kong 2007</a>; <a href="./references#CD009286-bbs2-0039" title="LiJ , He Q-Y, Han M-F. Recent effect of fluoxetine in improving neurologic impairment and preventing post-stroke depression in the early stage. Chinese Journal of Clinical Rehabilitation2004;8(7):1208-9. ">Li 2004a</a>; <a href="./references#CD009286-bbs2-0040" title="Li C-M, Jiang X-D, LiaoG , Lei J-M, LanS , Ni F-W. Effect of antidepressant drugs in early period on the recovery of post-stroke depression. Chinese Journal of Clinical Rehabilitation2004;8(19):3713-5. ">Li 2004b</a>; <a href="./references#CD009286-bbs2-0044" title="Li L-T, Wang S-H, Ge H-Y, ChenJ , Yue S-W, YuM . The beneficial effects of the herbal medicine free and easy wanderer plus (FEWP) and fluoxetine on post-stroke depression. Journal of Alternative and Complementary Medicine2008;14(7):841-6. ">Li 2008</a>; <a href="./references#CD009286-bbs2-0047" title="Marquez-RomeroJM , ArauzA , Ruiz-SandovalJL , Cruz-Estrada EdeL , Huerta-FrancoMR , Aguayo-LeytteG , et al. Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH): study protocol for a randomized, double-blind, placebo-controlled, multicenter trial. Trials2013;14:77. Marquez-RomeroJM , Reyes-MartínezM , Huerta-FrancoMR , Ruiz-FrancoA , SilosH , ArauzA . Fluoxetine for motor recovery after acute intracerebral hemorrhage, the FMRICH trial. Clinical Neurology and Neurosurgery2020;190:105656. Marquez-RomeroJM , Reyes-MartínezM , Huerta-FrancoMR , Ruiz-FrancoA , SilosH , ArauzA . Fluoxetine for motor recovery after acute intracerebral hemorrhage, the FMRICH Trial. Correspondence from Marquez-Romero2018. Marquez-RomeroJM . Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH). www.clinicaltrials.gov/ct2/show/NCT01737541 (first received 29 November 2012). ">Marquez Romero 2013</a>; <a href="./references#CD009286-bbs2-0054" title="Pan X-L, Chen H-F, ChengX , Hu C-C, Wang J-W, Fu Y-M, et al. Effects of paroxetine on motor and cognitive function recovery in patients with non-depressed ischemic stroke: an open randomized controlled study. Brain Impairment;doi: 10.1017/BrImp.2018.6. ">Pan 2018</a>; <a href="./references#CD009286-bbs2-0056" title="RasmussenA , LundeM , PoulsenD , SørensenK , QvitzauS , BechP . A double-blind placebo controlled study of sertraline in the prevention of depression in stroke patients. European Neuropyschopharmacology2002;12:231. RasmussenA , LundeM , PoulsenDL , SørensenK , QvitzauS , BechP . A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients. Psychosomatics2003;44(3):216-22. RasmussenA . Depression and stroke. Nordic Journal of Psychiatry2001;55(4):288. RasmussenA . Prophylactic treatment for post-stroke depression and comorbidity. Journal of Psychosomatic Research2000;48(3):66. ">Rasmussen 2003</a>; <a href="./references#CD009286-bbs2-0061" title="JorgeRE , AcionL , MoserD , AdamsHP , RobinsonRG . Escitalopram and enhancement of cognitive recovery following stroke. Archives of General Psychiatry2010;67(2):187-96. RobinsonRG , ArndtS . Incomplete financial disclosure in a study of escitalopram and problem solving therapy for prevention of post-stroke depression. JAMA2009;301:1023-4. RobinsonRG , JorgeRE , MoserDJ , AcionL , SolodkinA , SmallSL , et al. Escitalopram and problem-solving therapy for prevention of poststroke depression. JAMA2008;299(20):2391-400. ">Robinson 2008</a>; <a href="./references#CD009286-bbs2-0062" title="Savadi OskouieD , SharifipourE , Sadeghi BazarganiH , HashemilarM , NikanfarM , Ghazanfari AmlashiS , et al. Efficacy of citalopram on acute ischemic stroke outcome: a randomized clinical trial. Neurorehabilitation and Neural Repair2017;31(7):638-47. Savadi OskouieD . Evaluation of the effect of citalopram on three months functional prognosis of acute ischemic stroke patients: a randomized clinical trial. www.en.irct.ir/trial/1766 (first received 22 April 2012). ">Savadi Oskouie 2012</a>; <a href="./references#CD009286-bbs2-0063" title="ShahIA , AsimiRP , KawoosY , WaniMA , WaniMA , DarMA . Effect of fluoxetine on motor recovery after acute haemorrhagic stroke: a randomized trial. Journal of Neurology and Neurophysiology2016;7(2). [DOI: 10.4172/2155-9562.1000364]">Shah 2016</a>; <a href="./references#CD009286-bbs2-0064" title="Song J-G. Effects of fluoxetine hydrochloride on depressive symptoms and P300 after cerebral stroke. Chinese Journal of Clinical Rehabilitation2006;10(14):160-2. ">Song 2006</a>; <a href="./references#CD009286-bbs2-0067" title="Wen Z-X. The influence of post-stroke prophylactic anti-depression treatment on nerve functional rehabilitation. Acta Academiae Medicinae Qingdao Universitatis2006;42(3):253-4. ">Wen 2006</a>; <a href="./references#CD009286-bbs2-0068" title="WiartL , PetitH , JosephPA , MazauxJM , BaratM . Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke2000;31(8):1829-32. ">Wiart 2000</a>; <a href="./references#CD009286-bbs2-0069" title="XieR , LiuJ , QuanH . A prospective random clinical contrast study of treatment with sertraline in elderly patients with post-stroke depression. Chinese Journal of Clinical Neuroscience2005;13(3):294-7. ">Xie 2005</a>; <a href="./references#CD009286-bbs2-0070" title="XuJ , TanJ , OuL . A study on treatment of fluoxetine to depression in early recovery stage of cerebral infarction. Chinese Journal of Rehabilitation Medicine2001;16(5):281-3. ">Xu 2001</a>; <a href="./references#CD009286-bbs2-0071" title="XuJ , WangJ , LiuJ . Preventive effects of antidepressants on post-stroke depression. Chinese Mental Health Journal2006;20(3):186-8. ">Xu 2006</a>; <a href="./references#CD009286-bbs2-0073" title="YangJ . Therapeutic effect of paroxetine on patients with early poststroke depression and the serum interleukins. Chinese Journal of Cerebrovascular Diseases2011;8(5):235-8. ">Yang 2011</a>; <a href="./references#CD009286-bbs2-0074" title="Ye L-X, WangH , Wang Y-D, ZhongL , Liang D-S, GuoY . Effect of anti-depressive therapy on the rehabilitation of psychological and neurological function after stroke. Chinese Journal of Clinical Rehabilitation2004;8(31):6826-8. YeLX . Effect of paxil and berhomine on post-stroke anxiety-depression and neurological recovery. Chinese Journal of Clinical Rehabilitation2006;10(6):153-5. ">Ye 2004</a>; <a href="./references#CD009286-bbs2-0075" title="ZhaoP , Wang J-P. Effects of antidepressants on neurofunctional recovery of post-stroke patients with aphasia. Journal of Dalian Medical University2011;33(1):55-7. ">Zhao 2011</a>; <a href="./references#CD009286-bbs2-0076" title="Zhou Z-l, Liang L-Z, Yan Y-X. Preventive effects of fluoxetine on post-stroke depression. Chinese Journal of Modern Applied Pharmacy2008;25(3):263-4. ">Zhou 2008</a>). </p> </li> <li> <p>Five studies described participants as having an 'acute stroke'; so we have included these in the zero‐to‐three‐month group (<a href="./references#CD009286-bbs2-0011" title="CaoJX , LiuL , SunYT , ZengQH , WangY , ChenJC . Effects of the prophylactic use of escitalopram on the prognosis and the plasma copeptin level in patients with acute cerebral infarction. Brazilian Journal of Medical and Biological Research2020;53(11):e8930. CaoJX , LiuL , SunYT , ZengQH , YangZD , ChenJC . Escitalopram improves neural functional prognosis and endothelial dysfunction in patients with acute cerebral infarction. Restorative Neurology and Neuroscience2020;38(5):385-93. ">Cao 2020</a>; <a href="./references#CD009286-bbs2-0030" title="HeY , WangX , XiaoC . Prospective study of effects of paroxetine with mental intervention on depression and anxiety after stroke. Nervous Diseases and Mental Health2005;5(1):6-13. WangX , HeY , Xiao C-L. A clinical trial of paroxetine and psychotherapy in patients with post-stroke depression and anxiety. Chinese Mental Health Journal2005;19:564-6. ">He 2005</a>; <a href="./references#CD009286-bbs2-0038" title="LaiJ . The effect of using paroxetine to treat post stroke depression. Journal of Guangdong Medical College2006;24(6):585-6. ">Lai 2006</a>; <a href="./references#CD009286-bbs2-0042" title="Li W-Q, Li D-X. The efficacy of citalopram for post-stroke depression and its effects on stroke rehabilitation. International Journal of Cerebrovascular Diseases2006;14(4):275-8. ">Li 2006</a>; <a href="./references#CD009286-bbs2-0053" title="NCT02737930. Fluoxetine for visual recovery after ischaemic stroke (FLUORESCE). www.clinicaltrials.gov/ct2/show/NCT02737930 (first received 14 April 2016). ">NCT02737930</a>). </p> </li> <li> <p>Two further studies reported that the mean time since stroke was between five and 16 weeks, so we included these in the zero‐to three‐month group (<a href="./references#CD009286-bbs2-0059" title="JorgeRE , RobinsonRG , ArndtS , StarksteinS . Mortality and post-stroke depression: a placebo controlled trial of antidepressants. American Journal of Psychiatry2003;160:1823-9. NarushimaK , KosierJT , RobinsonRG . Preventing post-stroke depression: a 12 week double blind randomised treatment trial and 21 month follow-up. Journal of Nervous and Mental Diseases2002;190:296-303. RobinsonRG , SchultzSK , CastilloC , KopelT , KosierJT , NewmanRM , et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. American Journal of Psychiatry2000;157(3):351-9. ">Robinson 2000a</a>; <a href="./references#CD009286-bbs2-0060" title="JorgeRE , RobinsonRG , ArndtS , StarksteinS . Mortality and post-stroke depression: a placebo controlled trial of antidepressants. American Journal of Psychiatry2003;160:1823-9. NarushimaK , RobinsonRG . Preventing post-stroke depression: a 12 week double blind randomised treatment trial and 21 month follow-up. Journal of Nervous and Mental Diseases2002;190:296-303. RobinsonRG , SchultzSK , CastilloC , KopelT , KosierJT , NewmanRM , et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. American Journal of Psychiatry2000;157(3):351-9. ">Robinson 2000b</a>). </p> </li> <li> <p>One study, which did not recruit any participants, had an inclusion criterion of less than 15 days before stroke (<a href="./references#CD009286-bbs2-0052" title="NCT01674868. Fluoxetine for motor, aphasia, and neglect recovery after ischemic stroke (FLAN). www.clinicaltrials.gov/ct2/show/NCT01674868 (first received 29 August 2012). ">NCT01674868</a>). </p> </li> <li> <p>Four studies report recruiting participants three to six months (91 to 108 days) after stroke onset: <a href="./references#CD009286-bbs2-0019" title="DamM , ToninP , De BoniA , PizzolatoG , CassonS , ErmaniM , et al. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke1996;27(7):1211-4. ">Dam 1996</a> (described as participants being one to six months), <a href="./references#CD009286-bbs2-0049" title="Miao S-Y, Shi Y-J. Related factors of post-stroke depression and therapeutical effect of citalopram. Chinese Journal of Clinical Rehabilitation2004;8(19):3718-9. ">Miao 2004</a>, <a href="./references#CD009286-bbs2-0050" title="MurrayV , Von ArbinM , BartfaiA , Berggren A-L, Landtblom A-M, LumdmarkJ , et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry2005;66(6):708-16. ">Murray 2005</a>, and <a href="./references#CD009286-bbs2-0072" title="YangJ , ZhaoY , BaiS . Controlled study on antidepressant treatment of patients with post-stroke depression. Chinese Mental Health Journal2002;16(12):871-2. ">Yang 2002</a> ('recovery phase of stroke' two to six months). </p> </li> <li> <p>Two studies report recruiting participants at six to nine months (181 to 271 days) after stroke onset (<a href="./references#CD009286-bbs2-0028" title="Guo R-Y, SuL , WangCX . Effects of Linggui Bafa on the therapeutic effect and quality of life in patients of post-stroke depression. Chinese Acupuncture &amp; Moxibustion2009;29(10):785-90. ">Guo 2009</a>; <a href="./references#CD009286-bbs2-0042" title="Li W-Q, Li D-X. The efficacy of citalopram for post-stroke depression and its effects on stroke rehabilitation. International Journal of Cerebrovascular Diseases2006;14(4):275-8. ">Li 2006</a>). </p> </li> <li> <p>No study reported recruiting participants between nine and 12 months after stroke.</p> </li> <li> <p>One study reported the experimental and control group being median 10.5 months and 5.5 months after stroke, respectively (<a href="./references#CD009286-bbs2-0010" title="BurnsA , RussellE , Stratton-PowellH , TyrellP , O'NeillP , BaldwinR . Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry1999;14(8):681-5. ">Burns 1999</a>). </p> </li> <li> <p>Seventeen studies did not report the precise time (<a href="./references#CD009286-bbs2-0009" title="BrownKW , SloanRL , PentlandB . Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatrica Scandinavica1998;98(6):455-8. ">Brown 1998</a>; <a href="./references#CD009286-bbs2-0013" title="ChenW , Wang G-F, Chen X-H, Sheng Y-L, ZhuH . Effects of paroxetine on function recovery in patients with post-stroke depression. Chinese Journal of Clinical Rehabilitation2002;6(13):2014-5. ">Chen 2002</a>; <a href="./references#CD009286-bbs2-0014" title="ChenKN . Changes of neurotransmitter in patients with post-stroke depression observed with encephalofluctuography technology. Chinese Journal of Clinical Rehabilitation2005;9(16):118-9. ">Chen 2005a</a>; <a href="./references#CD009286-bbs2-0016" title="ChenZ , XuX , WuY , HuangL . Clinical efficacy of drug intervention in patients with acute depression after stroke. International Journal of Psychiatry2015;42(5):97-100. ">Chen 2015</a>; <a href="./references#CD009286-bbs2-0026" title="GlaxoSmithKline. An 8-week double-blind placebo controlled parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from depression following stroke. GSK Clinical Study Register www.gsk clinicalstudyregister.com (accessed 31 August 2012). ">GlaxoSmithKline 1998</a>; <a href="./references#CD009286-bbs2-0033" title="HuH , WangM . Effects of escitalopram on post-stroke depression and cognitive function of patients with neurological function. Hebei Medicine2018;24(2):325-8. ">Hu 2018</a>; <a href="./references#CD009286-bbs2-0035" title="JiaW . Effect of early intervention on recovery of motor function and recurrent stroke in patients with post-stroke depression. Chinese Journal of Clinical Rehabilitation2005;9(12):4-5. ">Jia 2005</a>; <a href="./references#CD009286-bbs2-0041" title="LiY , WangX , QianFS . Related factors of post-stroke depression and effect of paroxetine. Shandong Archives of Psychiatry2005;18(4):209-10. ">Li 2005</a>; <a href="./references#CD009286-bbs2-0043" title="LiZ . Clinical efficacy of paroxetine in the treatment of post-stroke depression. Modern Journal of Integrated Traditional Chinese and Western Medicine2007;16(34):5103-4. ">Li 2007</a>; <a href="./references#CD009286-bbs2-0045" title="LiJ , WangJ , LiY , ZhangW , ZhaoJ . Effects of escitalopram oxalate on post-stroke depression, cognition and neurological function. Journal of Hebei Medical University2017;38(5):589-92. ">Li 2017</a>; <a href="./references#CD009286-bbs2-0048" title="MearaRJ , ThalananyM , BalonwuV , HobsonP . The treatment of depression after stroke with the selective serotonin reuptake inhibitor sertraline. Cerebrovascular Diseases1998;8 Suppl 4:90. ">Meara 1998</a>; <a href="./references#CD009286-bbs2-0051" title="NCT00177424. Setraline for prevention post stroke depression and improving rehabilitation outcomes. clinicaltrials.gov/ct2/show/NCT00177424 (first received 15 September 2005). ">NCT00177424</a>; <a href="./references#CD009286-bbs2-0055" title="Guiraud-ChaumeilB , ParienteJ , Albucher J-F, LoubinouxI , CholletF . Rehabilitation after stroke [Recuperation neurologique post-ischemique]. Bulletin de l'Académie Nationale de Médecine2002;6:1015-24. ParienteJ , LoubinouxI , CarelC , AlbucherJF , LegerA , ManelfeC , et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Annals of Neurology2001;50(6):718-29. ">Pariente 2001</a>; <a href="./references#CD009286-bbs2-0057" title="RazazianN , EsmaeiliO , AlmasiA . Effect of fluoxetine on motor improvement in ischemic stroke patients: a double blind clinical trial study. Zahedan Journal of Research in Medical Sciences2016;18(7):e75492016. RazazianN . A survey for assessment of effectiveness of fluoxetine on motor improvement in ischemic stroke patients. www.en.irct.ir/trial/8797 (first received 9 January 2014). ">Razazian 2014</a>; <a href="./references#CD009286-bbs2-0058" title="RestifoDA , Lo PrestR , LanzaS , GiuffridaS , D'AleoG , Rifici Di BellaC , et al. Motor cortex reorganization induced by fluoxetine in poststroke hemiplegic patients undergoing rehabilitation therapy: a study with transcranial magnetic stimulation. Neurorehabilitation and Neural Repair2001;15(4):284. ">Restifo 2001</a>; <a href="./references#CD009286-bbs2-0065" title="WangX , TanZ , WuZ , GaoJ , FengM . The effects of anti-depression therapy on post-stroke depression and neurologic rehabilitation in the elderly patients. Chinese Journal of Geriatrics2003;22(5):270-3. ">Wang 2003</a>; <a href="./references#CD009286-bbs2-0066" title="WangX . The efficacy of paroxetine in the treatment of post-stroke depression in 55 cases. Chinese Community Physician (Medical Professional Half-monthly)2009;11(7):11. ">Wang 2009</a>). </p> </li> </ul> </p> </section> <section id="CD009286-sec-0046"> <h5 class="title">Depression as an inclusion criterion</h5> <p>Thirty‐seven studies included participants affected by depression (i.e. depression used as an inclusion criterion) (<a href="./references#CD009286-bbs2-0004" title="AndersenG , VestergaardK , LauritzenL . Effective treatment of post-stroke depression with selective serotonin reuptake inhibitors. Journal of Neurology1994;241:S42. AndersenG , VestergaardK , LauritzenL . Effective treatment of post-stroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke1994;25(6):1099-104. AndersenG , VestergaardK , LauritzenL . Post-stroke depression treated with citalopram. Acta Neurologica Scandinavica1994;89 Suppl 155:20. AndersenG , VestergaardK , LauritzenL . Post-stroke depression treated with citalopram - a selective serotonin reuptake inhibitor. Canadian Journal of Neurological Sciences1993;20:S115. AndersenG , VestergaardK , LauritzenL . Post-stroke depression treated with citalopram a selective serotonin reuptake inhibitor. In: 7th Scandinavian Meeting on Cerebrovascular Disease. 1993:54. AndersenG , VestergaardK , LauritzenLU . Effective treatment of depression following apoplexy with citalopram. Ugeskrift for Laeger1995;157(14):2000-3. FlickerC , AndersenG , BayerL . A placebo controlled study of citalopram treatment for post-stroke depression. In: 11th Annual Meeting of the American Association for Geriatric Psychiatry. 1998. ">Andersen 1994</a>; <a href="./references#CD009286-bbs2-0012" title="ChenWY , LiuFY , YangAP . Study of effect of integrative Chinese herbs with fluoxetine on rehabilitation of neurological impairment in patients with post-stroke depression. Journal of Chengdu University of Traditional Chinese Medicine2001;24(4):20-3. ">Chen 2001</a>; <a href="./references#CD009286-bbs2-0013" title="ChenW , Wang G-F, Chen X-H, Sheng Y-L, ZhuH . Effects of paroxetine on function recovery in patients with post-stroke depression. Chinese Journal of Clinical Rehabilitation2002;6(13):2014-5. ">Chen 2002</a>; <a href="./references#CD009286-bbs2-0014" title="ChenKN . Changes of neurotransmitter in patients with post-stroke depression observed with encephalofluctuography technology. Chinese Journal of Clinical Rehabilitation2005;9(16):118-9. ">Chen 2005a</a>; <a href="./references#CD009286-bbs2-0015" title="ChenT , LiJ , HanM . A study on paroxetine in the treatment for post-stroke depression. Jiangxi Medicine2005;40(7):382-4. ">Chen 2005b</a>; <a href="./references#CD009286-bbs2-0016" title="ChenZ , XuX , WuY , HuangL . Clinical efficacy of drug intervention in patients with acute depression after stroke. International Journal of Psychiatry2015;42(5):97-100. ">Chen 2015</a>; <a href="./references#CD009286-bbs2-0017" title="ChengF , ShaoG , BaoS . Study of effect on neurologic function rehabilitation in patient with post-stroke depression. Chinese Journal of Clinical Rehabilitation2003;7(1):108-9. ">Cheng 2003</a>; <a href="./references#CD009286-bbs2-0022" title="Feng B-L, Wang Q-C, Zheng-YuanLI . Influence of Jieyu Huoxue decoction on rehabilitation of patients with depression after cerebral infarction. Journal of Chinese Integrated Medicine2004;2(3):182-4. ">Feng 2004</a>; <a href="./references#CD009286-bbs2-0024" title="FruehwaldS , GatterbauerE , RehakP , BaumhacklU . Early fluoxetine treatment of post-stroke depression: a three-month double-blind placebo-controlled study with an open-label long-term follow up. Journal of Neurology2003;250(3):347-51. ">Fruehwald 2003</a>; <a href="./references#CD009286-bbs2-0026" title="GlaxoSmithKline. An 8-week double-blind placebo controlled parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from depression following stroke. GSK Clinical Study Register www.gsk clinicalstudyregister.com (accessed 31 August 2012). ">GlaxoSmithKline 1998</a>; <a href="./references#CD009286-bbs2-0028" title="Guo R-Y, SuL , WangCX . Effects of Linggui Bafa on the therapeutic effect and quality of life in patients of post-stroke depression. Chinese Acupuncture &amp; Moxibustion2009;29(10):785-90. ">Guo 2009</a>; <a href="./references#CD009286-bbs2-0030" title="HeY , WangX , XiaoC . Prospective study of effects of paroxetine with mental intervention on depression and anxiety after stroke. Nervous Diseases and Mental Health2005;5(1):6-13. WangX , HeY , Xiao C-L. A clinical trial of paroxetine and psychotherapy in patients with post-stroke depression and anxiety. Chinese Mental Health Journal2005;19:564-6. ">He 2005</a>; <a href="./references#CD009286-bbs2-0032" title="HuY , SuoA , XiangL . The comparative study of the effectiveness of fluoxetine on the stroke patients with depressive symptoms. Shanghai Archives of Psychiatry2002;14:149-50. ">Hu 2002</a>; <a href="./references#CD009286-bbs2-0033" title="HuH , WangM . Effects of escitalopram on post-stroke depression and cognitive function of patients with neurological function. Hebei Medicine2018;24(2):325-8. ">Hu 2018</a>; <a href="./references#CD009286-bbs2-0034" title="Huang X-H. The clinical correlation study and the effect of fluoxetine intervention on poststroke depression. Chinese Journal of Clinical Rehabilitation2002;6(15):2296-7. ">Huang 2002</a>; <a href="./references#CD009286-bbs2-0035" title="JiaW . Effect of early intervention on recovery of motor function and recurrent stroke in patients with post-stroke depression. Chinese Journal of Clinical Rehabilitation2005;9(12):4-5. ">Jia 2005</a>; <a href="./references#CD009286-bbs2-0038" title="LaiJ . The effect of using paroxetine to treat post stroke depression. Journal of Guangdong Medical College2006;24(6):585-6. ">Lai 2006</a>; <a href="./references#CD009286-bbs2-0039" title="LiJ , He Q-Y, Han M-F. Recent effect of fluoxetine in improving neurologic impairment and preventing post-stroke depression in the early stage. Chinese Journal of Clinical Rehabilitation2004;8(7):1208-9. ">Li 2004a</a>; <a href="./references#CD009286-bbs2-0040" title="Li C-M, Jiang X-D, LiaoG , Lei J-M, LanS , Ni F-W. Effect of antidepressant drugs in early period on the recovery of post-stroke depression. Chinese Journal of Clinical Rehabilitation2004;8(19):3713-5. ">Li 2004b</a>; <a href="./references#CD009286-bbs2-0041" title="LiY , WangX , QianFS . Related factors of post-stroke depression and effect of paroxetine. Shandong Archives of Psychiatry2005;18(4):209-10. ">Li 2005</a>; <a href="./references#CD009286-bbs2-0042" title="Li W-Q, Li D-X. The efficacy of citalopram for post-stroke depression and its effects on stroke rehabilitation. International Journal of Cerebrovascular Diseases2006;14(4):275-8. ">Li 2006</a>; <a href="./references#CD009286-bbs2-0044" title="Li L-T, Wang S-H, Ge H-Y, ChenJ , Yue S-W, YuM . The beneficial effects of the herbal medicine free and easy wanderer plus (FEWP) and fluoxetine on post-stroke depression. Journal of Alternative and Complementary Medicine2008;14(7):841-6. ">Li 2008</a>; <a href="./references#CD009286-bbs2-0045" title="LiJ , WangJ , LiY , ZhangW , ZhaoJ . Effects of escitalopram oxalate on post-stroke depression, cognition and neurological function. Journal of Hebei Medical University2017;38(5):589-92. ">Li 2017</a>; <a href="./references#CD009286-bbs2-0046" title="LiuY , XuR . Effect of citalopram treatment on post-stroke depression and neurological functional rehabilitation. Chinese Journal of Rehabilitation2006;21(3):174-5. ">Liu 2006</a>; <a href="./references#CD009286-bbs2-0048" title="MearaRJ , ThalananyM , BalonwuV , HobsonP . The treatment of depression after stroke with the selective serotonin reuptake inhibitor sertraline. Cerebrovascular Diseases1998;8 Suppl 4:90. ">Meara 1998</a>; <a href="./references#CD009286-bbs2-0049" title="Miao S-Y, Shi Y-J. Related factors of post-stroke depression and therapeutical effect of citalopram. Chinese Journal of Clinical Rehabilitation2004;8(19):3718-9. ">Miao 2004</a>; <a href="./references#CD009286-bbs2-0050" title="MurrayV , Von ArbinM , BartfaiA , Berggren A-L, Landtblom A-M, LumdmarkJ , et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry2005;66(6):708-16. ">Murray 2005</a>; <a href="./references#CD009286-bbs2-0059" title="JorgeRE , RobinsonRG , ArndtS , StarksteinS . Mortality and post-stroke depression: a placebo controlled trial of antidepressants. American Journal of Psychiatry2003;160:1823-9. NarushimaK , KosierJT , RobinsonRG . Preventing post-stroke depression: a 12 week double blind randomised treatment trial and 21 month follow-up. Journal of Nervous and Mental Diseases2002;190:296-303. RobinsonRG , SchultzSK , CastilloC , KopelT , KosierJT , NewmanRM , et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. American Journal of Psychiatry2000;157(3):351-9. ">Robinson 2000a</a>; <a href="./references#CD009286-bbs2-0064" title="Song J-G. Effects of fluoxetine hydrochloride on depressive symptoms and P300 after cerebral stroke. Chinese Journal of Clinical Rehabilitation2006;10(14):160-2. ">Song 2006</a>; <a href="./references#CD009286-bbs2-0065" title="WangX , TanZ , WuZ , GaoJ , FengM . The effects of anti-depression therapy on post-stroke depression and neurologic rehabilitation in the elderly patients. Chinese Journal of Geriatrics2003;22(5):270-3. ">Wang 2003</a>; <a href="./references#CD009286-bbs2-0066" title="WangX . The efficacy of paroxetine in the treatment of post-stroke depression in 55 cases. Chinese Community Physician (Medical Professional Half-monthly)2009;11(7):11. ">Wang 2009</a>; <a href="./references#CD009286-bbs2-0068" title="WiartL , PetitH , JosephPA , MazauxJM , BaratM . Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke2000;31(8):1829-32. ">Wiart 2000</a>; <a href="./references#CD009286-bbs2-0069" title="XieR , LiuJ , QuanH . A prospective random clinical contrast study of treatment with sertraline in elderly patients with post-stroke depression. Chinese Journal of Clinical Neuroscience2005;13(3):294-7. ">Xie 2005</a>; <a href="./references#CD009286-bbs2-0070" title="XuJ , TanJ , OuL . A study on treatment of fluoxetine to depression in early recovery stage of cerebral infarction. Chinese Journal of Rehabilitation Medicine2001;16(5):281-3. ">Xu 2001</a>; <a href="./references#CD009286-bbs2-0072" title="YangJ , ZhaoY , BaiS . Controlled study on antidepressant treatment of patients with post-stroke depression. Chinese Mental Health Journal2002;16(12):871-2. ">Yang 2002</a>; <a href="./references#CD009286-bbs2-0073" title="YangJ . Therapeutic effect of paroxetine on patients with early poststroke depression and the serum interleukins. Chinese Journal of Cerebrovascular Diseases2011;8(5):235-8. ">Yang 2011</a>; <a href="./references#CD009286-bbs2-0074" title="Ye L-X, WangH , Wang Y-D, ZhongL , Liang D-S, GuoY . Effect of anti-depressive therapy on the rehabilitation of psychological and neurological function after stroke. Chinese Journal of Clinical Rehabilitation2004;8(31):6826-8. YeLX . Effect of paxil and berhomine on post-stroke anxiety-depression and neurological recovery. Chinese Journal of Clinical Rehabilitation2006;10(6):153-5. ">Ye 2004</a>). </p> <p>Thirty‐nine studies did not use depression as an inclusion criterion (<a href="./references#CD009286-bbs2-0001" title="AclerM , AvesaniA , FiaschiA , ManganottiP . Serotonergic modulation of brain excitability and motor recovery in patients affected by stroke. A double blind placebo RCT. International Journal of Stroke2008;3:336. AclerM , RobolE , FiaschiA , ManganottiP . A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. Journal of Neurology2009;256(7):1152-8. ">Acler 2009</a>; <a href="./references#CD009286-bbs2-0002" title="ACTRN12611000774921. Assessment of fluoxetine in stroke recovery (AFFINITY) trial, 2011. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000774921 (first received 22 July 2011). ACTRN12619000986178. The assessment of fluoxetine in stroke recovery imaging and blood biomarkers sub-study AFFINITY BM. www.anzctr.org.au/Trial/Registration/TrialReview.aspx ?ACTRN=12619000986178 (first received 11 July 2019). AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):651-60. HankeyG . Assessment oF FluoxetINe In sTroke recoverY (AFFINITY). www.affinitytrial.org/ (accessed 19th February 2019). ">AFFINITY 2020</a>; <a href="./references#CD009286-bbs2-0003" title="AlmeidaOP , WaterreusA , HankeyGJ . Preventing depression after stroke: results from a randomized placebo-controlled trial. Journal of Clinical Psychiatry2006;67(7):1104-9. ">Almeida 2006</a>; <a href="./references#CD009286-bbs2-0005" title="AndersenG . The efficacy of citalopram treatment in acute stroke (TALOS). www.clinicaltrials.gov/ct2/show/NCT01937182 (first received 9 September 2013). DamsboAG , MortensenJK , KraglundKL , JohnsenSP , AndersenG , BlauenfeldtRA . Prestroke physical activity and poststroke cognitive performance. Cerebrovascular Diseases2020;49(6):632-8. KraglundKL , MortensenJK , DamsboAG , ModrauB , SimonsenSA , Iversen, HK, et al. Neuroregeneration and vascular protection by citalopram in acute ischemic stroke (TALOS). Stroke2018;49(11):2568-76. KraglundKL , MortensenJK , DamsboAG , ModrauB , SimonsenSA , IversenHK , et al. Neuroregeneration and vascular protection by citalopramin in acute ischemic stroke (TALOS). Stroke2018;49(11):2568-76. KraglundKL , MortensenJK , GroveEL , JohnsenSP , AndersenG . TALOS: a multicenter, randomised, double blind, placebo controlled trial to test the effects of citalopram in patients with acute stroke; protocol. International Journal of Stroke2015;10:985-87. KraglundKL , MortensenJK , JohnsenSP , AndersenG , GroveEL . Antiplatelet effects of citalopram in patients with ischaemic stroke: a randomized, placebo-controlled, double-blind study. Scientific Reports2019;9(1):200482019. ">Andersen 2013</a>; <a href="./references#CD009286-bbs2-0007" title="BembenekJP , NiewadaM , KlyszB , MazurA , KurczychK , GluszkiewiczM , et al. Fluoxetine for stroke recovery improvement - the doubleblind, randomised placebo-controlled FOCUS-Poland trial. Neurologia i Neurochirurgia Polska2020;54(6):544-51. Fluoxetine or control under supervision: Poland. Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products - EduraCT No: 2014-001335-372014. ">Bembenek 2020</a>; <a href="./references#CD009286-bbs2-0008" title="BirchenallJ , TérémetzM , RocaP , LamyJC , OppenheimC , MaierMA , et al. Individual recovery profiles of manual dexterity, and relation to corticospinal lesion load and excitability after stroke - a longitudinal pilot study. Neurophysiologie Clinique2019;49(2):149-64. NCT02063425. Evaluation by transcranial magnetic stimulation of the benefit of fluoxetine on motor recovery after stroke (EFLUSTIM). clinicaltrials.gov/ct2/show/NCT02063425 (first received 14 February 2014). ">Birchenall 2019</a>; <a href="./references#CD009286-bbs2-0009" title="BrownKW , SloanRL , PentlandB . Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatrica Scandinavica1998;98(6):455-8. ">Brown 1998</a>; <a href="./references#CD009286-bbs2-0010" title="BurnsA , RussellE , Stratton-PowellH , TyrellP , O'NeillP , BaldwinR . Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry1999;14(8):681-5. ">Burns 1999</a>; <a href="./references#CD009286-bbs2-0011" title="CaoJX , LiuL , SunYT , ZengQH , WangY , ChenJC . Effects of the prophylactic use of escitalopram on the prognosis and the plasma copeptin level in patients with acute cerebral infarction. Brazilian Journal of Medical and Biological Research2020;53(11):e8930. CaoJX , LiuL , SunYT , ZengQH , YangZD , ChenJC . Escitalopram improves neural functional prognosis and endothelial dysfunction in patients with acute cerebral infarction. Restorative Neurology and Neuroscience2020;38(5):385-93. ">Cao 2020</a>; <a href="./references#CD009286-bbs2-0018" title="CholletF , TardyJ , Albucher J-F, ThalamasE , BerardE , LamyC , et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurology2011;10(2):123-30. ">Chollet 2011</a>; <a href="./references#CD009286-bbs2-0019" title="DamM , ToninP , De BoniA , PizzolatoG , CassonS , ErmaniM , et al. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke1996;27(7):1211-4. ">Dam 1996</a>; <a href="./references#CD009286-bbs2-0020" title="DikeF . Pharmacological enhancement of motor function recovery in patients with ischaemic stroke: a trial of fluoxetine. www.pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=967 (last accessed 16 February 2021). DikeFO , EkehBC , OgunAS , EkrikpoEU , WalshakP , OgunniyAA . Pharmacological enhancement of motor function recovery in patients with ischaemic stroke: a trial of fluoxetine. Journal of Neurology and Stroke2019;9(1):47-51. ">Dike 2019</a>; <a href="./references#CD009286-bbs2-0021" title="EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661-9. ISRCTN13020412. Establishing the effect(s) and safety of fluoxetine initiated in the acute phase of stroke. www.isrctn.com/ISRCTN13020412 (first received 19 December 2014). LundströmE , IsakssonE , NäsmanP , WesterP , MårtenssonB , NorrvingB . Correction to: Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(388):s13063-020-04327-w. LundströmE , IsakssonE , Näsman P et al. Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(233):s13063-020-4124-7. LundstromE , IsakssonE , NasmanP , WesterP , MartenssonB , NorrvingB , et al. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661‐9. ">EFFECTS 2020</a>; <a href="./references#CD009286-bbs2-0023" title="Anonymous. The FOCUS (Fluoxetine or Control under Supervision) trial results: effects of a 6 month course of fluoxetine on the Stroke Impact Scale, mood and fatigue in patients with stroke. www.ed.ac.uk/clinical-brain-sciences/research/completed-studies-trials/focus-stroke-trial (accessed 12 02 2021). CookR , ThomasV , MartinR . Does fluoxetine improve recovery after stroke?BMJ2019;364:1029. DennisM , ForbesJ , GrahamC , HackettM , HankeyGJ , HouseA , et al. Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT. Health Technology Assessment2020;24(22):1-94. DennisM , ForbesJ , GrahamC , HackettML , HankeyGJ , HouseA , et al. Fluoxetine and fractures after stroke: exploratory analyses from the FOCUS Trial. Stroke2019;50(11):3280-2. FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet2019;393(10168):265-74. GrahamC , LewisS , ForbesJ , MeadG , HackettML , HankeyGJ , et al. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. Trials2017;18(1):627. LundstromE , DennisM , MeadG . The effects of fluoxetine on fracture risk after stroke: Further analyses from the focus trial. European Stroke Journal2019;4 suppl 1:7142019. MeadG , DennisM . Feasibility of reporting results of large randomised controlled trials to participants: experience from the Fluoxetine or Control under Supervision (FOCUS) trial. BMJ Open2020;10(11):e0404922020. MeadG . Fluoxetine Or Control Under Supervision (FOCUS) trial: to establish the effect(s) of routine administration of Fluoxetine in patients with a recent stroke. www.isrctn.com/ISRCTN83290762 (first received 23 May 2012). MeadGE , DennisMS , InnesK , MacLeodM , SandercockPA , HouseA , et al. A multicentre randomised trial to establish the effect(s) of routine administration of fluoxetine in patients with a recent stroke (Fluoxetine Or Control Under Supervision, FOCUS). In: 21st European Stroke Conference. 2012:Abst OAID 26. MeadGE , GrahamC , BillotL , NäsmanP , LundströmE , LewisS , on behalf of the FOCUS , AFFINITY and EFFECTS trialists. Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis. Trials2020;21(1):971. MeadGE , LeggL , TilneyR , HsiehCF , WuS , LundströmE , et al. Fluoxetine for stroke recovery: meta-analysis of randomized controlled trials. International Journal of Stroke2020;15(4):365-76. ">FOCUS 2019</a>; <a href="./references#CD009286-bbs2-0025" title="GaoJ , LinM , ZhaoJ , BiS , NiZ , ShangX . Different interventions for post-ischaemic stroke depression in different time periods: a single-blind randomized controlled trial with stratification by time after stroke. Clinical Rehabilitation2017;31(7):71-81. ">Gao 2017</a>; <a href="./references#CD009286-bbs2-0027" title="GongL , YangX , FengY , FeiZ , WangM , QinB , et al. The efficacy of integrative anti-depressive therapy on motor recovery after ischemic stroke: a randomized clinical trial. European Journal of Integrative Medicine2020;35:101102. ">Gong 2020</a>; <a href="./references#CD009286-bbs2-0029" title="HeP . Randomized controlled observation on the effect of early application of fluoxetine in preventing depression after stroke. Chinese Journal of Clinical Rehabilitation2004;8(28):6016-7. ">He 2004</a>; <a href="./references#CD009286-bbs2-0031" title="ChiCTR-TRC-12002078. Multi-center randomized clinical study of antidepressant treatment (fluoxetine) on secondary prevention of ischemic stroke. www.chictr.org.cn/showprojen.aspx?proj=7471 (first received 3 April 2012). GuoY , HeY , TangB , MaK , CaiZ , ZengS , et al. Effect of using fluoxetine at different time windows on neurological functional prognosis after ischaemic stroke. Restorative Neurology and Neuroscience2016;34:177-87. HeY , CaiZ , ZengS , ChenS , TangB , LiangY , et al. Effect of fluoxetine on three-year recurrence in acute ischemic stroke: a randomized controlled clinical study. Clinical Neurology and Neurosurgery2018;168:1-6. He Y-T, Tang B-S, Cai Z-L, Zeng S-L, JiangX , Guo Yi. Effects of fluoxetine on neural functional prognosis after ischemic stroke: a randomized controlled study in China. Journal of Stroke and Cerebrovascular Diseases2016;25(4):761-70. ">He 2016</a>; <a href="./references#CD009286-bbs2-0006" title="AsadollahiM , RamezaniM , KhanmoradiZ , KarimialavijehE . The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial. Clinical Rehabilitation2018;32(8):1069-75. ">Asadollahi 2018</a>; <a href="./references#CD009286-bbs2-0036" title="KimJS , Lee E-J, Chang D-ll, Park J-H, AhnSH , Cha J-K, et al. Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Psychiatry2017;4(1):33-41. LeeEJ , KimJS , ChangDI , ParkJH , AhnSH , ChaJK , et al. Differences in therapeutic responses and factors affecting post-stroke depression at a later stage according to baseline depression. Journal of Stroke2018;20(2):258-67. LeeEJ , KimJS , ChangDI , ParkJH , AhnSH , ChaJK , et al. Post-stroke depressive symptoms: varying responses to escitalopram by individual symptoms and lesion location. Journal of Geriatric Psychiatry and Neurology2020;10:891988720957108. LeeEJ , OhMS , KimJS , ChangDI , ParkJH , ChaJK , EMOTION investigators. Serotonin transporter gene polymorphisms may be associated with poststroke neurological recovery after escitalopram use. Journal of Neurology, Neurosurgery and Psychiatry2018;89(3):271-6. NCT01278498. The preventative effect of escitalopram on depression and related emotional disorders in acute stroke patients, 2011. clinicaltrials.gov/ct2/show/NCT01278498 (first received 19 January 2011). [NCT01278498]">Kim 2017</a>; <a href="./references#CD009286-bbs2-0037" title="KongY . Fluoxetine for poststroke depression: a randomized placebo controlled clinical trial. Neural Regeneration Research2007;2(3):162-5. ">Kong 2007</a>; <a href="./references#CD009286-bbs2-0043" title="LiZ . Clinical efficacy of paroxetine in the treatment of post-stroke depression. Modern Journal of Integrated Traditional Chinese and Western Medicine2007;16(34):5103-4. ">Li 2007</a>; <a href="./references#CD009286-bbs2-0047" title="Marquez-RomeroJM , ArauzA , Ruiz-SandovalJL , Cruz-Estrada EdeL , Huerta-FrancoMR , Aguayo-LeytteG , et al. Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH): study protocol for a randomized, double-blind, placebo-controlled, multicenter trial. Trials2013;14:77. Marquez-RomeroJM , Reyes-MartínezM , Huerta-FrancoMR , Ruiz-FrancoA , SilosH , ArauzA . Fluoxetine for motor recovery after acute intracerebral hemorrhage, the FMRICH trial. Clinical Neurology and Neurosurgery2020;190:105656. Marquez-RomeroJM , Reyes-MartínezM , Huerta-FrancoMR , Ruiz-FrancoA , SilosH , ArauzA . Fluoxetine for motor recovery after acute intracerebral hemorrhage, the FMRICH Trial. Correspondence from Marquez-Romero2018. Marquez-RomeroJM . Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH). www.clinicaltrials.gov/ct2/show/NCT01737541 (first received 29 November 2012). ">Marquez Romero 2013</a>; <a href="./references#CD009286-bbs2-0051" title="NCT00177424. Setraline for prevention post stroke depression and improving rehabilitation outcomes. clinicaltrials.gov/ct2/show/NCT00177424 (first received 15 September 2005). ">NCT00177424</a>; <a href="./references#CD009286-bbs2-0052" title="NCT01674868. Fluoxetine for motor, aphasia, and neglect recovery after ischemic stroke (FLAN). www.clinicaltrials.gov/ct2/show/NCT01674868 (first received 29 August 2012). ">NCT01674868</a>; <a href="./references#CD009286-bbs2-0053" title="NCT02737930. Fluoxetine for visual recovery after ischaemic stroke (FLUORESCE). www.clinicaltrials.gov/ct2/show/NCT02737930 (first received 14 April 2016). ">NCT02737930</a>; <a href="./references#CD009286-bbs2-0054" title="Pan X-L, Chen H-F, ChengX , Hu C-C, Wang J-W, Fu Y-M, et al. Effects of paroxetine on motor and cognitive function recovery in patients with non-depressed ischemic stroke: an open randomized controlled study. Brain Impairment;doi: 10.1017/BrImp.2018.6. ">Pan 2018</a>; <a href="./references#CD009286-bbs2-0055" title="Guiraud-ChaumeilB , ParienteJ , Albucher J-F, LoubinouxI , CholletF . Rehabilitation after stroke [Recuperation neurologique post-ischemique]. Bulletin de l'Académie Nationale de Médecine2002;6:1015-24. ParienteJ , LoubinouxI , CarelC , AlbucherJF , LegerA , ManelfeC , et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Annals of Neurology2001;50(6):718-29. ">Pariente 2001</a>; <a href="./references#CD009286-bbs2-0056" title="RasmussenA , LundeM , PoulsenD , SørensenK , QvitzauS , BechP . A double-blind placebo controlled study of sertraline in the prevention of depression in stroke patients. European Neuropyschopharmacology2002;12:231. RasmussenA , LundeM , PoulsenDL , SørensenK , QvitzauS , BechP . A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients. Psychosomatics2003;44(3):216-22. RasmussenA . Depression and stroke. Nordic Journal of Psychiatry2001;55(4):288. RasmussenA . Prophylactic treatment for post-stroke depression and comorbidity. Journal of Psychosomatic Research2000;48(3):66. ">Rasmussen 2003</a>; <a href="./references#CD009286-bbs2-0057" title="RazazianN , EsmaeiliO , AlmasiA . Effect of fluoxetine on motor improvement in ischemic stroke patients: a double blind clinical trial study. Zahedan Journal of Research in Medical Sciences2016;18(7):e75492016. RazazianN . A survey for assessment of effectiveness of fluoxetine on motor improvement in ischemic stroke patients. www.en.irct.ir/trial/8797 (first received 9 January 2014). ">Razazian 2014</a>; <a href="./references#CD009286-bbs2-0058" title="RestifoDA , Lo PrestR , LanzaS , GiuffridaS , D'AleoG , Rifici Di BellaC , et al. Motor cortex reorganization induced by fluoxetine in poststroke hemiplegic patients undergoing rehabilitation therapy: a study with transcranial magnetic stimulation. Neurorehabilitation and Neural Repair2001;15(4):284. ">Restifo 2001</a>; <a href="./references#CD009286-bbs2-0060" title="JorgeRE , RobinsonRG , ArndtS , StarksteinS . Mortality and post-stroke depression: a placebo controlled trial of antidepressants. American Journal of Psychiatry2003;160:1823-9. NarushimaK , RobinsonRG . Preventing post-stroke depression: a 12 week double blind randomised treatment trial and 21 month follow-up. Journal of Nervous and Mental Diseases2002;190:296-303. RobinsonRG , SchultzSK , CastilloC , KopelT , KosierJT , NewmanRM , et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. American Journal of Psychiatry2000;157(3):351-9. ">Robinson 2000b</a>; <a href="./references#CD009286-bbs2-0061" title="JorgeRE , AcionL , MoserD , AdamsHP , RobinsonRG . Escitalopram and enhancement of cognitive recovery following stroke. Archives of General Psychiatry2010;67(2):187-96. RobinsonRG , ArndtS . Incomplete financial disclosure in a study of escitalopram and problem solving therapy for prevention of post-stroke depression. JAMA2009;301:1023-4. RobinsonRG , JorgeRE , MoserDJ , AcionL , SolodkinA , SmallSL , et al. Escitalopram and problem-solving therapy for prevention of poststroke depression. JAMA2008;299(20):2391-400. ">Robinson 2008</a>; <a href="./references#CD009286-bbs2-0062" title="Savadi OskouieD , SharifipourE , Sadeghi BazarganiH , HashemilarM , NikanfarM , Ghazanfari AmlashiS , et al. Efficacy of citalopram on acute ischemic stroke outcome: a randomized clinical trial. Neurorehabilitation and Neural Repair2017;31(7):638-47. Savadi OskouieD . Evaluation of the effect of citalopram on three months functional prognosis of acute ischemic stroke patients: a randomized clinical trial. www.en.irct.ir/trial/1766 (first received 22 April 2012). ">Savadi Oskouie 2012</a>; <a href="./references#CD009286-bbs2-0063" title="ShahIA , AsimiRP , KawoosY , WaniMA , WaniMA , DarMA . Effect of fluoxetine on motor recovery after acute haemorrhagic stroke: a randomized trial. Journal of Neurology and Neurophysiology2016;7(2). [DOI: 10.4172/2155-9562.1000364]">Shah 2016</a>; <a href="./references#CD009286-bbs2-0067" title="Wen Z-X. The influence of post-stroke prophylactic anti-depression treatment on nerve functional rehabilitation. Acta Academiae Medicinae Qingdao Universitatis2006;42(3):253-4. ">Wen 2006</a>; <a href="./references#CD009286-bbs2-0071" title="XuJ , WangJ , LiuJ . Preventive effects of antidepressants on post-stroke depression. Chinese Mental Health Journal2006;20(3):186-8. ">Xu 2006</a>; <a href="./references#CD009286-bbs2-0075" title="ZhaoP , Wang J-P. Effects of antidepressants on neurofunctional recovery of post-stroke patients with aphasia. Journal of Dalian Medical University2011;33(1):55-7. ">Zhao 2011</a>; <a href="./references#CD009286-bbs2-0076" title="Zhou Z-l, Liang L-Z, Yan Y-X. Preventive effects of fluoxetine on post-stroke depression. Chinese Journal of Modern Applied Pharmacy2008;25(3):263-4. ">Zhou 2008</a>). </p> <p>The criteria for diagnosing depression varied between studies.</p> </section> </section> <section id="CD009286-sec-0047"> <h4 class="title">Excluded studies</h4> <p>Our table of excluded studies is as brief as possible and does not list studies that obviously do not fulfil the inclusion criteria. There are a total of 28 excluded studies. </p> <p>We describe a total of 28 studies in our table of excluded studies (<a href="./references#CD009286-bbs2-0077" title="ACTRN12619000573156. FRAMBOISE: Fluoxetine, Recovery And Motor BiOmarkers In StrokE. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=377306 (first received 11 April 2019). ">ACTRN12619000573156</a>; <a href="./references#CD009286-bbs2-0078" title="AndersenG , VestergaardK , RiisJO . Citalopram for post-stroke pathological crying. Lancet1993;342(8875):837-9. ">Andersen 1993</a>; <a href="./references#CD009286-bbs2-0079" title="AndersenG . Efficacy of escitalopram treatment in acute stroke and the role of specific genotypes in stroke. www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005541-12 (first received 27 February 2012). AndersenG . Escitalopram Treatment In Acute Stroke (ESTIAS). www.clinicaltrials.gov/ct2/show/NCT01561092 (first received 22 March 2012). ">Andersen 2012</a>; <a href="./references#CD009286-bbs2-0080" title="AndersonC , HackettM , CarterK , NiMC . Maximising outcome by overcoming depression in stroke (MOODS) trial. Cerebrovascular Diseases 20022002;13 Suppl 3:79. ">Anderson 2002</a>; <a href="./references#CD009286-bbs2-0081" title="Anonymous 2012. Stroke and depression. Johns Hopkins Medical Letter: Health After 502012;23(11):3. ">Anonymous 2012a</a>; <a href="./references#CD009286-bbs2-0082" title="Anonymous. Drug &amp; Device News. Medical Malpractice Law &amp; Strategy, New York Law Journal Newsletters2012;30(2):5. ">Anonymous 2012b</a>; <a href="./references#CD009286-bbs2-0083" title="BerendsHI , NijlantJM , PuttenMJ , MovigKL , IJzermanMJ . Single dose of fluoxetine increases muscle activation in chronic stroke patients. Clinical Neuropharmacology2009;32(1):1-5. [also known as Flu 2006]">Berends 2009</a>; <a href="./references#CD009286-bbs2-0085" title="Chen Ma, PingL . Effectiveness of paroxetine in the treatment of poststroke depression. Medicine2018;97(29):1-4. ">Chen 2019</a>; <a href="./references#CD009286-bbs2-0086" title="Choi-KwonS , ChoiJ , KwonSU , KangDW , KimJS . Fluoxetine improves the quality of life in patients with poststroke emotional disturbances. Cerebrovascular Diseases2008;26(3):266-71. ">Choi Kwon 2008</a>; <a href="./references#CD009286-bbs2-0087" title="FinkenzellerW , ZobelI , RietzS , SchrammE , BergerM . Interpersonal psychotherapy and pharmacotherapy for post-stroke depression. Feasibility and effectiveness. Der Nervenarzt2009;80(7):805-12. ">Finkenzeller 2009</a>; <a href="./references#CD009286-bbs2-0088" title="FosterE , YaroslavtsevaO , ChundamalaJ , LeibovitchF , EngJJ , AliF , et al. FLOW Trial: fluoxetine to open the critical period time window to improve motor recovery after stroke. International Journal of Stroke2019;14 Suppl 3:36. ">Foster 2019</a>; <a href="./references#CD009286-bbs2-0084" title="Bonin PintoC , Morales-QuezadaL , deToledo PizaPV , ZengD , Saleh VélezFG , FerreiraIS , et al. Combining fluoxetine and rTMS in poststroke motor recovery: a placebo-controlled double-blind randomized phase 2 clinical trial. Neurorehabilitation and Neural Repair2019;33:643-55. [DOI: 10.1177/1545968319860483.]NCT02208466. Effects rTMS combined with fluoxetine on motor recovery in stroke patients. www.clinicaltrials.gov/ct2/show/NCT02208466 (first received 5 August 2014). ">Bonin Pinto 2019</a>; <a href="./references#CD009286-bbs2-0089" title="GourabK , SchmitBD , HornbyGT . Increased lower limb spasticity but not strength or function following a single-dose serotonin reuptake inhibitor in chronic stroke. Archives of Physical Medicine and Rehabilitation2015;96(12):2112-9. ">Gourab 2015</a>; <a href="./references#CD009286-bbs2-0090" title="GraffagninoC . Poststroke depression and functional recovery (SADBRAIN). Duke University Medical Centre2002. ">Graffagnino 2002</a>; <a href="./references#CD009286-bbs2-0091" title="JiQM , XieLP . Efficacy of fluoxetine in the treatment of 20 patients with depression after stroke. Herald of Medicine2000;19(4):329. ">Ji 2000</a>; <a href="./references#CD009286-bbs2-0092" title="Dose-finding study of selective serotonin reuptake inhibitors to enhance neuroplasticity [Dose finding study but the intervention is a combination of an SSRI and paired associative stimulation, so we can exclude]. Source not provided from searches2020. ">Kitago 2020</a>; <a href="./references#CD009286-bbs2-0093" title="LiF , GuDX , CengSH , XuJW . Effect of paroxetine on prognosis of patients with post cerebral infarction depression. Chinese Journal of New Drugs and Clinical Remedies.2002;21(1):11-3. ">Li 2002</a>; <a href="./references#CD009286-bbs2-0094" title="LiangZ , ShuliangT . Clinical efficacy of fluoxetine in treatment of patients with depression after acute stroke. Chinese Journal of Clinical Rehabilitation2003;7(13):1924-5. ">Liang 2003</a>; <a href="./references#CD009286-bbs2-0095" title="Liu L-X. Recent effect of drug intervention on post-stroke anxiety. Chinese Journal of Clinical Rehabilitation2004;8(30):6600-1. ">Liu 2004</a>; <a href="./references#CD009286-bbs2-0096" title="LiuW , DingW . Study on the efficacy and mechanism of paroxetine hydrochloride combined with repetitive transcranial magnetic stimulation in the treatment of post-stroke depression. International Journal of Clinical and Experimental Medicine2020;13(10):7881-8. ">Liu 2020</a>; <a href="./references#CD009286-bbs2-0097" title="MosarrezaiiA , SalmasiBA , TaghaviSA . Studying effect of fluoxetine on improvement of motor performance in patients with ischemic stroke. Journal of Research in Medical and Dental Sciences2018;6(3):118-22. ">Mosarrezaii 2018</a>; <a href="./references#CD009286-bbs2-0098" title="NCT01963832. RCT of a neuroplasticity agent and CI therapy for severe arm paresis after stroke. clinicaltrials.gov/ct2/show/NCT01963832 (first received 16 October 2013). ">NCT01963832</a>; <a href="./references#CD009286-bbs2-0099" title="RobinsonRG , MikamiK , JangM , JorgeRE . Prevention of anxiety disorder after stroke. Journal of Neuropsychiatry and Clinical Neurosciences2011;23(2):18. ">Robinson 2011</a>; <a href="./references#CD009286-bbs2-0100" title="SitzerM , HuffW , SteckelR . Prevention of poststroke depression after acute ischemic stroke using the selective serotonin reuptake inhibitor sertraline (PreDis-study). Stroke2002;33(2):651-2. ">Sitzer 2002</a>; <a href="./references#CD009286-bbs2-0101" title="SunYT , BaoYH , WangSL , ChuJM , LiLP . Efficacy observation on the treatment of post-stroke depression by acupuncture at the acupoints based on ziwuliuzhu and Prozac. Chinese Acupuncture and Moxibustion2015;355(2):119-22. ">Sun 2015</a>; <a href="./references#CD009286-bbs2-0102" title="VogelAC , Okeng'oK , ChiwangaF , IsmailSS , BumaD , PothierL . MAMBO: Measuring Ambulation, Motor, and Behavioral Outcomes with post-stroke fluoxetine in Tanzania: protocol of a phase II clinical trial. Journal of the Neurological Sciences2020;408:116563. [PMID: DOI:10.1016/j.jns.2019.116563]">Vogel 2020</a>; <a href="./references#CD009286-bbs2-0103" title="XuB , ZhouWY , ZhangSJ . Observation of effect of Wulung capsule in treating post-stroke depression. Chinese Journal of Integrated Traditional and Western Medicine2007;27(7):640-2. ">Xu 2007</a>; <a href="./references#CD009286-bbs2-0104" title="ZhouB . Effects of fluoxetine on neurofunctional recovery of non depressed patients after stroke. Chinese Journal of Clinical Rehabilitation2003;7(3):374-5. ">Zhou 2003</a>). Eight of these studies were excluded during this update (<a href="./references#CD009286-bbs2-0077" title="ACTRN12619000573156. FRAMBOISE: Fluoxetine, Recovery And Motor BiOmarkers In StrokE. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=377306 (first received 11 April 2019). ">ACTRN12619000573156</a>; <a href="./references#CD009286-bbs2-0085" title="Chen Ma, PingL . Effectiveness of paroxetine in the treatment of poststroke depression. Medicine2018;97(29):1-4. ">Chen 2019</a>; <a href="./references#CD009286-bbs2-0088" title="FosterE , YaroslavtsevaO , ChundamalaJ , LeibovitchF , EngJJ , AliF , et al. FLOW Trial: fluoxetine to open the critical period time window to improve motor recovery after stroke. International Journal of Stroke2019;14 Suppl 3:36. ">Foster 2019</a>; <a href="./references#CD009286-bbs2-0084" title="Bonin PintoC , Morales-QuezadaL , deToledo PizaPV , ZengD , Saleh VélezFG , FerreiraIS , et al. Combining fluoxetine and rTMS in poststroke motor recovery: a placebo-controlled double-blind randomized phase 2 clinical trial. Neurorehabilitation and Neural Repair2019;33:643-55. [DOI: 10.1177/1545968319860483.]NCT02208466. Effects rTMS combined with fluoxetine on motor recovery in stroke patients. www.clinicaltrials.gov/ct2/show/NCT02208466 (first received 5 August 2014). ">Bonin Pinto 2019</a>; <a href="./references#CD009286-bbs2-0092" title="Dose-finding study of selective serotonin reuptake inhibitors to enhance neuroplasticity [Dose finding study but the intervention is a combination of an SSRI and paired associative stimulation, so we can exclude]. Source not provided from searches2020. ">Kitago 2020</a>; <a href="./references#CD009286-bbs2-0096" title="LiuW , DingW . Study on the efficacy and mechanism of paroxetine hydrochloride combined with repetitive transcranial magnetic stimulation in the treatment of post-stroke depression. International Journal of Clinical and Experimental Medicine2020;13(10):7881-8. ">Liu 2020</a>; <a href="./references#CD009286-bbs2-0097" title="MosarrezaiiA , SalmasiBA , TaghaviSA . Studying effect of fluoxetine on improvement of motor performance in patients with ischemic stroke. Journal of Research in Medical and Dental Sciences2018;6(3):118-22. ">Mosarrezaii 2018</a>; <a href="./references#CD009286-bbs2-0102" title="VogelAC , Okeng'oK , ChiwangaF , IsmailSS , BumaD , PothierL . MAMBO: Measuring Ambulation, Motor, and Behavioral Outcomes with post-stroke fluoxetine in Tanzania: protocol of a phase II clinical trial. Journal of the Neurological Sciences2020;408:116563. [PMID: DOI:10.1016/j.jns.2019.116563]">Vogel 2020</a>). </p> <section id="CD009286-sec-0048"> <h5 class="title">Ongoing studies</h5> <p>The following studies are either ongoing or are completed but have not yet published results (<a href="./references#CD009286-bbs2-0109" title="ChiCTR1800019467. The effect and mechanism of fluoxetine on the automatic regulation of cerebral blood flow for ischemic stroke. https://www.chictr.org.cn/showprojen.aspx?proj=32801. ">ChiCTR1800019467</a>; <a href="./references#CD009286-bbs2-0110" title="CTRI/2018/12/016568. An interventional study to look at efficacy of fluoxetine in patients with post-stroke anxiety. http://ctri.nic.in CTRI/2018/12/016568 (first received 10 December 2018). ">CTRI/2018/12/016568</a>; <a href="./references#CD009286-bbs2-0111" title="EudraCT 2005-005266-37. Influence of escitalopram on the incidence of depression and dementia following acute middle cerebral artery territory infarction. A randomised placebo-controlled double blind study. www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005266-37 (first received 7 April 2006). ">EudraCT 2005‐005266‐37</a>; <a href="./references#CD009286-bbs2-0112" title="IRCT201112228490N1. Effect of fluoxetine on functional recovery of patients with cerebrovascular accident following middle cerebral artery trunk obstruction: a randomized clinical trial. www.en.irct.ir/trial/8954 (first received 25 January 2012). ">IRCT201112228490N1</a>; <a href="./references#CD009286-bbs2-0113" title="IRCT2012101011062N1. A study of sertraline effect on quality of life in stroke inpatients. www.en.irct.ir/trial/11413 (first received 28 November 2012). ">IRCT2012101011062N1</a>; <a href="./references#CD009286-bbs2-0114" title="IRCT2017041720258N37. Evaluation of fluoxetine and standard treatment efficacy on change to side effect of stroke of ischemic strokes in both hemispheres in anterior circulation. www.irct.ir/trial/17976 (first received 11 October 2017). ">IRCT2017041720258N37</a>; <a href="./references#CD009286-bbs2-0115" title="IRCT20210307050617N1. The efficacy comparison of fluoxetine and citalopram on motor recovery after ischemic stroke: single-blind placebo-controlled randomized clinical trial. https://en.irct.ir/trial/54896 (first received 27 March 2021). ">IRCT20210307050617N1</a>; <a href="./references#CD009286-bbs2-0116" title="NCT02386475. Effect of serotonin and levodopa in ischemic stroke. www.clinicaltrials.gov/ct2/show/NCT02386475 (first received 12 March 2015). ">NCT02386475</a>; <a href="./references#CD009286-bbs2-0117" title="NCT02767999. Serotonin Selective Reuptake Inhibitor (SSRI) effects on cerebral connectivity in acute ischemic stroke (RECONISE). www.clinicaltrials.gov/ct2/show/NCT02767999 (first received 11 May 2016). ">NCT02767999</a>; <a href="./references#CD009286-bbs2-0118" title="NCT02865642. Cortical ischemic stroke and serotonin (CISS). www.clinicaltrials.gov/ct2/show/NCT02865642 (first received 12 August 2016). ">NCT02865642</a>; <a href="./references#CD009286-bbs2-0119" title="NCT03448159. Fluoxetine Opens Window to improve motor recovery after stroke (FLOW). www.clinicaltrials.gov/ct2/show/NCT03448159 (first received 27 February 2018). ">NCT03448159</a>; <a href="./references#CD009286-bbs2-0120" title="NCT03826875. Depression in hemorrhagic stroke. www.clinicaltrials.gov/ct2/show/NCT03826875 (first received 1 February 2019). ">NCT03826875</a>; <a href="./references#CD009286-bbs2-0121" title="TCTR20181216001. Randomized controlled trial of fluoxetine or placebo on quality of life after acute ischemic stroke. www.thaiclinicaltrials.org/show/TCTR20181216001 (first received 16 December 2018). ">TCTR20181216001</a>). See <a href="./references#CD009286-sec-0119" title="">Characteristics of ongoing studies</a>. </p> </section> <section id="CD009286-sec-0049"> <h5 class="title">Studies awaiting classification</h5> <p>The same studies that were listed as 'awaiting classification' in the previous version of the review of <a href="./references#CD009286-bbs2-0132" title="LeggLA , TilneyR , HsiehC , WuS , LundströmE , RudbergA , et al. Selective serotonin reuptake inhibitors for stroke recovery. Cochrane Database of Systematic Reviews2019, Issue 11. Art. No: CD009286. [DOI: 10.1002/14651858.CD009286.pub3]">Legg 2019</a> continue to be listed as 'awaiting classification' as no new information is available to change these classification (<a href="./references#CD009286-bbs2-0105" title="GuoY , HeY , TangB , MaK , CaiZ , ZengS , et al. Effect of using fluoxetine at different time windows on neurological functional prognosis after ischemic stroke. Restorative Neurology and Neuroscience2016;34(2):177–87. GuoY . Effect of using fluoxetine at different time windows after ischemic stroke on neurological functional prognosis: a randomized controlled trial. chictr.org.cn/showprojen.aspx?proj=12925 (first received 27 December 2015). ">Guo 2016</a>; <a href="./references#CD009286-bbs2-0106" title="ChiCTR-TRC-12002078. Multi-center randomized clinical study of antidepressant treatment (fluoxetine) on secondary prevention of ischemic stroke. www.chictr.org.cn/showprojen.aspx?proj=7471 (first received 3 April 2012). HeY , CaiZ , ZengS , ChenS , TangB , LiangY , et al. Effect of fluoxetine on three-year recurrence in acute ischemic stroke: a randomized controlled clinical study. Clinical Neurology and Neurosurgery2018;168:1-6. ">He 2018</a>; <a href="./references#CD009286-bbs2-0107" title="JurcauA , SimionA . Improved post-ischaemic stroke recovery over 1 year with escitalopram for 3 months. European Journal of Neurology2016;23:614. ">Jurcau 2016</a>; <a href="./references#CD009286-bbs2-0108" title="NCT00967408. Effects of clinical and functional outcome of escitalopram in adult stroke patients. clinicaltrials.gov/ct2/show/NCT00967408 (first received 27 August 2009). [NCT00967408]">NCT00967408</a>). See <a href="./references#CD009286-sec-0118" title="">Characteristics of studies awaiting classification</a>. </p> </section> </section> </section> <section id="CD009286-sec-0050"> <h3 class="title">Risk of bias in included studies</h3> <p>All 76 studies were randomised controlled trials (RCTs). We could not assess risk of bias in one study as there are no published data, just information on a trials register (<a href="./references#CD009286-bbs2-0053" title="NCT02737930. Fluoxetine for visual recovery after ischaemic stroke (FLUORESCE). www.clinicaltrials.gov/ct2/show/NCT02737930 (first received 14 April 2016). ">NCT02737930</a>). Thirty‐two studies were at low risk of bias for random sequence generation and 44 at unclear risk. See <a href="#CD009286-fig-0002">Figure 2</a> and <a href="#CD009286-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD009286-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009286-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD009286-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each 'risk of bias' item presented as percentages across all included studies." data-id="CD009286-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'risk of bias' item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD009286-sec-0051"> <h4 class="title">Allocation</h4> <p>For allocation concealment, we assessed 21 studies to be at low risk of bias and 55 studies to be at unclear risk. <a href="#CD009286-fig-0002">Figure 2</a> and <a href="#CD009286-fig-0003">Figure 3</a> demonstrate selection bias. </p> </section> <section id="CD009286-sec-0052"> <h4 class="title">Blinding</h4> <p>For performance bias, we assessed 26 studies to be at low risk of bias, 23 studies to be at unclear risk of bias, and 26 studies to be at high risk of bias for blinding of participants. </p> <p>For blinding of outcome we assessed 25 studies to be a low risk of bias, 48 studies to be at unclear risk of bias, and two studies to be at high risk of bias. <a href="#CD009286-fig-0002">Figure 2</a> and <a href="#CD009286-fig-0003">Figure 3</a> demonstrate blinding. </p> </section> <section id="CD009286-sec-0053"> <h4 class="title">Incomplete outcome data</h4> <p>For incomplete outcome data we assessed 28 studies to be at low risk of bias, 20 studies to be at unclear risk of bias, and 27 studies to be at high risk of bias. <a href="#CD009286-fig-0002">Figure 2</a> and <a href="#CD009286-fig-0003">Figure 3</a> demonstrate attrition bias. </p> </section> <section id="CD009286-sec-0054"> <h4 class="title">Selective reporting</h4> <p>We assessed 20 studies to be at low risk of bias, 46 studies to be at unclear risk of bias, and nine studies to be a high risk of bias for selective outcome reporting. <a href="#CD009286-fig-0002">Figure 2</a> and <a href="#CD009286-fig-0003">Figure 3</a> demonstrate reporting bias. </p> </section> <section id="CD009286-sec-0055"> <h4 class="title">Other potential sources of bias</h4> <section id="CD009286-sec-0056"> <h5 class="title">Other sources of bias</h5> <p>These are shown in the final column of <a href="#CD009286-fig-0002">Figure 2</a> and <a href="#CD009286-fig-0003">Figure 3</a>. There were 23 studies at low risk of bias, seven at high risk, and the rest were at unclear risk. </p> </section> <section id="CD009286-sec-0057"> <h5 class="title">Low risk of bias across all domains</h5> <p>Six trials were at low risk of bias across all domains (<a href="./references#CD009286-bbs2-0002" title="ACTRN12611000774921. Assessment of fluoxetine in stroke recovery (AFFINITY) trial, 2011. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000774921 (first received 22 July 2011). ACTRN12619000986178. The assessment of fluoxetine in stroke recovery imaging and blood biomarkers sub-study AFFINITY BM. www.anzctr.org.au/Trial/Registration/TrialReview.aspx ?ACTRN=12619000986178 (first received 11 July 2019). AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):651-60. HankeyG . Assessment oF FluoxetINe In sTroke recoverY (AFFINITY). www.affinitytrial.org/ (accessed 19th February 2019). ">AFFINITY 2020</a>; <a href="./references#CD009286-bbs2-0006" title="AsadollahiM , RamezaniM , KhanmoradiZ , KarimialavijehE . The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial. Clinical Rehabilitation2018;32(8):1069-75. ">Asadollahi 2018</a>; <a href="./references#CD009286-bbs2-0007" title="BembenekJP , NiewadaM , KlyszB , MazurA , KurczychK , GluszkiewiczM , et al. Fluoxetine for stroke recovery improvement - the doubleblind, randomised placebo-controlled FOCUS-Poland trial. Neurologia i Neurochirurgia Polska2020;54(6):544-51. Fluoxetine or control under supervision: Poland. Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products - EduraCT No: 2014-001335-372014. ">Bembenek 2020</a>; <a href="./references#CD009286-bbs2-0021" title="EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661-9. ISRCTN13020412. Establishing the effect(s) and safety of fluoxetine initiated in the acute phase of stroke. www.isrctn.com/ISRCTN13020412 (first received 19 December 2014). LundströmE , IsakssonE , NäsmanP , WesterP , MårtenssonB , NorrvingB . Correction to: Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(388):s13063-020-04327-w. LundströmE , IsakssonE , Näsman P et al. Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(233):s13063-020-4124-7. LundstromE , IsakssonE , NasmanP , WesterP , MartenssonB , NorrvingB , et al. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661‐9. ">EFFECTS 2020</a>; <a href="./references#CD009286-bbs2-0023" title="Anonymous. The FOCUS (Fluoxetine or Control under Supervision) trial results: effects of a 6 month course of fluoxetine on the Stroke Impact Scale, mood and fatigue in patients with stroke. www.ed.ac.uk/clinical-brain-sciences/research/completed-studies-trials/focus-stroke-trial (accessed 12 02 2021). CookR , ThomasV , MartinR . Does fluoxetine improve recovery after stroke?BMJ2019;364:1029. DennisM , ForbesJ , GrahamC , HackettM , HankeyGJ , HouseA , et al. Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT. Health Technology Assessment2020;24(22):1-94. DennisM , ForbesJ , GrahamC , HackettML , HankeyGJ , HouseA , et al. Fluoxetine and fractures after stroke: exploratory analyses from the FOCUS Trial. Stroke2019;50(11):3280-2. FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet2019;393(10168):265-74. GrahamC , LewisS , ForbesJ , MeadG , HackettML , HankeyGJ , et al. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. Trials2017;18(1):627. LundstromE , DennisM , MeadG . The effects of fluoxetine on fracture risk after stroke: Further analyses from the focus trial. European Stroke Journal2019;4 suppl 1:7142019. MeadG , DennisM . Feasibility of reporting results of large randomised controlled trials to participants: experience from the Fluoxetine or Control under Supervision (FOCUS) trial. BMJ Open2020;10(11):e0404922020. MeadG . Fluoxetine Or Control Under Supervision (FOCUS) trial: to establish the effect(s) of routine administration of Fluoxetine in patients with a recent stroke. www.isrctn.com/ISRCTN83290762 (first received 23 May 2012). MeadGE , DennisMS , InnesK , MacLeodM , SandercockPA , HouseA , et al. A multicentre randomised trial to establish the effect(s) of routine administration of fluoxetine in patients with a recent stroke (Fluoxetine Or Control Under Supervision, FOCUS). In: 21st European Stroke Conference. 2012:Abst OAID 26. MeadGE , GrahamC , BillotL , NäsmanP , LundströmE , LewisS , on behalf of the FOCUS , AFFINITY and EFFECTS trialists. Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis. Trials2020;21(1):971. MeadGE , LeggL , TilneyR , HsiehCF , WuS , LundströmE , et al. Fluoxetine for stroke recovery: meta-analysis of randomized controlled trials. International Journal of Stroke2020;15(4):365-76. ">FOCUS 2019</a>; <a href="./references#CD009286-bbs2-0047" title="Marquez-RomeroJM , ArauzA , Ruiz-SandovalJL , Cruz-Estrada EdeL , Huerta-FrancoMR , Aguayo-LeytteG , et al. Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH): study protocol for a randomized, double-blind, placebo-controlled, multicenter trial. Trials2013;14:77. Marquez-RomeroJM , Reyes-MartínezM , Huerta-FrancoMR , Ruiz-FrancoA , SilosH , ArauzA . Fluoxetine for motor recovery after acute intracerebral hemorrhage, the FMRICH trial. Clinical Neurology and Neurosurgery2020;190:105656. Marquez-RomeroJM , Reyes-MartínezM , Huerta-FrancoMR , Ruiz-FrancoA , SilosH , ArauzA . Fluoxetine for motor recovery after acute intracerebral hemorrhage, the FMRICH Trial. Correspondence from Marquez-Romero2018. Marquez-RomeroJM . Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH). www.clinicaltrials.gov/ct2/show/NCT01737541 (first received 29 November 2012). ">Marquez Romero 2013</a>) (<a href="#CD009286-fig-0002">Figure 2</a>; <a href="#CD009286-fig-0003">Figure 3</a>). For two of these trials, the final judgement was made after obtaining further information from the trialists (<a href="./references#CD009286-bbs2-0006" title="AsadollahiM , RamezaniM , KhanmoradiZ , KarimialavijehE . The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial. Clinical Rehabilitation2018;32(8):1069-75. ">Asadollahi 2018</a>; <a href="./references#CD009286-bbs2-0007" title="BembenekJP , NiewadaM , KlyszB , MazurA , KurczychK , GluszkiewiczM , et al. Fluoxetine for stroke recovery improvement - the doubleblind, randomised placebo-controlled FOCUS-Poland trial. Neurologia i Neurochirurgia Polska2020;54(6):544-51. Fluoxetine or control under supervision: Poland. Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products - EduraCT No: 2014-001335-372014. ">Bembenek 2020</a>). </p> <p>Following editorial review, one trial that had been included as low risk of bias across all domains in the previous review was re‐categorised as unclear risk of bias for 'other sources of bias' as there were baseline differences in motor scores (<a href="./references#CD009286-bbs2-0018" title="CholletF , TardyJ , Albucher J-F, ThalamasE , BerardE , LamyC , et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurology2011;10(2):123-30. ">Chollet 2011</a>). </p> <section id="CD009286-sec-0058"> <h6 class="title">Publication bias</h6> <p>We performed a funnel plot for the outcome of disability, for all trials irrespective of risk of bias (<a href="#CD009286-fig-0004">Figure 4</a>). This suggests publication bias, with a cluster of studies in the upper left portion of the graph. </p> <div class="figure" id="CD009286-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot, all studies irrespective or risk of bias, for disability at end of treatment." data-id="CD009286-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot, all studies irrespective or risk of bias, for disability at end of treatment.</p> </div> </div> </div> </section> </section> </section> </section> <section id="CD009286-sec-0059"> <h3 class="title" id="CD009286-sec-0059">Effects of interventions</h3> <p>See: <a href="./full#CD009286-tbl-0001"><b>Summary of findings 1</b> Fluoxetine versus control at end of treatment, for stroke recovery, using data from high quality trials only</a> </p> <section id="CD009286-sec-0060"> <h4 class="title">Primary outcomes (low risk of bias trials only)</h4> <section id="CD009286-sec-0061"> <h5 class="title">Disability score at the end of treatment </h5> <p>Of the six studies at low risk of bias in all seven domains, two reported Barthel score as median and interquartile range (QR) (<a href="./references#CD009286-bbs2-0007" title="BembenekJP , NiewadaM , KlyszB , MazurA , KurczychK , GluszkiewiczM , et al. Fluoxetine for stroke recovery improvement - the doubleblind, randomised placebo-controlled FOCUS-Poland trial. Neurologia i Neurochirurgia Polska2020;54(6):544-51. Fluoxetine or control under supervision: Poland. Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products - EduraCT No: 2014-001335-372014. ">Bembenek 2020</a>; <a href="./references#CD009286-bbs2-0047" title="Marquez-RomeroJM , ArauzA , Ruiz-SandovalJL , Cruz-Estrada EdeL , Huerta-FrancoMR , Aguayo-LeytteG , et al. Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH): study protocol for a randomized, double-blind, placebo-controlled, multicenter trial. Trials2013;14:77. Marquez-RomeroJM , Reyes-MartínezM , Huerta-FrancoMR , Ruiz-FrancoA , SilosH , ArauzA . Fluoxetine for motor recovery after acute intracerebral hemorrhage, the FMRICH trial. Clinical Neurology and Neurosurgery2020;190:105656. Marquez-RomeroJM , Reyes-MartínezM , Huerta-FrancoMR , Ruiz-FrancoA , SilosH , ArauzA . Fluoxetine for motor recovery after acute intracerebral hemorrhage, the FMRICH Trial. Correspondence from Marquez-Romero2018. Marquez-RomeroJM . Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH). www.clinicaltrials.gov/ct2/show/NCT01737541 (first received 29 November 2012). ">Marquez Romero 2013</a>). For one study (<a href="./references#CD009286-bbs2-0047" title="Marquez-RomeroJM , ArauzA , Ruiz-SandovalJL , Cruz-Estrada EdeL , Huerta-FrancoMR , Aguayo-LeytteG , et al. Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH): study protocol for a randomized, double-blind, placebo-controlled, multicenter trial. Trials2013;14:77. Marquez-RomeroJM , Reyes-MartínezM , Huerta-FrancoMR , Ruiz-FrancoA , SilosH , ArauzA . Fluoxetine for motor recovery after acute intracerebral hemorrhage, the FMRICH trial. Clinical Neurology and Neurosurgery2020;190:105656. Marquez-RomeroJM , Reyes-MartínezM , Huerta-FrancoMR , Ruiz-FrancoA , SilosH , ArauzA . Fluoxetine for motor recovery after acute intracerebral hemorrhage, the FMRICH Trial. Correspondence from Marquez-Romero2018. Marquez-RomeroJM . Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH). www.clinicaltrials.gov/ct2/show/NCT01737541 (first received 29 November 2012). ">Marquez Romero 2013</a>), we converted the median Barthel score and IQR to mean and standard deviation (SD) using a method described in <a href="./references#CD009286-bbs2-0150" title="WanX , WangW , LiuJ , TongT . Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Medical Research Methodology2014;14:135.">Wan 2014</a>. </p> <p>For <a href="./references#CD009286-bbs2-0007" title="BembenekJP , NiewadaM , KlyszB , MazurA , KurczychK , GluszkiewiczM , et al. Fluoxetine for stroke recovery improvement - the doubleblind, randomised placebo-controlled FOCUS-Poland trial. Neurologia i Neurochirurgia Polska2020;54(6):544-51. Fluoxetine or control under supervision: Poland. Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products - EduraCT No: 2014-001335-372014. ">Bembenek 2020</a>, <a href="./references#CD009286-bbs2-0002" title="ACTRN12611000774921. Assessment of fluoxetine in stroke recovery (AFFINITY) trial, 2011. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000774921 (first received 22 July 2011). ACTRN12619000986178. The assessment of fluoxetine in stroke recovery imaging and blood biomarkers sub-study AFFINITY BM. www.anzctr.org.au/Trial/Registration/TrialReview.aspx ?ACTRN=12619000986178 (first received 11 July 2019). AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):651-60. HankeyG . Assessment oF FluoxetINe In sTroke recoverY (AFFINITY). www.affinitytrial.org/ (accessed 19th February 2019). ">AFFINITY 2020</a>, <a href="./references#CD009286-bbs2-0021" title="EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661-9. ISRCTN13020412. Establishing the effect(s) and safety of fluoxetine initiated in the acute phase of stroke. www.isrctn.com/ISRCTN13020412 (first received 19 December 2014). LundströmE , IsakssonE , NäsmanP , WesterP , MårtenssonB , NorrvingB . Correction to: Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(388):s13063-020-04327-w. LundströmE , IsakssonE , Näsman P et al. Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(233):s13063-020-4124-7. LundstromE , IsakssonE , NasmanP , WesterP , MartenssonB , NorrvingB , et al. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661‐9. ">EFFECTS 2020</a>, and <a href="./references#CD009286-bbs2-0023" title="Anonymous. The FOCUS (Fluoxetine or Control under Supervision) trial results: effects of a 6 month course of fluoxetine on the Stroke Impact Scale, mood and fatigue in patients with stroke. www.ed.ac.uk/clinical-brain-sciences/research/completed-studies-trials/focus-stroke-trial (accessed 12 02 2021). CookR , ThomasV , MartinR . Does fluoxetine improve recovery after stroke?BMJ2019;364:1029. DennisM , ForbesJ , GrahamC , HackettM , HankeyGJ , HouseA , et al. Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT. Health Technology Assessment2020;24(22):1-94. DennisM , ForbesJ , GrahamC , HackettML , HankeyGJ , HouseA , et al. Fluoxetine and fractures after stroke: exploratory analyses from the FOCUS Trial. Stroke2019;50(11):3280-2. FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet2019;393(10168):265-74. GrahamC , LewisS , ForbesJ , MeadG , HackettML , HankeyGJ , et al. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. Trials2017;18(1):627. LundstromE , DennisM , MeadG . The effects of fluoxetine on fracture risk after stroke: Further analyses from the focus trial. European Stroke Journal2019;4 suppl 1:7142019. MeadG , DennisM . Feasibility of reporting results of large randomised controlled trials to participants: experience from the Fluoxetine or Control under Supervision (FOCUS) trial. BMJ Open2020;10(11):e0404922020. MeadG . Fluoxetine Or Control Under Supervision (FOCUS) trial: to establish the effect(s) of routine administration of Fluoxetine in patients with a recent stroke. www.isrctn.com/ISRCTN83290762 (first received 23 May 2012). MeadGE , DennisMS , InnesK , MacLeodM , SandercockPA , HouseA , et al. A multicentre randomised trial to establish the effect(s) of routine administration of fluoxetine in patients with a recent stroke (Fluoxetine Or Control Under Supervision, FOCUS). In: 21st European Stroke Conference. 2012:Abst OAID 26. MeadGE , GrahamC , BillotL , NäsmanP , LundströmE , LewisS , on behalf of the FOCUS , AFFINITY and EFFECTS trialists. Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis. Trials2020;21(1):971. MeadGE , LeggL , TilneyR , HsiehCF , WuS , LundströmE , et al. Fluoxetine for stroke recovery: meta-analysis of randomized controlled trials. International Journal of Stroke2020;15(4):365-76. ">FOCUS 2019</a> the authors supplied the mean and SD of the activities of daily living score (five questions about activities done during a typical day) of the Stroke Impact Scale.    </p> <p>One did not report disability or independence and so is not included in the analyses of disability and independence (<a href="./references#CD009286-bbs2-0006" title="AsadollahiM , RamezaniM , KhanmoradiZ , KarimialavijehE . The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial. Clinical Rehabilitation2018;32(8):1069-75. ">Asadollahi 2018</a>). </p> <p>There was no difference in measures of disability between selective serotonin reuptake inhibitors (SSRIs) and placebo (<a href="./references#CD009286-fig-0005" title="">Analysis 1.1</a>):  the standard mean difference (SMD) with a fixed‐effect model (SMD −0.00, 95% CI −0.05 to 0.05; P = 0.98; 5 studies, 5436 participants; high‐quality evidence) with no heterogeneity (I<sup>2</sup> = 0%).  </p> </section> <section id="CD009286-sec-0062"> <h5 class="title">Independent on modified Rankin score (mRS 0 to 2) at the end of treatment</h5> <p>We combined data from the  five studies at low risk of bias across all seven domains for the outcome of independent on mRS 0 to 2 using a risk ratio with a fixed‐effect model (RR 0.98, 95% CI 0.93 to 1.03; P = 0.37; 5 studies, 5926 participants, high‐quality evidence).  The I<sup>2</sup> was 32%, moderate heterogeneity (<a href="./references#CD009286-fig-0006" title="">Analysis 1.2</a>). </p> </section> </section> <section id="CD009286-sec-0063"> <h4 class="title">Secondary outcomes (low risk of bias trials only)</h4> <section id="CD009286-sec-0064"> <h5 class="title">Impairments: neurological deficit score at the end of treatment</h5> <p>One study (30 participants) of high quality reported neurological deficit scores. The study authors reported no difference in neurological score for participants who received and SSRI compared with those who received a placebo (<a href="./references#CD009286-fig-0007" title="">Analysis 1.3</a>). </p> </section> <section id="CD009286-sec-0065"> <h5 class="title">Impairments: motor deficits at end of treatment</h5> <p>We combined data for the six low risk of bias studies that reported motor deficits, using the SMD with a fixed‐effect model. The analysis found no difference between SSRI and placebo (SMD 0.03, 95% CI −0.02 to 0.08; P = 0.23; 6 studies, 5518 participants, I<sup>2</sup> = 75%, substantial heterogeneity, moderate‐quality evidence) (<a href="./references#CD009286-fig-0008" title="">Analysis 1.4</a>). </p> <p>We downgraded the evidence to 'moderate' as the data from several trials were by self‐report rather than by an objective assessment of deficits. Note that  data from <a href="./references#CD009286-bbs2-0047" title="Marquez-RomeroJM , ArauzA , Ruiz-SandovalJL , Cruz-Estrada EdeL , Huerta-FrancoMR , Aguayo-LeytteG , et al. Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH): study protocol for a randomized, double-blind, placebo-controlled, multicenter trial. Trials2013;14:77. Marquez-RomeroJM , Reyes-MartínezM , Huerta-FrancoMR , Ruiz-FrancoA , SilosH , ArauzA . Fluoxetine for motor recovery after acute intracerebral hemorrhage, the FMRICH trial. Clinical Neurology and Neurosurgery2020;190:105656. Marquez-RomeroJM , Reyes-MartínezM , Huerta-FrancoMR , Ruiz-FrancoA , SilosH , ArauzA . Fluoxetine for motor recovery after acute intracerebral hemorrhage, the FMRICH Trial. Correspondence from Marquez-Romero2018. Marquez-RomeroJM . Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH). www.clinicaltrials.gov/ct2/show/NCT01737541 (first received 29 November 2012). ">Marquez Romero 2013</a>  are means and SDs estimated from reported medians and interquartile ranges using a method described in <a href="./references#CD009286-bbs2-0150" title="WanX , WangW , LiuJ , TongT . Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Medical Research Methodology2014;14:135.">Wan 2014</a>. </p> </section> <section id="CD009286-sec-0066"> <h5 class="title">Depression severity at end of treatment (continuous data) </h5> <p>We combined data from the four studies with an overall low risk of bias for the outcome of depression severity using the SMD with a fixed‐effect model (SMD −0.14, 95% CI −0.19 to −0.08; P &lt; 0.01; 4 studies, 5356  participants; high‐quality evidence). Participants who received fluoxetine had significantly lower end‐of‐treatment scores on measures of depression than those participants receiving placebo (<a href="./references#CD009286-fig-0009" title="">Analysis 1.5</a>) with moderate heterogeneity (I<sup>2</sup> = 36%, P &lt; 0.01). </p> </section> <section id="CD009286-sec-0067"> <h5 class="title">Depression at the end of treatment (dichotomous data) </h5> <p>Data were available for three studies at low risk of bias (<a href="./references#CD009286-fig-0010" title="">Analysis 1.6</a>). Risk of depression was lower in the SSRI group (RR 0.75, 95% CI 0.65 to 0.86; 3 studies, 5907 participants, P &lt; 0.01 ), with no important heterogeneity (I<sup>2</sup> = 0%). This was assessed as high‐quality evidence. </p> </section> <section id="CD009286-sec-0068"> <h5 class="title">Anxiety severity at end of treatment (continuous data)</h5> <p>No studies at low risk of bias reported measures of anxiety.</p> </section> <section id="CD009286-sec-0069"> <h5 class="title">Anxiety severity at end of treatment (dichotomous data)</h5> <p>No studies at low risk of bias reported number of diagnoses of anxiety.</p> </section> <section id="CD009286-sec-0070"> <h5 class="title">Death at end of treatment </h5> <p>We combined data for the six studies with an overall low risk of bias for the outcome of death, using a risk ratio with a fixed‐effect model. The analysis found no difference in the total number of deaths between SSRI and placebo (RR 1.01, 95% CI 0.82 to 1.24; P = 0.98;  6 studies, 6090 participants, moderate quality evidence), with no evidence of heterogeneity (I<sup>2</sup> = 0%) (<a href="./references#CD009286-fig-0011" title="">Analysis 1.7</a>). </p> </section> <section id="CD009286-sec-0071"> <h5 class="title">Side effects: seizures at end of treatment</h5> <p>We combined data for the six  studies with an overall low risk of bias for the outcome of seizures, using a risk ratio with a fixed‐effect model. The analysis showed more patients had seizures in the SSRI than control group (RR 1.40, 95% CI 1.00 to 1.98; P = 0.05; 6 studies, 6080 participants, moderate‐quality evidence because wide confidence intervals), with moderate heterogeneity (I<sup>2</sup> = 45%) (<a href="./references#CD009286-fig-0012" title="">Analysis 1.8</a>). </p> </section> <section id="CD009286-sec-0072"> <h5 class="title">Gastrointestinal side effects at end of treatment</h5> <p>One study (30 participants) of high quality reported 'gastrointestinal side effects' at the end of treatment. The study authors reported no difference in 'gastrointestinal side effects' for participants who received and SSRI compared with those who received a placebo (<a href="./references#CD009286-fig-0013" title="">Analysis 1.9</a>). </p> </section> <section id="CD009286-sec-0073"> <h5 class="title">Side effects: bleeding at end of treatment</h5> <p>We combined data from the six studies at low risk of bias using a risk ratio with fixed‐effects model (<a href="./references#CD009286-fig-0014" title="">Analysis 1.10</a>). The risk ratio was 1.08 (95% CI 0.69 to 1.70; P = 0.73, 6 trials, 6088 participants, high‐quality evidence). There was no important heterogeneity I<sup>2</sup> = 0%). </p> </section> <section id="CD009286-sec-0074"> <h5 class="title">Side effects: fractures at end of treatment</h5> <p>We combined data from the six studies at low risk of bias. SSRIs were associated with higher risk of fractures (RR 2.35, 95% 1.62 to 3.41, 6 studies, 6080 participants, high‐quality evidence, P &lt; 0.01, I<sup>2</sup> = 0%, no important heterogeneity) (<a href="./references#CD009286-fig-0015" title="">Analysis 1.11</a>). </p> </section> <section id="CD009286-sec-0075"> <h5 class="title">Cognition at end of treatment (continuous data)</h5> <p>Of the six studies at low risk of bias, four studies reported the memory domain of the Stroke Impact Scale (<a href="./references#CD009286-bbs2-0002" title="ACTRN12611000774921. Assessment of fluoxetine in stroke recovery (AFFINITY) trial, 2011. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000774921 (first received 22 July 2011). ACTRN12619000986178. The assessment of fluoxetine in stroke recovery imaging and blood biomarkers sub-study AFFINITY BM. www.anzctr.org.au/Trial/Registration/TrialReview.aspx ?ACTRN=12619000986178 (first received 11 July 2019). AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):651-60. HankeyG . Assessment oF FluoxetINe In sTroke recoverY (AFFINITY). www.affinitytrial.org/ (accessed 19th February 2019). ">AFFINITY 2020</a>; <a href="./references#CD009286-bbs2-0007" title="BembenekJP , NiewadaM , KlyszB , MazurA , KurczychK , GluszkiewiczM , et al. Fluoxetine for stroke recovery improvement - the doubleblind, randomised placebo-controlled FOCUS-Poland trial. Neurologia i Neurochirurgia Polska2020;54(6):544-51. Fluoxetine or control under supervision: Poland. Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products - EduraCT No: 2014-001335-372014. ">Bembenek 2020</a>;  <a href="./references#CD009286-bbs2-0021" title="EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661-9. ISRCTN13020412. Establishing the effect(s) and safety of fluoxetine initiated in the acute phase of stroke. www.isrctn.com/ISRCTN13020412 (first received 19 December 2014). LundströmE , IsakssonE , NäsmanP , WesterP , MårtenssonB , NorrvingB . Correction to: Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(388):s13063-020-04327-w. LundströmE , IsakssonE , Näsman P et al. Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(233):s13063-020-4124-7. LundstromE , IsakssonE , NasmanP , WesterP , MartenssonB , NorrvingB , et al. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661‐9. ">EFFECTS 2020</a>; <a href="./references#CD009286-bbs2-0023" title="Anonymous. The FOCUS (Fluoxetine or Control under Supervision) trial results: effects of a 6 month course of fluoxetine on the Stroke Impact Scale, mood and fatigue in patients with stroke. www.ed.ac.uk/clinical-brain-sciences/research/completed-studies-trials/focus-stroke-trial (accessed 12 02 2021). CookR , ThomasV , MartinR . Does fluoxetine improve recovery after stroke?BMJ2019;364:1029. DennisM , ForbesJ , GrahamC , HackettM , HankeyGJ , HouseA , et al. Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT. Health Technology Assessment2020;24(22):1-94. DennisM , ForbesJ , GrahamC , HackettML , HankeyGJ , HouseA , et al. Fluoxetine and fractures after stroke: exploratory analyses from the FOCUS Trial. Stroke2019;50(11):3280-2. FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet2019;393(10168):265-74. GrahamC , LewisS , ForbesJ , MeadG , HackettML , HankeyGJ , et al. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. Trials2017;18(1):627. LundstromE , DennisM , MeadG . The effects of fluoxetine on fracture risk after stroke: Further analyses from the focus trial. European Stroke Journal2019;4 suppl 1:7142019. MeadG , DennisM . Feasibility of reporting results of large randomised controlled trials to participants: experience from the Fluoxetine or Control under Supervision (FOCUS) trial. BMJ Open2020;10(11):e0404922020. MeadG . Fluoxetine Or Control Under Supervision (FOCUS) trial: to establish the effect(s) of routine administration of Fluoxetine in patients with a recent stroke. www.isrctn.com/ISRCTN83290762 (first received 23 May 2012). MeadGE , DennisMS , InnesK , MacLeodM , SandercockPA , HouseA , et al. A multicentre randomised trial to establish the effect(s) of routine administration of fluoxetine in patients with a recent stroke (Fluoxetine Or Control Under Supervision, FOCUS). In: 21st European Stroke Conference. 2012:Abst OAID 26. MeadGE , GrahamC , BillotL , NäsmanP , LundströmE , LewisS , on behalf of the FOCUS , AFFINITY and EFFECTS trialists. Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis. Trials2020;21(1):971. MeadGE , LeggL , TilneyR , HsiehCF , WuS , LundströmE , et al. Fluoxetine for stroke recovery: meta-analysis of randomized controlled trials. International Journal of Stroke2020;15(4):365-76. ">FOCUS 2019</a>). MD was ‐1.22 (95% CI ‐2.37 to ‐0.07) in favour of control, 4 trials, 5373 participants, I<sup>2</sup> 72%, P = 0.04 (<a href="./references#CD009286-fig-0016" title="">Analysis 1.12</a>). There was substantial  heterogeneity. We downgraded to moderate‐quality evidence because the cognition outcomes were self‐reported, not directly measured.  Note that the size of the mean difference between treatment and placebo is very small.  </p> </section> <section id="CD009286-sec-0076"> <h5 class="title">Leaving the study early (before the end of scheduled follow‐up) for reasons other than death </h5> <p>We combined data for studies with an overall low risk of bias for the outcome of leaving the study before the end of scheduled follow‐up, using a risk ratio with a fixed‐effect model. The analysis suggested  a slight excess of people leaving early in the SSRI group with no evidence of heterogeneity (RR 1.57, 95% CI 1.03  to 2.40, P = 0. 04, 6 studies, 6090 participants; I<sup>2</sup> = 0%, no important heterogeneity, high‐quality evidence) (<a href="./references#CD009286-fig-0017" title="">Analysis 1.13</a>). </p> </section> <section id="CD009286-sec-0077"> <h5 class="title">Fatigue </h5> <p>Four trials reported SF36 Vitality score as a measure of fatigue (<a href="./references#CD009286-bbs2-0002" title="ACTRN12611000774921. Assessment of fluoxetine in stroke recovery (AFFINITY) trial, 2011. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000774921 (first received 22 July 2011). ACTRN12619000986178. The assessment of fluoxetine in stroke recovery imaging and blood biomarkers sub-study AFFINITY BM. www.anzctr.org.au/Trial/Registration/TrialReview.aspx ?ACTRN=12619000986178 (first received 11 July 2019). AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):651-60. HankeyG . Assessment oF FluoxetINe In sTroke recoverY (AFFINITY). www.affinitytrial.org/ (accessed 19th February 2019). ">AFFINITY 2020</a>; <a href="./references#CD009286-bbs2-0021" title="EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661-9. ISRCTN13020412. Establishing the effect(s) and safety of fluoxetine initiated in the acute phase of stroke. www.isrctn.com/ISRCTN13020412 (first received 19 December 2014). LundströmE , IsakssonE , NäsmanP , WesterP , MårtenssonB , NorrvingB . Correction to: Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(388):s13063-020-04327-w. LundströmE , IsakssonE , Näsman P et al. Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(233):s13063-020-4124-7. LundstromE , IsakssonE , NasmanP , WesterP , MartenssonB , NorrvingB , et al. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661‐9. ">EFFECTS 2020</a>; <a href="./references#CD009286-bbs2-0007" title="BembenekJP , NiewadaM , KlyszB , MazurA , KurczychK , GluszkiewiczM , et al. Fluoxetine for stroke recovery improvement - the doubleblind, randomised placebo-controlled FOCUS-Poland trial. Neurologia i Neurochirurgia Polska2020;54(6):544-51. Fluoxetine or control under supervision: Poland. Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products - EduraCT No: 2014-001335-372014. ">Bembenek 2020</a>; <a href="./references#CD009286-bbs2-0023" title="Anonymous. The FOCUS (Fluoxetine or Control under Supervision) trial results: effects of a 6 month course of fluoxetine on the Stroke Impact Scale, mood and fatigue in patients with stroke. www.ed.ac.uk/clinical-brain-sciences/research/completed-studies-trials/focus-stroke-trial (accessed 12 02 2021). CookR , ThomasV , MartinR . Does fluoxetine improve recovery after stroke?BMJ2019;364:1029. DennisM , ForbesJ , GrahamC , HackettM , HankeyGJ , HouseA , et al. Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT. Health Technology Assessment2020;24(22):1-94. DennisM , ForbesJ , GrahamC , HackettML , HankeyGJ , HouseA , et al. Fluoxetine and fractures after stroke: exploratory analyses from the FOCUS Trial. Stroke2019;50(11):3280-2. FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet2019;393(10168):265-74. GrahamC , LewisS , ForbesJ , MeadG , HackettML , HankeyGJ , et al. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. Trials2017;18(1):627. LundstromE , DennisM , MeadG . The effects of fluoxetine on fracture risk after stroke: Further analyses from the focus trial. European Stroke Journal2019;4 suppl 1:7142019. MeadG , DennisM . Feasibility of reporting results of large randomised controlled trials to participants: experience from the Fluoxetine or Control under Supervision (FOCUS) trial. BMJ Open2020;10(11):e0404922020. MeadG . Fluoxetine Or Control Under Supervision (FOCUS) trial: to establish the effect(s) of routine administration of Fluoxetine in patients with a recent stroke. www.isrctn.com/ISRCTN83290762 (first received 23 May 2012). MeadGE , DennisMS , InnesK , MacLeodM , SandercockPA , HouseA , et al. A multicentre randomised trial to establish the effect(s) of routine administration of fluoxetine in patients with a recent stroke (Fluoxetine Or Control Under Supervision, FOCUS). In: 21st European Stroke Conference. 2012:Abst OAID 26. MeadGE , GrahamC , BillotL , NäsmanP , LundströmE , LewisS , on behalf of the FOCUS , AFFINITY and EFFECTS trialists. Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis. Trials2020;21(1):971. MeadGE , LeggL , TilneyR , HsiehCF , WuS , LundströmE , et al. Fluoxetine for stroke recovery: meta-analysis of randomized controlled trials. International Journal of Stroke2020;15(4):365-76. ">FOCUS 2019</a>). The mean difference between groups was ‐0.06 (95% CI ‐1.24 to 1.11; 5524 participants, P = 0.92, I<sup>2</sup> = 0, no important heterogeneity, moderate‐quality evidence). We downgraded quality because of wide confidence intervals (<a href="./references#CD009286-fig-0018" title="">Analysis 1.14</a>).  </p> </section> <section id="CD009286-sec-0078"> <h5 class="title">Quality of life</h5> <p>Three trials used EQ5 5DL and reported mean and standard deviation in each group which enabled us to perform a meta‐analysis. (<a href="./references#CD009286-bbs2-0023" title="Anonymous. The FOCUS (Fluoxetine or Control under Supervision) trial results: effects of a 6 month course of fluoxetine on the Stroke Impact Scale, mood and fatigue in patients with stroke. www.ed.ac.uk/clinical-brain-sciences/research/completed-studies-trials/focus-stroke-trial (accessed 12 02 2021). CookR , ThomasV , MartinR . Does fluoxetine improve recovery after stroke?BMJ2019;364:1029. DennisM , ForbesJ , GrahamC , HackettM , HankeyGJ , HouseA , et al. Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT. Health Technology Assessment2020;24(22):1-94. DennisM , ForbesJ , GrahamC , HackettML , HankeyGJ , HouseA , et al. Fluoxetine and fractures after stroke: exploratory analyses from the FOCUS Trial. Stroke2019;50(11):3280-2. FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet2019;393(10168):265-74. GrahamC , LewisS , ForbesJ , MeadG , HackettML , HankeyGJ , et al. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. Trials2017;18(1):627. LundstromE , DennisM , MeadG . The effects of fluoxetine on fracture risk after stroke: Further analyses from the focus trial. European Stroke Journal2019;4 suppl 1:7142019. MeadG , DennisM . Feasibility of reporting results of large randomised controlled trials to participants: experience from the Fluoxetine or Control under Supervision (FOCUS) trial. BMJ Open2020;10(11):e0404922020. MeadG . Fluoxetine Or Control Under Supervision (FOCUS) trial: to establish the effect(s) of routine administration of Fluoxetine in patients with a recent stroke. www.isrctn.com/ISRCTN83290762 (first received 23 May 2012). MeadGE , DennisMS , InnesK , MacLeodM , SandercockPA , HouseA , et al. A multicentre randomised trial to establish the effect(s) of routine administration of fluoxetine in patients with a recent stroke (Fluoxetine Or Control Under Supervision, FOCUS). In: 21st European Stroke Conference. 2012:Abst OAID 26. MeadGE , GrahamC , BillotL , NäsmanP , LundströmE , LewisS , on behalf of the FOCUS , AFFINITY and EFFECTS trialists. Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis. Trials2020;21(1):971. MeadGE , LeggL , TilneyR , HsiehCF , WuS , LundströmE , et al. Fluoxetine for stroke recovery: meta-analysis of randomized controlled trials. International Journal of Stroke2020;15(4):365-76. ">FOCUS 2019</a>; <a href="./references#CD009286-bbs2-0002" title="ACTRN12611000774921. Assessment of fluoxetine in stroke recovery (AFFINITY) trial, 2011. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000774921 (first received 22 July 2011). ACTRN12619000986178. The assessment of fluoxetine in stroke recovery imaging and blood biomarkers sub-study AFFINITY BM. www.anzctr.org.au/Trial/Registration/TrialReview.aspx ?ACTRN=12619000986178 (first received 11 July 2019). AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):651-60. HankeyG . Assessment oF FluoxetINe In sTroke recoverY (AFFINITY). www.affinitytrial.org/ (accessed 19th February 2019). ">AFFINITY 2020</a>; <a href="./references#CD009286-bbs2-0021" title="EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661-9. ISRCTN13020412. Establishing the effect(s) and safety of fluoxetine initiated in the acute phase of stroke. www.isrctn.com/ISRCTN13020412 (first received 19 December 2014). LundströmE , IsakssonE , NäsmanP , WesterP , MårtenssonB , NorrvingB . Correction to: Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(388):s13063-020-04327-w. LundströmE , IsakssonE , Näsman P et al. Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(233):s13063-020-4124-7. LundstromE , IsakssonE , NasmanP , WesterP , MartenssonB , NorrvingB , et al. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661‐9. ">EFFECTS 2020</a> ). The mean difference between groups was ‐0.00  (95% CI ‐0.02 to 0.02), 5482 participants, P = 0. 93 ; I<sup>2</sup> = 0, no important heterogeneity, high ‐ quality of evidence) (<a href="./references#CD009286-fig-0019" title="">Analysis 1.15</a>). </p> </section> <section id="CD009286-sec-0079"> <h5 class="title">Healthcare costs</h5> <p>No trial reported healthcare costs.  </p> </section> <section id="CD009286-sec-0080"> <h5 class="title">Outcomes at the end of follow‐up</h5> <p>We repeated the analyses above for all outcomes reported at the end of follow‐up for the studies at low risk of bias across all domains. Four studies collected data on outcomes 12 months after completing the intervention and so we selected this time point for our analyses (<a href="./references#CD009286-bbs2-0002" title="ACTRN12611000774921. Assessment of fluoxetine in stroke recovery (AFFINITY) trial, 2011. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000774921 (first received 22 July 2011). ACTRN12619000986178. The assessment of fluoxetine in stroke recovery imaging and blood biomarkers sub-study AFFINITY BM. www.anzctr.org.au/Trial/Registration/TrialReview.aspx ?ACTRN=12619000986178 (first received 11 July 2019). AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):651-60. HankeyG . Assessment oF FluoxetINe In sTroke recoverY (AFFINITY). www.affinitytrial.org/ (accessed 19th February 2019). ">AFFINITY 2020</a>; <a href="./references#CD009286-bbs2-0007" title="BembenekJP , NiewadaM , KlyszB , MazurA , KurczychK , GluszkiewiczM , et al. Fluoxetine for stroke recovery improvement - the doubleblind, randomised placebo-controlled FOCUS-Poland trial. Neurologia i Neurochirurgia Polska2020;54(6):544-51. Fluoxetine or control under supervision: Poland. Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products - EduraCT No: 2014-001335-372014. ">Bembenek 2020</a>; <a href="./references#CD009286-bbs2-0021" title="EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661-9. ISRCTN13020412. Establishing the effect(s) and safety of fluoxetine initiated in the acute phase of stroke. www.isrctn.com/ISRCTN13020412 (first received 19 December 2014). LundströmE , IsakssonE , NäsmanP , WesterP , MårtenssonB , NorrvingB . Correction to: Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(388):s13063-020-04327-w. LundströmE , IsakssonE , Näsman P et al. Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(233):s13063-020-4124-7. LundstromE , IsakssonE , NasmanP , WesterP , MartenssonB , NorrvingB , et al. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661‐9. ">EFFECTS 2020</a>; <a href="./references#CD009286-bbs2-0023" title="Anonymous. The FOCUS (Fluoxetine or Control under Supervision) trial results: effects of a 6 month course of fluoxetine on the Stroke Impact Scale, mood and fatigue in patients with stroke. www.ed.ac.uk/clinical-brain-sciences/research/completed-studies-trials/focus-stroke-trial (accessed 12 02 2021). CookR , ThomasV , MartinR . Does fluoxetine improve recovery after stroke?BMJ2019;364:1029. DennisM , ForbesJ , GrahamC , HackettM , HankeyGJ , HouseA , et al. Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT. Health Technology Assessment2020;24(22):1-94. DennisM , ForbesJ , GrahamC , HackettML , HankeyGJ , HouseA , et al. Fluoxetine and fractures after stroke: exploratory analyses from the FOCUS Trial. Stroke2019;50(11):3280-2. FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet2019;393(10168):265-74. GrahamC , LewisS , ForbesJ , MeadG , HackettML , HankeyGJ , et al. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. Trials2017;18(1):627. LundstromE , DennisM , MeadG . The effects of fluoxetine on fracture risk after stroke: Further analyses from the focus trial. European Stroke Journal2019;4 suppl 1:7142019. MeadG , DennisM . Feasibility of reporting results of large randomised controlled trials to participants: experience from the Fluoxetine or Control under Supervision (FOCUS) trial. BMJ Open2020;10(11):e0404922020. MeadG . Fluoxetine Or Control Under Supervision (FOCUS) trial: to establish the effect(s) of routine administration of Fluoxetine in patients with a recent stroke. www.isrctn.com/ISRCTN83290762 (first received 23 May 2012). MeadGE , DennisMS , InnesK , MacLeodM , SandercockPA , HouseA , et al. A multicentre randomised trial to establish the effect(s) of routine administration of fluoxetine in patients with a recent stroke (Fluoxetine Or Control Under Supervision, FOCUS). In: 21st European Stroke Conference. 2012:Abst OAID 26. MeadGE , GrahamC , BillotL , NäsmanP , LundströmE , LewisS , on behalf of the FOCUS , AFFINITY and EFFECTS trialists. Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis. Trials2020;21(1):971. MeadGE , LeggL , TilneyR , HsiehCF , WuS , LundströmE , et al. Fluoxetine for stroke recovery: meta-analysis of randomized controlled trials. International Journal of Stroke2020;15(4):365-76. ">FOCUS 2019</a>). Two studies have not yet published their 12‐month data and so are not included in this meta‐analysis (<a href="./references#CD009286-bbs2-0002" title="ACTRN12611000774921. Assessment of fluoxetine in stroke recovery (AFFINITY) trial, 2011. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000774921 (first received 22 July 2011). ACTRN12619000986178. The assessment of fluoxetine in stroke recovery imaging and blood biomarkers sub-study AFFINITY BM. www.anzctr.org.au/Trial/Registration/TrialReview.aspx ?ACTRN=12619000986178 (first received 11 July 2019). AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):651-60. HankeyG . Assessment oF FluoxetINe In sTroke recoverY (AFFINITY). www.affinitytrial.org/ (accessed 19th February 2019). ">AFFINITY 2020</a>; <a href="./references#CD009286-bbs2-0021" title="EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661-9. ISRCTN13020412. Establishing the effect(s) and safety of fluoxetine initiated in the acute phase of stroke. www.isrctn.com/ISRCTN13020412 (first received 19 December 2014). LundströmE , IsakssonE , NäsmanP , WesterP , MårtenssonB , NorrvingB . Correction to: Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(388):s13063-020-04327-w. LundströmE , IsakssonE , Näsman P et al. Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(233):s13063-020-4124-7. LundstromE , IsakssonE , NasmanP , WesterP , MartenssonB , NorrvingB , et al. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661‐9. ">EFFECTS 2020</a>). We analysed available data for other two studies (<a href="./references#CD009286-bbs2-0007" title="BembenekJP , NiewadaM , KlyszB , MazurA , KurczychK , GluszkiewiczM , et al. Fluoxetine for stroke recovery improvement - the doubleblind, randomised placebo-controlled FOCUS-Poland trial. Neurologia i Neurochirurgia Polska2020;54(6):544-51. Fluoxetine or control under supervision: Poland. Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products - EduraCT No: 2014-001335-372014. ">Bembenek 2020</a>; <a href="./references#CD009286-bbs2-0023" title="Anonymous. The FOCUS (Fluoxetine or Control under Supervision) trial results: effects of a 6 month course of fluoxetine on the Stroke Impact Scale, mood and fatigue in patients with stroke. www.ed.ac.uk/clinical-brain-sciences/research/completed-studies-trials/focus-stroke-trial (accessed 12 02 2021). CookR , ThomasV , MartinR . Does fluoxetine improve recovery after stroke?BMJ2019;364:1029. DennisM , ForbesJ , GrahamC , HackettM , HankeyGJ , HouseA , et al. Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT. Health Technology Assessment2020;24(22):1-94. DennisM , ForbesJ , GrahamC , HackettML , HankeyGJ , HouseA , et al. Fluoxetine and fractures after stroke: exploratory analyses from the FOCUS Trial. Stroke2019;50(11):3280-2. FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet2019;393(10168):265-74. GrahamC , LewisS , ForbesJ , MeadG , HackettML , HankeyGJ , et al. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. Trials2017;18(1):627. LundstromE , DennisM , MeadG . The effects of fluoxetine on fracture risk after stroke: Further analyses from the focus trial. European Stroke Journal2019;4 suppl 1:7142019. MeadG , DennisM . Feasibility of reporting results of large randomised controlled trials to participants: experience from the Fluoxetine or Control under Supervision (FOCUS) trial. BMJ Open2020;10(11):e0404922020. MeadG . Fluoxetine Or Control Under Supervision (FOCUS) trial: to establish the effect(s) of routine administration of Fluoxetine in patients with a recent stroke. www.isrctn.com/ISRCTN83290762 (first received 23 May 2012). MeadGE , DennisMS , InnesK , MacLeodM , SandercockPA , HouseA , et al. A multicentre randomised trial to establish the effect(s) of routine administration of fluoxetine in patients with a recent stroke (Fluoxetine Or Control Under Supervision, FOCUS). In: 21st European Stroke Conference. 2012:Abst OAID 26. MeadGE , GrahamC , BillotL , NäsmanP , LundströmE , LewisS , on behalf of the FOCUS , AFFINITY and EFFECTS trialists. Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis. Trials2020;21(1):971. MeadGE , LeggL , TilneyR , HsiehCF , WuS , LundströmE , et al. Fluoxetine for stroke recovery: meta-analysis of randomized controlled trials. International Journal of Stroke2020;15(4):365-76. ">FOCUS 2019</a>).   </p> <p>These analyses are shown in <a href="./references#CD009286-fig-0022" title="">Analysis 2.1</a> to <a href="./references#CD009286-fig-0031" title="">Analysis 2.10</a>. There was no clear evidence of differences between SSRI and control for any outcome.  </p> </section> </section> <section id="CD009286-sec-0081"> <h4 class="title">Subgroup analyses by intervention characteristics and subsets of participant</h4> <p>We did not perform preplanned subgroup analyses by intervention characteristics and subsets of participant (including with or without depression) of the studies at low risk of bias, because they all used fluoxetine and all did not require participants to have depression to enter the trial.  </p> </section> <section id="CD009286-sec-0082"> <h4 class="title">Sensitivity analysis</h4> <section id="CD009286-sec-0083"> <h5 class="title">Inclusion of all studies regardless of 'Risk of bias' judgement for the  co‐primary outcomes </h5> <p>We included all studies reporting disability, regardless of 'Risk of bias' judgement for the co‐primary outcome of disability at the end of treatment using a SMD and a fixed‐effect model.  </p> <p>For disability, participants who received an SSRI intervention had significantly lower end‐of‐treatment scores than those participants receiving placebo or standard care/practice  (SMD ‐0.18, 95% CI ‐0.23 to ‐0.14; P &lt; 0.00001; 32 studies, 7667 participants) with considerable heterogeneity (I<sup>2</sup> = 94% ) (<a href="./references#CD009286-fig-0020" title="">Analysis 1.16</a>). Our post‐hoc analysis (Funnel plot, <a href="#CD009286-fig-0004">Figure 4</a>) demonstrated an absence of studies in the right hand side of the plot, consistent with publication bias.  </p> <p>We included all studies regardless of risk of bias judgement for the co‐primary outcome of independence.  </p> <p>Note that previously <a href="./references#CD009286-bbs2-0005" title="AndersenG . The efficacy of citalopram treatment in acute stroke (TALOS). www.clinicaltrials.gov/ct2/show/NCT01937182 (first received 9 September 2013). DamsboAG , MortensenJK , KraglundKL , JohnsenSP , AndersenG , BlauenfeldtRA . Prestroke physical activity and poststroke cognitive performance. Cerebrovascular Diseases2020;49(6):632-8. KraglundKL , MortensenJK , DamsboAG , ModrauB , SimonsenSA , Iversen, HK, et al. Neuroregeneration and vascular protection by citalopram in acute ischemic stroke (TALOS). Stroke2018;49(11):2568-76. KraglundKL , MortensenJK , DamsboAG , ModrauB , SimonsenSA , IversenHK , et al. Neuroregeneration and vascular protection by citalopramin in acute ischemic stroke (TALOS). Stroke2018;49(11):2568-76. KraglundKL , MortensenJK , GroveEL , JohnsenSP , AndersenG . TALOS: a multicenter, randomised, double blind, placebo controlled trial to test the effects of citalopram in patients with acute stroke; protocol. International Journal of Stroke2015;10:985-87. KraglundKL , MortensenJK , JohnsenSP , AndersenG , GroveEL . Antiplatelet effects of citalopram in patients with ischaemic stroke: a randomized, placebo-controlled, double-blind study. Scientific Reports2019;9(1):200482019. ">Andersen 2013</a> had the mRS data entered as a continuous variable for disability; for this update we have entered it only as dichotomous data for mRS.  </p> <p>The mRS 0 to 2 at the end of treatment was similar in the two groups (RR 0.97, 95% CI 0.93 to 1.01; P = 0.18, I<sup>2</sup> = 59%,  8 studies, 6792 participants) (<a href="./references#CD009286-fig-0021" title="">Analysis 1.17</a>). </p> </section> <section id="CD009286-sec-0084"> <h5 class="title">Meta‐analysis using the alternate meta‐analytical effects model (fixed‐effect or random‐effects) for the primary outcomes from the high‐quality studies  </h5> <p>We re‐analysed the data for our primary outcomes (disability score and independence (0‐2 on mRS) using the random‐effects analysis for the high‐quality studies. This made no difference to the results (<a href="#CD009286-tbl-0002">Table 1</a>). </p> <div class="table" id="CD009286-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Sensitivity analysis for co‐primary outcomes depending on the method of analysis</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>mRS (RR and 95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Disability (SMD and 95% CI)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fixed‐effect</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.93, 1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.0 (‐0.05, 0.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Random‐effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.92, 1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.00 (‐0.05, 0.05)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval<br/>mRS: modified Rankin Scale<br/>RR: risk ratio<br/>SMD: standardised mean difference </p> </div> </div> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009286-sec-0085" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009286-sec-0085"></div> <section id="CD009286-sec-0086"> <h3 class="title" id="CD009286-sec-0086">Summary of main results</h3> <p>For this update we included 76 studies with 13,029 participants, of which 38 used fluoxetine and the remaining studies used other selective serotonin reuptake inhibitors (SSRIs) . Data from our co‐primary outcomes (disability, independence) were not collected in many of the studies.   </p> <p>Six studies were at low risk of bias across all key domains; these all recruited participants who were less than 90 days after stroke onset, none used depression as an inclusion criterion; and they all compared fluoxetine with placebo.  Comparing fluoxetine to placebo in these trials, we found high‐quality evidence of no beneficial effects of fluoxetine on our co‐primary outcomes (disability and independence) at end of treatment. We found high‐quality evidence that fluoxetine reduced the severity of depression evaluated using a continuous outcome and the number of participants with depression at end of treatment. We found an excess of participants having seizures and bone fractures amongst those allocated to fluoxetine. Cognition was lower at the end of treatment in the SSRI group. As we included only high‐quality studies in our main analyses, we did not downgrade for quality of trials; the main reason for downgrading quality was because of imprecision. </p> <p>There are data on outcomes at end of follow‐up for two trials (<a href="./references#CD009286-bbs2-0007" title="BembenekJP , NiewadaM , KlyszB , MazurA , KurczychK , GluszkiewiczM , et al. Fluoxetine for stroke recovery improvement - the doubleblind, randomised placebo-controlled FOCUS-Poland trial. Neurologia i Neurochirurgia Polska2020;54(6):544-51. Fluoxetine or control under supervision: Poland. Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products - EduraCT No: 2014-001335-372014. ">Bembenek 2020</a>; <a href="./references#CD009286-bbs2-0023" title="Anonymous. The FOCUS (Fluoxetine or Control under Supervision) trial results: effects of a 6 month course of fluoxetine on the Stroke Impact Scale, mood and fatigue in patients with stroke. www.ed.ac.uk/clinical-brain-sciences/research/completed-studies-trials/focus-stroke-trial (accessed 12 02 2021). CookR , ThomasV , MartinR . Does fluoxetine improve recovery after stroke?BMJ2019;364:1029. DennisM , ForbesJ , GrahamC , HackettM , HankeyGJ , HouseA , et al. Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT. Health Technology Assessment2020;24(22):1-94. DennisM , ForbesJ , GrahamC , HackettML , HankeyGJ , HouseA , et al. Fluoxetine and fractures after stroke: exploratory analyses from the FOCUS Trial. Stroke2019;50(11):3280-2. FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet2019;393(10168):265-74. GrahamC , LewisS , ForbesJ , MeadG , HackettML , HankeyGJ , et al. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. Trials2017;18(1):627. LundstromE , DennisM , MeadG . The effects of fluoxetine on fracture risk after stroke: Further analyses from the focus trial. European Stroke Journal2019;4 suppl 1:7142019. MeadG , DennisM . Feasibility of reporting results of large randomised controlled trials to participants: experience from the Fluoxetine or Control under Supervision (FOCUS) trial. BMJ Open2020;10(11):e0404922020. MeadG . Fluoxetine Or Control Under Supervision (FOCUS) trial: to establish the effect(s) of routine administration of Fluoxetine in patients with a recent stroke. www.isrctn.com/ISRCTN83290762 (first received 23 May 2012). MeadGE , DennisMS , InnesK , MacLeodM , SandercockPA , HouseA , et al. A multicentre randomised trial to establish the effect(s) of routine administration of fluoxetine in patients with a recent stroke (Fluoxetine Or Control Under Supervision, FOCUS). In: 21st European Stroke Conference. 2012:Abst OAID 26. MeadGE , GrahamC , BillotL , NäsmanP , LundströmE , LewisS , on behalf of the FOCUS , AFFINITY and EFFECTS trialists. Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis. Trials2020;21(1):971. MeadGE , LeggL , TilneyR , HsiehCF , WuS , LundströmE , et al. Fluoxetine for stroke recovery: meta-analysis of randomized controlled trials. International Journal of Stroke2020;15(4):365-76. ">FOCUS 2019</a>); follow‐up data will be available for two other studies in due course (<a href="./references#CD009286-bbs2-0002" title="ACTRN12611000774921. Assessment of fluoxetine in stroke recovery (AFFINITY) trial, 2011. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000774921 (first received 22 July 2011). ACTRN12619000986178. The assessment of fluoxetine in stroke recovery imaging and blood biomarkers sub-study AFFINITY BM. www.anzctr.org.au/Trial/Registration/TrialReview.aspx ?ACTRN=12619000986178 (first received 11 July 2019). AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):651-60. HankeyG . Assessment oF FluoxetINe In sTroke recoverY (AFFINITY). www.affinitytrial.org/ (accessed 19th February 2019). ">AFFINITY 2020</a>; <a href="./references#CD009286-bbs2-0021" title="EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661-9. ISRCTN13020412. Establishing the effect(s) and safety of fluoxetine initiated in the acute phase of stroke. www.isrctn.com/ISRCTN13020412 (first received 19 December 2014). LundströmE , IsakssonE , NäsmanP , WesterP , MårtenssonB , NorrvingB . Correction to: Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(388):s13063-020-04327-w. LundströmE , IsakssonE , Näsman P et al. Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(233):s13063-020-4124-7. LundstromE , IsakssonE , NasmanP , WesterP , MartenssonB , NorrvingB , et al. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661‐9. ">EFFECTS 2020</a>). </p> <p>When we performed a meta‐analysis of disability for all studies irrespective of risk of bias, we found a small beneficial effect of SSRI but with high heterogeneity. There was no difference in the proportion of participants independent at follow‐up; for this outcome there was evidence of publication bias on our funnel plot.  </p> </section> <section id="CD009286-sec-0087"> <h3 class="title" id="CD009286-sec-0087">Overall completeness and applicability of evidence</h3> <p>This review includes studies from different settings (e.g. countries; high‐, middle‐ and low‐income settings; healthcare systems), with different criteria for selecting participants (e.g. methods of pre‐randomisation diagnosis and investigation, inclusion and exclusion criteria), that may reflect differences between the trial protocol and routine clinical practice (e.g. inclusion of participants based on a diagnosis of stroke made using brain imaging: brain imaging is unlikely to be either available or affordable in routine clinical care in many low‐ and middle‐income country settings); and different characteristics of randomised participants (e.g. baseline demographic and clinical characteristics, stroke severity, time since stroke onset, presence or absence of depression, severity of depression). These study characteristics may in part explain the heterogeneity of results, but we know from our previous review that the most probable cause of heterogeneity is study quality. </p> <p>There is a discordance between the results for disability (one of our co‐primary outcomes) between the studies at low risk of bias, which showed no effect, and all studies irrespective of bias (a positive effect). This is because trials at high risk of bias tended to be positive. </p> <p>The results of the meta‐analysis of the seven studies at low risk of bias are applicable to clinical practice throughout the world, for both ischaemic and haemorrhagic stroke. </p> <p>There is a theoretical risk that SSRIs might carry particular risks in people with haemorrhagic stroke, due to their effects on platelet aggregation and bleeding, but there was no evidence of this based on data from the individual studies; to explore this further we are planning an individual patient meta‐analysis (<a href="./references#CD009286-bbs2-0021" title="EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661-9. ISRCTN13020412. Establishing the effect(s) and safety of fluoxetine initiated in the acute phase of stroke. www.isrctn.com/ISRCTN13020412 (first received 19 December 2014). LundströmE , IsakssonE , NäsmanP , WesterP , MårtenssonB , NorrvingB . Correction to: Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(388):s13063-020-04327-w. LundströmE , IsakssonE , Näsman P et al. Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(233):s13063-020-4124-7. LundstromE , IsakssonE , NasmanP , WesterP , MartenssonB , NorrvingB , et al. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661‐9. ">EFFECTS 2020</a>; <a href="./references#CD009286-bbs2-0023" title="Anonymous. The FOCUS (Fluoxetine or Control under Supervision) trial results: effects of a 6 month course of fluoxetine on the Stroke Impact Scale, mood and fatigue in patients with stroke. www.ed.ac.uk/clinical-brain-sciences/research/completed-studies-trials/focus-stroke-trial (accessed 12 02 2021). CookR , ThomasV , MartinR . Does fluoxetine improve recovery after stroke?BMJ2019;364:1029. DennisM , ForbesJ , GrahamC , HackettM , HankeyGJ , HouseA , et al. Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT. Health Technology Assessment2020;24(22):1-94. DennisM , ForbesJ , GrahamC , HackettML , HankeyGJ , HouseA , et al. Fluoxetine and fractures after stroke: exploratory analyses from the FOCUS Trial. Stroke2019;50(11):3280-2. FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet2019;393(10168):265-74. GrahamC , LewisS , ForbesJ , MeadG , HackettML , HankeyGJ , et al. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. Trials2017;18(1):627. LundstromE , DennisM , MeadG . The effects of fluoxetine on fracture risk after stroke: Further analyses from the focus trial. European Stroke Journal2019;4 suppl 1:7142019. MeadG , DennisM . Feasibility of reporting results of large randomised controlled trials to participants: experience from the Fluoxetine or Control under Supervision (FOCUS) trial. BMJ Open2020;10(11):e0404922020. MeadG . Fluoxetine Or Control Under Supervision (FOCUS) trial: to establish the effect(s) of routine administration of Fluoxetine in patients with a recent stroke. www.isrctn.com/ISRCTN83290762 (first received 23 May 2012). MeadGE , DennisMS , InnesK , MacLeodM , SandercockPA , HouseA , et al. A multicentre randomised trial to establish the effect(s) of routine administration of fluoxetine in patients with a recent stroke (Fluoxetine Or Control Under Supervision, FOCUS). In: 21st European Stroke Conference. 2012:Abst OAID 26. MeadGE , GrahamC , BillotL , NäsmanP , LundströmE , LewisS , on behalf of the FOCUS , AFFINITY and EFFECTS trialists. Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis. Trials2020;21(1):971. MeadGE , LeggL , TilneyR , HsiehCF , WuS , LundströmE , et al. Fluoxetine for stroke recovery: meta-analysis of randomized controlled trials. International Journal of Stroke2020;15(4):365-76. ">FOCUS 2019</a>). We noted that those allocated control had better cognition at the end of treatment, although the effect size was very small, and of uncertain clinical relevance. According to the NHS in the UK, confusion is a rare side effect of SSRIs (<a href="./references#CD009286-bbs2-0140" title="NHS. Side effects-selective serotonin reuptake inhibitors (SSRI). www.nhs.uk (accessed 10 August 2021).">NHS 2021</a> , but on the other hand, there is also systematic review evidence that fluoxetine might improve cognition in people with dementia (<a href="./references#CD009286-bbs2-0152" title="XieY , LiuPP , LianYJ , Liu H-B, Kang J-S. The effect of selective serotonin reuptake inhibitors on cognitive function in patients with Alzheimer’s disease and vascular dementia: focusing on fluoxetine with long follow-up periods. Signal Transduction and Targeted Therapy2019;4:30. [DOI: 10.1038/s41392-019-0064-7]">Xie 2019</a>). Our finding might also have been due to chance. We plan to explore in more detail the impact of fluoxetine on cognition when we perform our individual patient data meta‐analysis from the three large studies. </p> <p>There were no data on anxiety from the studies, even though anxiety is a common problem after stroke. </p> <p>We were unable to explore the influence of the type of SSRI, as all the high‐quality trials used fluoxetine. </p> <p>The full searches were last performed in January 2021; the lead review author (GM) searched WHO ICTRP in August 2021 and did not find any further new eligible studies. We are not aware of any other new studies published since January 2021 that are likely to change the results of the review. </p> <p>We have data on follow‐up after treatment end for only two studies (<a href="./references#CD009286-bbs2-0007" title="BembenekJP , NiewadaM , KlyszB , MazurA , KurczychK , GluszkiewiczM , et al. Fluoxetine for stroke recovery improvement - the doubleblind, randomised placebo-controlled FOCUS-Poland trial. Neurologia i Neurochirurgia Polska2020;54(6):544-51. Fluoxetine or control under supervision: Poland. Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products - EduraCT No: 2014-001335-372014. ">Bembenek 2020</a>; <a href="./references#CD009286-bbs2-0023" title="Anonymous. The FOCUS (Fluoxetine or Control under Supervision) trial results: effects of a 6 month course of fluoxetine on the Stroke Impact Scale, mood and fatigue in patients with stroke. www.ed.ac.uk/clinical-brain-sciences/research/completed-studies-trials/focus-stroke-trial (accessed 12 02 2021). CookR , ThomasV , MartinR . Does fluoxetine improve recovery after stroke?BMJ2019;364:1029. DennisM , ForbesJ , GrahamC , HackettM , HankeyGJ , HouseA , et al. Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT. Health Technology Assessment2020;24(22):1-94. DennisM , ForbesJ , GrahamC , HackettML , HankeyGJ , HouseA , et al. Fluoxetine and fractures after stroke: exploratory analyses from the FOCUS Trial. Stroke2019;50(11):3280-2. FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet2019;393(10168):265-74. GrahamC , LewisS , ForbesJ , MeadG , HackettML , HankeyGJ , et al. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. Trials2017;18(1):627. LundstromE , DennisM , MeadG . The effects of fluoxetine on fracture risk after stroke: Further analyses from the focus trial. European Stroke Journal2019;4 suppl 1:7142019. MeadG , DennisM . Feasibility of reporting results of large randomised controlled trials to participants: experience from the Fluoxetine or Control under Supervision (FOCUS) trial. BMJ Open2020;10(11):e0404922020. MeadG . Fluoxetine Or Control Under Supervision (FOCUS) trial: to establish the effect(s) of routine administration of Fluoxetine in patients with a recent stroke. www.isrctn.com/ISRCTN83290762 (first received 23 May 2012). MeadGE , DennisMS , InnesK , MacLeodM , SandercockPA , HouseA , et al. A multicentre randomised trial to establish the effect(s) of routine administration of fluoxetine in patients with a recent stroke (Fluoxetine Or Control Under Supervision, FOCUS). In: 21st European Stroke Conference. 2012:Abst OAID 26. MeadGE , GrahamC , BillotL , NäsmanP , LundströmE , LewisS , on behalf of the FOCUS , AFFINITY and EFFECTS trialists. Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis. Trials2020;21(1):971. MeadGE , LeggL , TilneyR , HsiehCF , WuS , LundströmE , et al. Fluoxetine for stroke recovery: meta-analysis of randomized controlled trials. International Journal of Stroke2020;15(4):365-76. ">FOCUS 2019</a>). Two large studies have unpublished data for outcome six months after treatment end (12 months after randomisation) (<a href="./references#CD009286-bbs2-0002" title="ACTRN12611000774921. Assessment of fluoxetine in stroke recovery (AFFINITY) trial, 2011. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000774921 (first received 22 July 2011). ACTRN12619000986178. The assessment of fluoxetine in stroke recovery imaging and blood biomarkers sub-study AFFINITY BM. www.anzctr.org.au/Trial/Registration/TrialReview.aspx ?ACTRN=12619000986178 (first received 11 July 2019). AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):651-60. HankeyG . Assessment oF FluoxetINe In sTroke recoverY (AFFINITY). www.affinitytrial.org/ (accessed 19th February 2019). ">AFFINITY 2020</a>; <a href="./references#CD009286-bbs2-0021" title="EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661-9. ISRCTN13020412. Establishing the effect(s) and safety of fluoxetine initiated in the acute phase of stroke. www.isrctn.com/ISRCTN13020412 (first received 19 December 2014). LundströmE , IsakssonE , NäsmanP , WesterP , MårtenssonB , NorrvingB . Correction to: Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(388):s13063-020-04327-w. LundströmE , IsakssonE , Näsman P et al. Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(233):s13063-020-4124-7. LundstromE , IsakssonE , NasmanP , WesterP , MartenssonB , NorrvingB , et al. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661‐9. ">EFFECTS 2020</a>); these data will be incorporated into an individual patient data meta‐analysis in due course (<a href="./references#CD009286-bbs2-0137" title="MeadGE , GrahamC , BillotL , NäsmanP , LundströmE , LewisS , forFOCUS , AFFINITY and EFFECTS trialists. Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis. Trials2020;21(1):971. [DOI: https://doi.org/10.1186/s13063-020-04875-1]">Mead 2020</a>). </p> <p>We did not include studies which combined an SSRI with another active treatment (either drugs or another type of intervention), and either compared with control or the active treatment alone. It is possible that SSRIS could modify (either enhance or reduce) training‐induced brain plasticity and hence functional recovery. Thus, the absence of an effect of SSRIs on disability might have been because the SSRI was not coupled with a domain‐specific behavioural rehabilitation intervention. In the future, a systematic review of SSRIs plus training would be of interest. </p> </section> <section id="CD009286-sec-0088"> <h3 class="title" id="CD009286-sec-0088">Quality of the evidence</h3> <p>For the evaluation of quality of the evidence, we contacted authors of primary studies as yet unpublished for data on outcomes. For studies which we thought would fall into the category of being at low risk of bias across all the domains, but where some of the methodology was not reported in sufficient detail to enable us to make a final judgement, we contacted authors to clarify methodology. We also contacted authors of primary studies when it appeared that the same (or similar) group of patients had been described in more than one publication, in order to avoid double counting participants, and for one study, we also contacted the editors of the respective journals. </p> <p>We used the Cochrane risk of bias tool to assess study methods. As in the previous update (<a href="./references#CD009286-bbs2-0132" title="LeggLA , TilneyR , HsiehC , WuS , LundströmE , RudbergA , et al. Selective serotonin reuptake inhibitors for stroke recovery. Cochrane Database of Systematic Reviews2019, Issue 11. Art. No: CD009286. [DOI: 10.1002/14651858.CD009286.pub3]">Legg 2019</a>), we restricted our meta‐analyses to studies at low risk of bias, because in the first review, <a href="./references#CD009286-bbs2-0156" title="MeadGE , HankeyGJ , KutlubaevMA , LeeR , BaileyM , HackettML . Selective serotonin reuptake inhibitors (SSRIs) for stroke. Cochrane Database of Systematic Reviews2011, Issue 10. Art. No: CD009286. [DOI: 10.1002/14651858.CD009286]">Mead 2011</a>, there was evidence that the apparently beneficial effects of SSRI on recovery was due to methodological limitations of the included trials. This observation was confirmed by the sensitivity analyses that we performed for these two previous reviews. </p> <p>The meta‐analysis of the high‐quality studies is dominated by three trials (<a href="./references#CD009286-bbs2-0002" title="ACTRN12611000774921. Assessment of fluoxetine in stroke recovery (AFFINITY) trial, 2011. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000774921 (first received 22 July 2011). ACTRN12619000986178. The assessment of fluoxetine in stroke recovery imaging and blood biomarkers sub-study AFFINITY BM. www.anzctr.org.au/Trial/Registration/TrialReview.aspx ?ACTRN=12619000986178 (first received 11 July 2019). AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):651-60. HankeyG . Assessment oF FluoxetINe In sTroke recoverY (AFFINITY). www.affinitytrial.org/ (accessed 19th February 2019). ">AFFINITY 2020</a>; <a href="./references#CD009286-bbs2-0021" title="EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661-9. ISRCTN13020412. Establishing the effect(s) and safety of fluoxetine initiated in the acute phase of stroke. www.isrctn.com/ISRCTN13020412 (first received 19 December 2014). LundströmE , IsakssonE , NäsmanP , WesterP , MårtenssonB , NorrvingB . Correction to: Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(388):s13063-020-04327-w. LundströmE , IsakssonE , Näsman P et al. Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(233):s13063-020-4124-7. LundstromE , IsakssonE , NasmanP , WesterP , MartenssonB , NorrvingB , et al. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661‐9. ">EFFECTS 2020</a>; <a href="./references#CD009286-bbs2-0023" title="Anonymous. The FOCUS (Fluoxetine or Control under Supervision) trial results: effects of a 6 month course of fluoxetine on the Stroke Impact Scale, mood and fatigue in patients with stroke. www.ed.ac.uk/clinical-brain-sciences/research/completed-studies-trials/focus-stroke-trial (accessed 12 02 2021). CookR , ThomasV , MartinR . Does fluoxetine improve recovery after stroke?BMJ2019;364:1029. DennisM , ForbesJ , GrahamC , HackettM , HankeyGJ , HouseA , et al. Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT. Health Technology Assessment2020;24(22):1-94. DennisM , ForbesJ , GrahamC , HackettML , HankeyGJ , HouseA , et al. Fluoxetine and fractures after stroke: exploratory analyses from the FOCUS Trial. Stroke2019;50(11):3280-2. FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet2019;393(10168):265-74. GrahamC , LewisS , ForbesJ , MeadG , HackettML , HankeyGJ , et al. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. Trials2017;18(1):627. LundstromE , DennisM , MeadG . The effects of fluoxetine on fracture risk after stroke: Further analyses from the focus trial. European Stroke Journal2019;4 suppl 1:7142019. MeadG , DennisM . Feasibility of reporting results of large randomised controlled trials to participants: experience from the Fluoxetine or Control under Supervision (FOCUS) trial. BMJ Open2020;10(11):e0404922020. MeadG . Fluoxetine Or Control Under Supervision (FOCUS) trial: to establish the effect(s) of routine administration of Fluoxetine in patients with a recent stroke. www.isrctn.com/ISRCTN83290762 (first received 23 May 2012). MeadGE , DennisMS , InnesK , MacLeodM , SandercockPA , HouseA , et al. A multicentre randomised trial to establish the effect(s) of routine administration of fluoxetine in patients with a recent stroke (Fluoxetine Or Control Under Supervision, FOCUS). In: 21st European Stroke Conference. 2012:Abst OAID 26. MeadGE , GrahamC , BillotL , NäsmanP , LundströmE , LewisS , on behalf of the FOCUS , AFFINITY and EFFECTS trialists. Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis. Trials2020;21(1):971. MeadGE , LeggL , TilneyR , HsiehCF , WuS , LundströmE , et al. Fluoxetine for stroke recovery: meta-analysis of randomized controlled trials. International Journal of Stroke2020;15(4):365-76. ">FOCUS 2019</a>). All three of these trials were neutral for their primary outcome (modified Rankin score (mRS) at six months). </p> <p>We performed sensitivity analyses of our two co‐primary outcomes (disability and independence) by including all the available outcome data, irrespective of risk of bias. Like our initial (hypothesis‐generating) Cochrane Review (<a href="./references#CD009286-bbs2-0156" title="MeadGE , HankeyGJ , KutlubaevMA , LeeR , BaileyM , HackettML . Selective serotonin reuptake inhibitors (SSRIs) for stroke. Cochrane Database of Systematic Reviews2011, Issue 10. Art. No: CD009286. [DOI: 10.1002/14651858.CD009286]">Mead 2011</a>), we found that SSRIs reduced disability at the end of treatment. However, it is highly likely that this positive effect is due to biases in trial quality. Publication bias might also be a problem, as suggested by the funnel plot (<a href="#CD009286-fig-0004">Figure 4</a>). </p> <p>We also performed sensitivity analyses to explore whether a random‐effects model would make any difference to outcome, but it did not (<a href="#CD009286-tbl-0002">Table 1</a>). </p> </section> <section id="CD009286-sec-0089"> <h3 class="title" id="CD009286-sec-0089">Potential biases in the review process</h3> <p>We conducted the review using robust Cochrane methodology, with two review authors independently assessing studies for eligibility, extracting data, and carrying out risk of bias assessment. As five review authors (MD, GEM, EL, GH, MH) were also authors of the <a href="./references#CD009286-bbs2-0002" title="ACTRN12611000774921. Assessment of fluoxetine in stroke recovery (AFFINITY) trial, 2011. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000774921 (first received 22 July 2011). ACTRN12619000986178. The assessment of fluoxetine in stroke recovery imaging and blood biomarkers sub-study AFFINITY BM. www.anzctr.org.au/Trial/Registration/TrialReview.aspx ?ACTRN=12619000986178 (first received 11 July 2019). AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):651-60. HankeyG . Assessment oF FluoxetINe In sTroke recoverY (AFFINITY). www.affinitytrial.org/ (accessed 19th February 2019). ">AFFINITY 2020</a>, <a href="./references#CD009286-bbs2-0023" title="Anonymous. The FOCUS (Fluoxetine or Control under Supervision) trial results: effects of a 6 month course of fluoxetine on the Stroke Impact Scale, mood and fatigue in patients with stroke. www.ed.ac.uk/clinical-brain-sciences/research/completed-studies-trials/focus-stroke-trial (accessed 12 02 2021). CookR , ThomasV , MartinR . Does fluoxetine improve recovery after stroke?BMJ2019;364:1029. DennisM , ForbesJ , GrahamC , HackettM , HankeyGJ , HouseA , et al. Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT. Health Technology Assessment2020;24(22):1-94. DennisM , ForbesJ , GrahamC , HackettML , HankeyGJ , HouseA , et al. Fluoxetine and fractures after stroke: exploratory analyses from the FOCUS Trial. Stroke2019;50(11):3280-2. FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet2019;393(10168):265-74. GrahamC , LewisS , ForbesJ , MeadG , HackettML , HankeyGJ , et al. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. Trials2017;18(1):627. LundstromE , DennisM , MeadG . The effects of fluoxetine on fracture risk after stroke: Further analyses from the focus trial. European Stroke Journal2019;4 suppl 1:7142019. MeadG , DennisM . Feasibility of reporting results of large randomised controlled trials to participants: experience from the Fluoxetine or Control under Supervision (FOCUS) trial. BMJ Open2020;10(11):e0404922020. MeadG . Fluoxetine Or Control Under Supervision (FOCUS) trial: to establish the effect(s) of routine administration of Fluoxetine in patients with a recent stroke. www.isrctn.com/ISRCTN83290762 (first received 23 May 2012). MeadGE , DennisMS , InnesK , MacLeodM , SandercockPA , HouseA , et al. A multicentre randomised trial to establish the effect(s) of routine administration of fluoxetine in patients with a recent stroke (Fluoxetine Or Control Under Supervision, FOCUS). In: 21st European Stroke Conference. 2012:Abst OAID 26. MeadGE , GrahamC , BillotL , NäsmanP , LundströmE , LewisS , on behalf of the FOCUS , AFFINITY and EFFECTS trialists. Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis. Trials2020;21(1):971. MeadGE , LeggL , TilneyR , HsiehCF , WuS , LundströmE , et al. Fluoxetine for stroke recovery: meta-analysis of randomized controlled trials. International Journal of Stroke2020;15(4):365-76. ">FOCUS 2019</a>, and <a href="./references#CD009286-bbs2-0021" title="EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661-9. ISRCTN13020412. Establishing the effect(s) and safety of fluoxetine initiated in the acute phase of stroke. www.isrctn.com/ISRCTN13020412 (first received 19 December 2014). LundströmE , IsakssonE , NäsmanP , WesterP , MårtenssonB , NorrvingB . Correction to: Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(388):s13063-020-04327-w. LundströmE , IsakssonE , Näsman P et al. Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(233):s13063-020-4124-7. LundstromE , IsakssonE , NasmanP , WesterP , MartenssonB , NorrvingB , et al. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661‐9. ">EFFECTS 2020</a> trials, we ensured that assessment of risk of bias and data extraction for these trials was not performed by these review authors; except for unpublished data on mean (SD) for the Stroke Impact Scale scores, fatigue and quality of life, which were provided by the trial statisticians and entered into forest plots by one review author (GEM). </p> <p>Our searches identified one systematic review that included several trials from China that we had not identified in the previous review (<a href="./references#CD009286-bbs2-0133" title="Li, X, ZhangC . Comparative efficacy of nine antidepressants in treating Chinese patients with post-stroke depression: a network meta-analysis. Journal of Affective Disorders2020;266:540-8.">Li 2020</a>). These trials are now included. Thus, it is possible, though unlikely, that there are other trials that have been published since the <a href="./references#CD009286-bbs2-0133" title="Li, X, ZhangC . Comparative efficacy of nine antidepressants in treating Chinese patients with post-stroke depression: a network meta-analysis. Journal of Affective Disorders2020;266:540-8.">Li 2020</a> review that our searches might not have identified. </p> <p>After editorial review in July 2021, we decided to perform a final check of the WHO ICTRP (that had last been searched about a year previously) to check for any new ongoing studies. This search was done by one review author only (GEM) and so it is possible, though very unlikely, that new studies were missed. </p> </section> <section id="CD009286-sec-0090"> <h3 class="title" id="CD009286-sec-0090">Agreements and disagreements with other studies or reviews</h3> <p>This review has demonstrated that SSRIs do not improve recovery after stroke. This is in contrast with several other meta‐analyses which showed that SSRIs might improve recovery, but these meta‐analyses did not include two recently published large high‐quality trials which were both neutral (<a href="./references#CD009286-bbs2-0002" title="ACTRN12611000774921. Assessment of fluoxetine in stroke recovery (AFFINITY) trial, 2011. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000774921 (first received 22 July 2011). ACTRN12619000986178. The assessment of fluoxetine in stroke recovery imaging and blood biomarkers sub-study AFFINITY BM. www.anzctr.org.au/Trial/Registration/TrialReview.aspx ?ACTRN=12619000986178 (first received 11 July 2019). AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):651-60. HankeyG . Assessment oF FluoxetINe In sTroke recoverY (AFFINITY). www.affinitytrial.org/ (accessed 19th February 2019). ">AFFINITY 2020</a>; <a href="./references#CD009286-bbs2-0021" title="EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661-9. ISRCTN13020412. Establishing the effect(s) and safety of fluoxetine initiated in the acute phase of stroke. www.isrctn.com/ISRCTN13020412 (first received 19 December 2014). LundströmE , IsakssonE , NäsmanP , WesterP , MårtenssonB , NorrvingB . Correction to: Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(388):s13063-020-04327-w. LundströmE , IsakssonE , Näsman P et al. Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials2020;21(233):s13063-020-4124-7. LundstromE , IsakssonE , NasmanP , WesterP , MartenssonB , NorrvingB , et al. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2020;19(8):661‐9. ">EFFECTS 2020</a>). In this meta‐analysis, we were also able to explore the influence of SSRIs on other important outcomes, that previous reviews had not done, because there had previously been insufficient data. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009286-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram for this update" data-id="CD009286-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flow diagram for this update</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/full#CD009286-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009286-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009286-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/full#CD009286-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009286-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-FIG-03" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each 'risk of bias' item presented as percentages across all included studies." data-id="CD009286-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'risk of bias' item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/full#CD009286-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009286-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Funnel plot, all studies irrespective or risk of bias, for disability at end of treatment." data-id="CD009286-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot, all studies irrespective or risk of bias, for disability at end of treatment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/full#CD009286-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009286-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 1: Disability (primary outcome). Studies at low risk of bias" data-id="CD009286-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 1: Disability (primary outcome). Studies at low risk of bias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#CD009286-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009286-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 2: Independent on modified Rankin score (mRS 0 to 2) (primary outcome). Studies at low risk of bias" data-id="CD009286-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 2: Independent on modified Rankin score (mRS 0 to 2) (primary outcome). Studies at low risk of bias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#CD009286-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009286-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 3: Neurological deficit score (studies at low risk of bias)" data-id="CD009286-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 3: Neurological deficit score (studies at low risk of bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#CD009286-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009286-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 4: Motor deficits (studies at low risk of bias)" data-id="CD009286-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 4: Motor deficits (studies at low risk of bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#CD009286-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009286-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 5: Depression, continuous data (studies at low risk of bias)" data-id="CD009286-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 5: Depression, continuous data (studies at low risk of bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#CD009286-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009286-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 6: Depression, dichotomous data (studies at low risk of bias)" data-id="CD009286-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 6: Depression, dichotomous data (studies at low risk of bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#CD009286-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009286-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 7: Death (trials at low risk of bias)" data-id="CD009286-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 7: Death (trials at low risk of bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#CD009286-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009286-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 8: Seizures (studies at low risk of bias)" data-id="CD009286-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 8: Seizures (studies at low risk of bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#CD009286-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009286-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 9: Gastrointestinal side effects (studies at low risk of bias)" data-id="CD009286-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 9: Gastrointestinal side effects (studies at low risk of bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#CD009286-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009286-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 10: Bleeding (studies at low risk of bias)" data-id="CD009286-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 10: Bleeding (studies at low risk of bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#CD009286-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009286-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 11: Fractures (studies at low risk of only)" data-id="CD009286-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 11: Fractures (studies at low risk of only) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#CD009286-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009286-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 12: Cognition (trials at low risk of bias)" data-id="CD009286-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 12: Cognition (trials at low risk of bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#CD009286-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009286-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 13: Leaving the study before the end of scheduled follow‐up for reasons other than death (trials at low risk of bias)" data-id="CD009286-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 13: Leaving the study before the end of scheduled follow‐up for reasons other than death (trials at low risk of bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#CD009286-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009286-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 14: Fatigue at end of treatment (studies at low risk of bias only)" data-id="CD009286-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 14: Fatigue at end of treatment (studies at low risk of bias only) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#CD009286-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009286-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 15: Quality of life at end of treatment (studies at low risk of bias)" data-id="CD009286-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 15: Quality of life at end of treatment (studies at low risk of bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#CD009286-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009286-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 16: Disability (all studies regardless of risk of bias)" data-id="CD009286-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 16: Disability (all studies regardless of risk of bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#CD009286-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009286-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 17: Independent on modified Rankin score (mRS 0 to 2) (all studies regardless of risk of bias)" data-id="CD009286-fig-0021" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: SSRI versus control at end of treatment, by SSRI, Outcome 17: Independent on modified Rankin score (mRS 0 to 2) (all studies regardless of risk of bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#CD009286-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009286-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: SSRI versus control at end of follow up, by SSRI, Outcome 1: Disability (studies at low risk of bias only)" data-id="CD009286-fig-0022" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: SSRI versus control at end of follow up, by SSRI, Outcome 1: Disability (studies at low risk of bias only) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#CD009286-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009286-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: SSRI versus control at end of follow up, by SSRI, Outcome 2: Independent on modified rankin score (0‐2) (studies at low risk of bias only)" data-id="CD009286-fig-0023" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: SSRI versus control at end of follow up, by SSRI, Outcome 2: Independent on modified rankin score (0‐2) (studies at low risk of bias only) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#CD009286-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009286-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: SSRI versus control at end of follow up, by SSRI, Outcome 3: Depression, continuous data (studies at low risk of bias only)" data-id="CD009286-fig-0024" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: SSRI versus control at end of follow up, by SSRI, Outcome 3: Depression, continuous data (studies at low risk of bias only) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#CD009286-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009286-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: SSRI versus control at end of follow up, by SSRI, Outcome 4: Depression, dichotomous (studies at low risk of bias only)" data-id="CD009286-fig-0025" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: SSRI versus control at end of follow up, by SSRI, Outcome 4: Depression, dichotomous (studies at low risk of bias only) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#CD009286-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009286-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: SSRI versus control at end of follow up, by SSRI, Outcome 5: Motor deficits (studies at low risk of bias only)" data-id="CD009286-fig-0026" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: SSRI versus control at end of follow up, by SSRI, Outcome 5: Motor deficits (studies at low risk of bias only) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#CD009286-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009286-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: SSRI versus control at end of follow up, by SSRI, Outcome 6: Cognition (studies at low risk of bias only)" data-id="CD009286-fig-0027" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: SSRI versus control at end of follow up, by SSRI, Outcome 6: Cognition (studies at low risk of bias only) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#CD009286-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009286-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: SSRI versus control at end of follow up, by SSRI, Outcome 7: Death (studies at low risk of bias only)" data-id="CD009286-fig-0028" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: SSRI versus control at end of follow up, by SSRI, Outcome 7: Death (studies at low risk of bias only) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#CD009286-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009286-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: SSRI versus control at end of follow up, by SSRI, Outcome 8: Leaving the trial before the end of follow‐up, for reasons other than death ( studies at low risk of bias)" data-id="CD009286-fig-0029" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: SSRI versus control at end of follow up, by SSRI, Outcome 8: Leaving the trial before the end of follow‐up, for reasons other than death ( studies at low risk of bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#CD009286-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009286-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: SSRI versus control at end of follow up, by SSRI, Outcome 9: Disability, all studies irrespective of risk of bias" data-id="CD009286-fig-0030" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: SSRI versus control at end of follow up, by SSRI, Outcome 9: Disability, all studies irrespective of risk of bias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#CD009286-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009286-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/urn:x-wiley:14651858:media:CD009286:CD009286-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: SSRI versus control at end of follow up, by SSRI, Outcome 10: Independent on mRS (0‐2) all studies irrespective of risk of bias" data-id="CD009286-fig-0031" src="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_t/tCD009286-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: SSRI versus control at end of follow up, by SSRI, Outcome 10: Independent on mRS (0‐2) all studies irrespective of risk of bias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#CD009286-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/media/CDSR/CD009286/image_n/nCD009286-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009286-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Fluoxetine versus control at end of treatment, for stroke recovery, using data from high quality trials only</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fluoxetine versus control at end of treatment, by SSRI, for stroke recovery*</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with stroke recovery<br/><b>Settings:</b> hospital<br/><b>Intervention:</b> fluoxetine versus control at end of treatment </p> <p>*Summary of findings table based on studies with low risk of bias.</p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Fluoxetine versus control at end of treatment</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disability (primary analysis)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.0 (‐0.05, 0.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5436 <br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Independent on modified Rankin score (mRS 0 to 2) (primary analysis)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.98<br/>(0.93 to 1.03) </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5926 <br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1541/2971 (i.e. 52 per hundred)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1498/2955</p> <p>(i.e. 51 per hundred)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological deficit score</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.39 (95% CI (‐1.12 to 0.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 participants, one study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This is a small effect (based on the 'rule‐of‐thumb' method for interpreting SMD)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depression (continuous data)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.14 (‐0.19 to ‐0.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5356<br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This is a small effect (based on the 'rule‐of‐thumb' method for interpreting SMD)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/>(0.82 to 1.24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6090<br/>(6 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>168/3029 (i.e. 55 per thousand)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>170/3061</p> <p>(i.e. 56 per thousand)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of seizures</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.40<br/>(1.00 to 1.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6080 <br/>(6 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54/3024 (i.e. 18 per thousand)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76/3056 (i.e. 25 per thousand)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bone fractures</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.35 <br/>(1.62 to 3.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6080<br/>(6 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕ ⊕ <br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40/3024</p> <p>(i.e. 13 per thousand)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>93/3056</p> <p>(i.e. 30 per thousand)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the mean control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Neurological deficit from only one trial of 30 people so we have downgraded for imprecision (<a href="./references#CD009286-bbs2-0126" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">GRADE 2013</a>). </p> <p><sup>b</sup>Death downgraded for imprecision. </p> <p><sup>c</sup>Seizures downgraded for imprecision. </p> <p>Note that because we included only the low risk of bias studies in our review, none of the evidence was downgraded because of study quality. </p> <p>A range of different outcome scales were used for disability (including Barthel Index and daily activities subscale of the Stroke Impact Scale), and depression (including emotional role function of the Stroke Impact Scale). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Fluoxetine versus control at end of treatment, for stroke recovery, using data from high quality trials only</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/full#CD009286-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009286-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Sensitivity analysis for co‐primary outcomes depending on the method of analysis</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>mRS (RR and 95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Disability (SMD and 95% CI)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fixed‐effect</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.93, 1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.0 (‐0.05, 0.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Random‐effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.92, 1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.00 (‐0.05, 0.05)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>CI: confidence interval<br/>mRS: modified Rankin Scale<br/>RR: risk ratio<br/>SMD: standardised mean difference </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Sensitivity analysis for co‐primary outcomes depending on the method of analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/full#CD009286-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009286-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">SSRI versus control at end of treatment, by SSRI</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Disability (primary outcome). Studies at low risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5436</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.05, 0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Fluoxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5436</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.05, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Independent on modified Rankin score (mRS 0 to 2) (primary outcome). Studies at low risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5926</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.93, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Neurological deficit score (studies at low risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐1.12, 0.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Fluoxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐1.12, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Motor deficits (studies at low risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.02, 0.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Fluoxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.02, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Depression, continuous data (studies at low risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.19, ‐0.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Fluoxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.19, ‐0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Depression, dichotomous data (studies at low risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5907</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.65, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Fluoxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5907</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.65, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Death (trials at low risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6090</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.82, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Fluoxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6090</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.82, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Seizures (studies at low risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6080</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.00, 1.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Fluoxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6080</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.00, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Gastrointestinal side effects (studies at low risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.33, 8.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Fluoxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.33, 8.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Bleeding (studies at low risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6088</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.69, 1.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Fluoxetine (except for Asadollahi 2018)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6088</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.69, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Fractures (studies at low risk of only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6080</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.35 [1.62, 3.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Cognition (trials at low risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.22 [‐2.37, ‐0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Leaving the study before the end of scheduled follow‐up for reasons other than death (trials at low risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6090</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [1.03, 2.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 Fluoxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6090</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [1.03, 2.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Fatigue at end of treatment (studies at low risk of bias only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐1.24, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Quality of life at end of treatment (studies at low risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.02, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Disability (all studies regardless of risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.23, ‐0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.1 Fluoxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6590</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.13, ‐0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.2 Sertraline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.38 [‐1.76, ‐0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.3 Paroxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.29 [‐1.55, ‐1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.4 Citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>446</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.68 [‐0.88, ‐0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.5 Escitalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.67 [‐1.00, ‐0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Independent on modified Rankin score (mRS 0 to 2) (all studies regardless of risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6792</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.93, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.1 Fluoxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6039</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.94, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.2 Sertraline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.97, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.3 Citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.82, 0.98]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">SSRI versus control at end of treatment, by SSRI</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#CD009286-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009286-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">SSRI versus control at end of follow up, by SSRI</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Disability (studies at low risk of bias only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.24 [‐2.59, 2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Independent on modified rankin score (0‐2) (studies at low risk of bias only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.89, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Depression, continuous data (studies at low risk of bias only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2684</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.36, 0.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Depression, dichotomous (studies at low risk of bias only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3083</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.73, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Motor deficits (studies at low risk of bias only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2688</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.77 [‐3.00, 1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Cognition (studies at low risk of bias only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2689</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐2.32, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Death (studies at low risk of bias only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.77, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Leaving the trial before the end of follow‐up, for reasons other than death ( studies at low risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.54, 1.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Disability, all studies irrespective of risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2691</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐2.56, 2.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Independent on mRS (0‐2) all studies irrespective of risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.89, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">SSRI versus control at end of follow up, by SSRI</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009286.pub4/references#CD009286-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009286.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009286-note-0016">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009286-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009286-note-0014">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD009286-note-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD009286-note-0011">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD009286-note-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD009286-note-0015">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD009286-note-0009">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD009286-note-0007">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD009286-note-0008">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009286\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009286\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009286\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009286\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009286\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009286\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009286\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009286\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009286\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009286\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009286\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009286\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009286\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009286\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009286\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009286\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009286\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009286\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=77cjsSG8&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009286.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009286.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009286.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009286.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009286.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718536514"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009286.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718536518"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009286.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dd2b6bea8f401',t:'MTc0MDcxODUzNi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 